roamfseavekcusjmqiqsjcdkvqxqiqckvekaosvi length 6 327388 page 327388 <!DOCTYPE html>
<html class="client-nojs vector-feature-language-in-header-enabled vector-feature-language-in-main-page-header-disabled vector-feature-sticky-header-disabled vector-feature-page-tools-pinned-disabled vector-feature-toc-pinned-clientpref-1 vector-feature-main-menu-pinned-disabled vector-feature-limited-width-clientpref-1 vector-feature-limited-width-content-enabled vector-feature-custom-font-size-clientpref-0 vector-feature-client-preferences-disabled vector-feature-client-prefs-pinned-clientpref-0 vector-feature-night-mode-disabled skin-theme-clientpref-day vector-toc-available" lang="en" dir="ltr">
<head>
<meta charset="UTF-8">
<title>Prescription drug prices in the United States - Wikipedia</title>




<meta name="ResourceLoaderDynamicStyles" content="">

<meta name="generator" content="MediaWiki 1.43.0-wmf.2">
<meta name="referrer" content="origin">
<meta name="referrer" content="origin-when-cross-origin">
<meta name="robots" content="max-image-preview:standard">
<meta name="format-detection" content="telephone=no">
<meta name="viewport" content="width=1000">
<meta property="og:title" content="Prescription drug prices in the United States - Wikipedia">
<meta property="og:type" content="website">












</head>
<body class="skin-vector skin-vector-search-vue mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-Prescription_drug_prices_in_the_United_States rootpage-Prescription_drug_prices_in_the_United_States skin-vector-2022 action-view"><a class="mw-jump-link" href="#bodyContent">Jump to content</a>
<div class="vector-header-container">
	<header class="vector-header mw-header">
		<div class="vector-header-start">
			<nav class="vector-main-menu-landmark" aria-label="Site" role="navigation">
				
<div id="vector-main-menu-dropdown" class="vector-dropdown vector-main-menu-dropdown vector-button-flush-left vector-button-flush-right"  >
	<input type="checkbox" id="vector-main-menu-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-main-menu-dropdown" class="vector-dropdown-checkbox "  aria-label="Main menu"  >
	<label id="vector-main-menu-dropdown-label" for="vector-main-menu-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true"  ><span class="vector-icon mw-ui-icon-menu mw-ui-icon-wikimedia-menu"></span>

<span class="vector-dropdown-label-text">Main menu</span>
	</label>
	<div class="vector-dropdown-content">


				<div id="vector-main-menu-unpinned-container" class="vector-unpinned-container">
		
<div id="vector-main-menu" class="vector-main-menu vector-pinnable-element">
	<div
	class="vector-pinnable-header vector-main-menu-pinnable-header vector-pinnable-header-unpinned"
	data-feature-name="main-menu-pinned"
	data-pinnable-element-id="vector-main-menu"
	data-pinned-container-id="vector-main-menu-pinned-container"
	data-unpinned-container-id="vector-main-menu-unpinned-container"
>
	<div class="vector-pinnable-header-label">Main menu</div>
	<button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-main-menu.pin">move to sidebar</button>
	<button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-main-menu.unpin">hide</button>
</div>

	
<div id="p-navigation" class="vector-menu mw-portlet mw-portlet-navigation"  >
	<div class="vector-menu-heading">
		Navigation
	</div>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			<li id="n-mainpage-description" class="mw-list-item"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z"><span>Main page</span></a></li><li id="n-contents" class="mw-list-item"><a href="/wiki/Wikipedia:Contents" title="Guides to browsing Wikipedia"><span>Contents</span></a></li><li id="n-currentevents" class="mw-list-item"><a href="/wiki/Portal:Current_events" title="Articles related to current events"><span>Current events</span></a></li><li id="n-randompage" class="mw-list-item"><a href="/wiki/Special:Random" title="Visit a randomly selected article [x]" accesskey="x"><span>Random article</span></a></li><li id="n-aboutsite" class="mw-list-item"><a href="/wiki/Wikipedia:About" title="Learn about Wikipedia and how it works"><span>About Wikipedia</span></a></li><li id="n-contactpage" class="mw-list-item"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia"><span>Contact us</span></a></li><li id="n-sitesupport" class="mw-list-item"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us by donating to the Wikimedia Foundation"><span>Donate</span></a></li>
		</ul>
		
	</div>
</div>

	
	
<div id="p-interaction" class="vector-menu mw-portlet mw-portlet-interaction"  >
	<div class="vector-menu-heading">
		Contribute
	</div>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			<li id="n-help" class="mw-list-item"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia"><span>Help</span></a></li><li id="n-introduction" class="mw-list-item"><a href="/wiki/Help:Introduction" title="Learn how to edit Wikipedia"><span>Learn to edit</span></a></li><li id="n-portal" class="mw-list-item"><a href="/wiki/Wikipedia:Community_portal" title="The hub for editors"><span>Community portal</span></a></li><li id="n-recentchanges" class="mw-list-item"><a href="/wiki/Special:RecentChanges" title="A list of recent changes to Wikipedia [r]" accesskey="r"><span>Recent changes</span></a></li><li id="n-upload" class="mw-list-item"><a href="/wiki/Wikipedia:File_upload_wizard" title="Add images or other media for use on Wikipedia"><span>Upload file</span></a></li>
		</ul>
		
	</div>
</div>

</div>

				</div>

	</div>
</div>

		</nav>
			
<a href="/wiki/Main_Page" class="mw-logo">
	<img class="mw-logo-icon" src="/static/images/icons/wikipedia.png" alt="" aria-hidden="true" height="50" width="50">
	<span class="mw-logo-container">
		<img class="mw-logo-wordmark" alt="Wikipedia" src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" style="width: 7.5em; height: 1.125em;">
		<img class="mw-logo-tagline" alt="The Free Encyclopedia" src="/static/images/mobile/copyright/wikipedia-tagline-en.svg" width="117" height="13" style="width: 7.3125em; height: 0.8125em;">
	</span>
</a>

		</div>
		<div class="vector-header-end">
			
<div id="p-search" role="search" class="vector-search-box-vue  vector-search-box-collapses vector-search-box-show-thumbnail vector-search-box-auto-expand-width vector-search-box">
	<a href="/wiki/Special:Search" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only search-toggle" id="" title="Search Wikipedia [f]" accesskey="f"><span class="vector-icon mw-ui-icon-search mw-ui-icon-wikimedia-search"></span>

<span>Search</span>
	</a>
	<div class="vector-typeahead-search-container">
		<div class="cdx-typeahead-search cdx-typeahead-search--show-thumbnail cdx-typeahead-search--auto-expand-width">
			<form action="/w/index.php" id="searchform" class="cdx-search-input cdx-search-input--has-end-button">
				<div id="simpleSearch" class="cdx-search-input__input-wrapper"  data-search-loc="header-moved">
					<div class="cdx-text-input cdx-text-input--has-start-icon">
						<input
							class="cdx-text-input__input"
							 type="search" name="search" placeholder="Search Wikipedia" aria-label="Search Wikipedia" autocapitalize="sentences" title="Search Wikipedia [f]" accesskey="f" id="searchInput"
							>
						<span class="cdx-text-input__icon cdx-text-input__start-icon"></span>
					</div>
					<input type="hidden" name="title" value="Special:Search">
				</div>
				<button class="cdx-button cdx-search-input__end-button">Search</button>
			</form>
		</div>
	</div>
</div>

			<nav class="vector-user-links vector-user-links-wide" aria-label="Personal tools" role="navigation" >
	<div class="vector-user-links-main">
	
<div id="p-vector-user-menu-preferences" class="vector-menu mw-portlet emptyPortlet"  >
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			
		</ul>
		
	</div>
</div>

	
<div id="p-vector-user-menu-userpage" class="vector-menu mw-portlet emptyPortlet"  >
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			
		</ul>
		
	</div>
</div>

	<nav class="vector-client-prefs-landmark" aria-label="Appearance">
		
		
	</nav>
	
<div id="p-vector-user-menu-notifications" class="vector-menu mw-portlet emptyPortlet"  >
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			
		</ul>
		
	</div>
</div>

	
<div id="p-vector-user-menu-overflow" class="vector-menu mw-portlet"  >
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			<li id="pt-createaccount-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="/w/index.php?title=Special:CreateAccount&amp;returnto=Prescription+drug+prices+in+the+United+States" title="You are encouraged to create an account and log in; however, it is not mandatory" class=""><span>Create account</span></a>
</li>
<li id="pt-login-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="/w/index.php?title=Special:UserLogin&amp;returnto=Prescription+drug+prices+in+the+United+States" title="You&#039;re encouraged to log in; however, it&#039;s not mandatory. [o]" accesskey="o" class=""><span>Log in</span></a>
</li>

			
		</ul>
		
	</div>
</div>

	</div>
	
<div id="vector-user-links-dropdown" class="vector-dropdown vector-user-menu vector-button-flush-right vector-user-menu-logged-out"  title="Log in and more options" >
	<input type="checkbox" id="vector-user-links-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-user-links-dropdown" class="vector-dropdown-checkbox "  aria-label="Personal tools"  >
	<label id="vector-user-links-dropdown-label" for="vector-user-links-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true"  ><span class="vector-icon mw-ui-icon-ellipsis mw-ui-icon-wikimedia-ellipsis"></span>

<span class="vector-dropdown-label-text">Personal tools</span>
	</label>
	<div class="vector-dropdown-content">


		
<div id="p-personal" class="vector-menu mw-portlet mw-portlet-personal user-links-collapsible-item"  title="User menu" >
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			<li id="pt-createaccount" class="user-links-collapsible-item mw-list-item"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Prescription+drug+prices+in+the+United+States" title="You are encouraged to create an account and log in; however, it is not mandatory"><span class="vector-icon mw-ui-icon-userAdd mw-ui-icon-wikimedia-userAdd"></span> <span>Create account</span></a></li><li id="pt-login" class="user-links-collapsible-item mw-list-item"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Prescription+drug+prices+in+the+United+States" title="You&#039;re encouraged to log in; however, it&#039;s not mandatory. [o]" accesskey="o"><span class="vector-icon mw-ui-icon-logIn mw-ui-icon-wikimedia-logIn"></span> <span>Log in</span></a></li>
		</ul>
		
	</div>
</div>

<div id="p-user-menu-anon-editor" class="vector-menu mw-portlet mw-portlet-user-menu-anon-editor"  >
	<div class="vector-menu-heading">
		Pages for logged out editors <a href="/wiki/Help:Introduction" aria-label="Learn more about editing"><span>learn more</span></a>
	</div>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			<li id="pt-anoncontribs" class="mw-list-item"><a href="/wiki/Special:MyContributions" title="A list of edits made from this IP address [y]" accesskey="y"><span>Contributions</span></a></li><li id="pt-anontalk" class="mw-list-item"><a href="/wiki/Special:MyTalk" title="Discussion about edits from this IP address [n]" accesskey="n"><span>Talk</span></a></li>
		</ul>
		
	</div>
</div>

	
	</div>
</div>

</nav>

		</div>
	</header>
</div>
<div class="mw-page-container">
	<div class="mw-page-container-inner">
		<div class="vector-sitenotice-container">
			<div id="siteNotice"><!-- CentralNotice --></div>
		</div>
		<div class="vector-column-start">
			<div class="vector-main-menu-container">
		<div id="mw-navigation">
			<nav id="mw-panel" class="vector-main-menu-landmark" aria-label="Site" role="navigation">
				<div id="vector-main-menu-pinned-container" class="vector-pinned-container">
				
				</div>
		</nav>
		</div>
	</div>
	<div class="vector-sticky-pinned-container">
				<nav id="mw-panel-toc" role="navigation" aria-label="Contents" data-event-name="ui.sidebar-toc" class="mw-table-of-contents-container vector-toc-landmark">
					<div id="vector-toc-pinned-container" class="vector-pinned-container">
					<div id="vector-toc" class="vector-toc vector-pinnable-element">
	<div
	class="vector-pinnable-header vector-toc-pinnable-header vector-pinnable-header-pinned"
	data-feature-name="toc-pinned"
	data-pinnable-element-id="vector-toc"
	
	
>
	<h2 class="vector-pinnable-header-label">Contents</h2>
	<button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-toc.pin">move to sidebar</button>
	<button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-toc.unpin">hide</button>
</div>


	<ul class="vector-toc-contents" id="mw-panel-toc-list">
		<li id="toc-mw-content-text"
			class="vector-toc-list-item vector-toc-level-1">
			<a href="#" class="vector-toc-link">
				<div class="vector-toc-text">(Top)</div>
			</a>
		</li>
		<li id="toc-History"
		class="vector-toc-list-item vector-toc-level-1">
		<a class="vector-toc-link" href="#History">
			<div class="vector-toc-text">
			<span class="vector-toc-numb">1</span>History</div>
		</a>
		
			<button aria-controls="toc-History-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle">
				<span class="vector-icon vector-icon--x-small mw-ui-icon-wikimedia-expand"></span>
				<span>Toggle History subsection</span>
			</button>
		
		<ul id="toc-History-sublist" class="vector-toc-list">
			<li id="toc-Attempts_to_repeal_negotiation_ban"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Attempts_to_repeal_negotiation_ban">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">1.1</span>Attempts to repeal negotiation ban</div>
			</a>
			
			<ul id="toc-Attempts_to_repeal_negotiation_ban-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Affordable_Care_Act"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Affordable_Care_Act">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">1.2</span>Affordable Care Act</div>
			</a>
			
			<ul id="toc-Affordable_Care_Act-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Generic_price_spikes"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Generic_price_spikes">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">1.3</span>Generic price spikes</div>
			</a>
			
			<ul id="toc-Generic_price_spikes-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Trump_Executive_Orders"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Trump_Executive_Orders">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">1.4</span>Trump Executive Orders</div>
			</a>
			
			<ul id="toc-Trump_Executive_Orders-sublist" class="vector-toc-list">
			</ul>
		</li>
	</ul>
	</li>
	<li id="toc-Drug_expenditures"
		class="vector-toc-list-item vector-toc-level-1">
		<a class="vector-toc-link" href="#Drug_expenditures">
			<div class="vector-toc-text">
			<span class="vector-toc-numb">2</span>Drug expenditures</div>
		</a>
		
			<button aria-controls="toc-Drug_expenditures-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle">
				<span class="vector-icon vector-icon--x-small mw-ui-icon-wikimedia-expand"></span>
				<span>Toggle Drug expenditures subsection</span>
			</button>
		
		<ul id="toc-Drug_expenditures-sublist" class="vector-toc-list">
			<li id="toc-Specialty_pharmaceuticals_in_the_US"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Specialty_pharmaceuticals_in_the_US">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">2.1</span>Specialty pharmaceuticals in the US</div>
			</a>
			
			<ul id="toc-Specialty_pharmaceuticals_in_the_US-sublist" class="vector-toc-list">
			</ul>
		</li>
	</ul>
	</li>
	<li id="toc-Effects"
		class="vector-toc-list-item vector-toc-level-1">
		<a class="vector-toc-link" href="#Effects">
			<div class="vector-toc-text">
			<span class="vector-toc-numb">3</span>Effects</div>
		</a>
		
			<button aria-controls="toc-Effects-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle">
				<span class="vector-icon vector-icon--x-small mw-ui-icon-wikimedia-expand"></span>
				<span>Toggle Effects subsection</span>
			</button>
		
		<ul id="toc-Effects-sublist" class="vector-toc-list">
			<li id="toc-Prescription_non-compliance_and_health_effects"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Prescription_non-compliance_and_health_effects">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">3.1</span>Prescription non-compliance and health effects</div>
			</a>
			
			<ul id="toc-Prescription_non-compliance_and_health_effects-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Prescriptions_from_other_countries"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Prescriptions_from_other_countries">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">3.2</span>Prescriptions from other countries</div>
			</a>
			
			<ul id="toc-Prescriptions_from_other_countries-sublist" class="vector-toc-list">
			</ul>
		</li>
	</ul>
	</li>
	<li id="toc-Reasons_for_high_prices"
		class="vector-toc-list-item vector-toc-level-1">
		<a class="vector-toc-link" href="#Reasons_for_high_prices">
			<div class="vector-toc-text">
			<span class="vector-toc-numb">4</span>Reasons for high prices</div>
		</a>
		
			<button aria-controls="toc-Reasons_for_high_prices-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle">
				<span class="vector-icon vector-icon--x-small mw-ui-icon-wikimedia-expand"></span>
				<span>Toggle Reasons for high prices subsection</span>
			</button>
		
		<ul id="toc-Reasons_for_high_prices-sublist" class="vector-toc-list">
			<li id="toc-Variability_and_non-transparency"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Variability_and_non-transparency">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">4.1</span>Variability and non-transparency</div>
			</a>
			
			<ul id="toc-Variability_and_non-transparency-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Market_exclusivity"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Market_exclusivity">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">4.2</span>Market exclusivity</div>
			</a>
			
			<ul id="toc-Market_exclusivity-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Drug_company_profits"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Drug_company_profits">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">4.3</span>Drug company profits</div>
			</a>
			
			<ul id="toc-Drug_company_profits-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Orphan_drugs"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Orphan_drugs">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">4.4</span>Orphan drugs</div>
			</a>
			
			<ul id="toc-Orphan_drugs-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-FDA_backlog_in_generic_drug_application_review"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#FDA_backlog_in_generic_drug_application_review">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">4.5</span>FDA backlog in generic drug application review</div>
			</a>
			
			<ul id="toc-FDA_backlog_in_generic_drug_application_review-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Research_and_development"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Research_and_development">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">4.6</span>Research and development</div>
			</a>
			
			<ul id="toc-Research_and_development-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Intermediaries"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Intermediaries">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">4.7</span>Intermediaries</div>
			</a>
			
			<ul id="toc-Intermediaries-sublist" class="vector-toc-list">
				<li id="toc-Pharmacy_benefit_managers"
			class="vector-toc-list-item vector-toc-level-3">
			<a class="vector-toc-link" href="#Pharmacy_benefit_managers">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">4.7.1</span>Pharmacy benefit managers</div>
			</a>
			
			<ul id="toc-Pharmacy_benefit_managers-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Drug_rebates"
			class="vector-toc-list-item vector-toc-level-3">
			<a class="vector-toc-link" href="#Drug_rebates">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">4.7.2</span>Drug rebates</div>
			</a>
			
			<ul id="toc-Drug_rebates-sublist" class="vector-toc-list">
			</ul>
		</li>
	</ul>
		</li>
	</ul>
	</li>
	<li id="toc-Solutions"
		class="vector-toc-list-item vector-toc-level-1">
		<a class="vector-toc-link" href="#Solutions">
			<div class="vector-toc-text">
			<span class="vector-toc-numb">5</span>Solutions</div>
		</a>
		
			<button aria-controls="toc-Solutions-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle">
				<span class="vector-icon vector-icon--x-small mw-ui-icon-wikimedia-expand"></span>
				<span>Toggle Solutions subsection</span>
			</button>
		
		<ul id="toc-Solutions-sublist" class="vector-toc-list">
			<li id="toc-Discounts_and_drug_coupons"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Discounts_and_drug_coupons">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">5.1</span>Discounts and drug coupons</div>
			</a>
			
			<ul id="toc-Discounts_and_drug_coupons-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Generics_versus_brand-name_products"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Generics_versus_brand-name_products">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">5.2</span>Generics versus brand-name products</div>
			</a>
			
			<ul id="toc-Generics_versus_brand-name_products-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Value-based_prices"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Value-based_prices">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">5.3</span>Value-based prices</div>
			</a>
			
			<ul id="toc-Value-based_prices-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Policy_makers"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Policy_makers">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">5.4</span>Policy makers</div>
			</a>
			
			<ul id="toc-Policy_makers-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-New_legislation"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#New_legislation">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">5.5</span>New legislation</div>
			</a>
			
			<ul id="toc-New_legislation-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Canada&#039;s_model"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Canada&#039;s_model">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">5.6</span>Canada's model</div>
			</a>
			
			<ul id="toc-Canada&#039;s_model-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Healthcare_providers"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Healthcare_providers">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">5.7</span>Healthcare providers</div>
			</a>
			
			<ul id="toc-Healthcare_providers-sublist" class="vector-toc-list">
			</ul>
		</li>
		<li id="toc-Medicare_for_All"
			class="vector-toc-list-item vector-toc-level-2">
			<a class="vector-toc-link" href="#Medicare_for_All">
				<div class="vector-toc-text">
				<span class="vector-toc-numb">5.8</span>Medicare for All</div>
			</a>
			
			<ul id="toc-Medicare_for_All-sublist" class="vector-toc-list">
			</ul>
		</li>
	</ul>
	</li>
	<li id="toc-See_also"
		class="vector-toc-list-item vector-toc-level-1">
		<a class="vector-toc-link" href="#See_also">
			<div class="vector-toc-text">
			<span class="vector-toc-numb">6</span>See also</div>
		</a>
		
		<ul id="toc-See_also-sublist" class="vector-toc-list">
		</ul>
	</li>
	<li id="toc-References"
		class="vector-toc-list-item vector-toc-level-1">
		<a class="vector-toc-link" href="#References">
			<div class="vector-toc-text">
			<span class="vector-toc-numb">7</span>References</div>
		</a>
		
		<ul id="toc-References-sublist" class="vector-toc-list">
		</ul>
	</li>
	<li id="toc-Further_reading"
		class="vector-toc-list-item vector-toc-level-1">
		<a class="vector-toc-link" href="#Further_reading">
			<div class="vector-toc-text">
			<span class="vector-toc-numb">8</span>Further reading</div>
		</a>
		
		<ul id="toc-Further_reading-sublist" class="vector-toc-list">
		</ul>
	</li>
</ul>
</div>

					</div>
		</nav>
			</div>
		</div>
		<div class="mw-content-container">
			<main id="content" class="mw-body" role="main">
				<header class="mw-body-header vector-page-titlebar">
					<nav role="navigation" aria-label="Contents" class="vector-toc-landmark">
						
<div id="vector-page-titlebar-toc" class="vector-dropdown vector-page-titlebar-toc vector-button-flush-left"  >
	<input type="checkbox" id="vector-page-titlebar-toc-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-page-titlebar-toc" class="vector-dropdown-checkbox "  aria-label="Toggle the table of contents"  >
	<label id="vector-page-titlebar-toc-label" for="vector-page-titlebar-toc-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true"  ><span class="vector-icon mw-ui-icon-listBullet mw-ui-icon-wikimedia-listBullet"></span>

<span class="vector-dropdown-label-text">Toggle the table of contents</span>
	</label>
	<div class="vector-dropdown-content">


							<div id="vector-page-titlebar-toc-unpinned-container" class="vector-unpinned-container">
			</div>
		
	</div>
</div>

					</nav>
					<h1 id="firstHeading" class="firstHeading mw-first-heading"><span class="mw-page-title-main">Prescription drug prices in the United States</span></h1>
							
<div id="p-lang-btn" class="vector-dropdown mw-portlet mw-portlet-lang"  >
	<input type="checkbox" id="p-lang-btn-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-p-lang-btn" class="vector-dropdown-checkbox mw-interlanguage-selector" aria-label="Go to an article in another language. Available in 1 language"   >
	<label id="p-lang-btn-label" for="p-lang-btn-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--action-progressive mw-portlet-lang-heading-1" aria-hidden="true"  ><span class="vector-icon mw-ui-icon-language-progressive mw-ui-icon-wikimedia-language-progressive"></span>

<span class="vector-dropdown-label-text">1 language</span>
	</label>
	<div class="vector-dropdown-content">

		<div class="vector-menu-content">
			
			<ul class="vector-menu-content-list">
				
				<li class="interlanguage-link interwiki-zh mw-list-item"><a href="https://zh.wikipedia.org/wiki/%E7%BE%8E%E5%9C%8B%E8%99%95%E6%96%B9%E8%97%A5%E5%83%B9%E6%A0%BC" title="美國處方藥價格 – Chinese" lang="zh" hreflang="zh" class="interlanguage-link-target"><span>中文</span></a></li>
			</ul>
			<div class="after-portlet after-portlet-lang"><span class="wb-langlinks-edit wb-langlinks-link"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q7240898#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>
		</div>

	</div>
</div>
</header>
				<div class="vector-page-toolbar">
					<div class="vector-page-toolbar-container">
						<div id="left-navigation">
							<nav aria-label="Namespaces">
								
<div id="p-associated-pages" class="vector-menu vector-menu-tabs mw-portlet mw-portlet-associated-pages"  >
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			<li id="ca-nstab-main" class="selected vector-tab-noicon mw-list-item"><a href="/wiki/Prescription_drug_prices_in_the_United_States" title="View the content page [c]" accesskey="c"><span>Article</span></a></li><li id="ca-talk" class="vector-tab-noicon mw-list-item"><a href="/wiki/Talk:Prescription_drug_prices_in_the_United_States" rel="discussion" title="Discuss improvements to the content page [t]" accesskey="t"><span>Talk</span></a></li>
		</ul>
		
	</div>
</div>

								
<div id="p-variants" class="vector-dropdown emptyPortlet"  >
	<input type="checkbox" id="p-variants-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-p-variants" class="vector-dropdown-checkbox " aria-label="Change language variant"   >
	<label id="p-variants-label" for="p-variants-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet" aria-hidden="true"  ><span class="vector-dropdown-label-text">English</span>
	</label>
	<div class="vector-dropdown-content">


					
<div id="p-variants" class="vector-menu mw-portlet mw-portlet-variants emptyPortlet"  >
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			
		</ul>
		
	</div>
</div>

				
	</div>
</div>

							</nav>
						</div>
						<div id="right-navigation" class="vector-collapsible">
							<nav aria-label="Views">
								
<div id="p-views" class="vector-menu vector-menu-tabs mw-portlet mw-portlet-views"  >
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			<li id="ca-view" class="selected vector-tab-noicon mw-list-item"><a href="/wiki/Prescription_drug_prices_in_the_United_States"><span>Read</span></a></li><li id="ca-edit" class="vector-tab-noicon mw-list-item"><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit" title="Edit this page [e]" accesskey="e"><span>Edit</span></a></li><li id="ca-history" class="vector-tab-noicon mw-list-item"><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=history" title="Past revisions of this page [h]" accesskey="h"><span>View history</span></a></li>
		</ul>
		
	</div>
</div>

							</nav>
				
							<nav class="vector-page-tools-landmark" aria-label="Page tools">
								
<div id="vector-page-tools-dropdown" class="vector-dropdown vector-page-tools-dropdown"  >
	<input type="checkbox" id="vector-page-tools-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-page-tools-dropdown" class="vector-dropdown-checkbox "  aria-label="Tools"  >
	<label id="vector-page-tools-dropdown-label" for="vector-page-tools-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet" aria-hidden="true"  ><span class="vector-dropdown-label-text">Tools</span>
	</label>
	<div class="vector-dropdown-content">


									<div id="vector-page-tools-unpinned-container" class="vector-unpinned-container">
						
<div id="vector-page-tools" class="vector-page-tools vector-pinnable-element">
	<div
	class="vector-pinnable-header vector-page-tools-pinnable-header vector-pinnable-header-unpinned"
	data-feature-name="page-tools-pinned"
	data-pinnable-element-id="vector-page-tools"
	data-pinned-container-id="vector-page-tools-pinned-container"
	data-unpinned-container-id="vector-page-tools-unpinned-container"
>
	<div class="vector-pinnable-header-label">Tools</div>
	<button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-page-tools.pin">move to sidebar</button>
	<button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-page-tools.unpin">hide</button>
</div>

	
<div id="p-cactions" class="vector-menu mw-portlet mw-portlet-cactions emptyPortlet vector-has-collapsible-items"  title="More options" >
	<div class="vector-menu-heading">
		Actions
	</div>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			<li id="ca-more-view" class="selected vector-more-collapsible-item mw-list-item"><a href="/wiki/Prescription_drug_prices_in_the_United_States"><span>Read</span></a></li><li id="ca-more-edit" class="vector-more-collapsible-item mw-list-item"><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit" title="Edit this page [e]" accesskey="e"><span>Edit</span></a></li><li id="ca-more-history" class="vector-more-collapsible-item mw-list-item"><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=history"><span>View history</span></a></li>
		</ul>
		
	</div>
</div>

<div id="p-tb" class="vector-menu mw-portlet mw-portlet-tb"  >
	<div class="vector-menu-heading">
		General
	</div>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			<li id="t-whatlinkshere" class="mw-list-item"><a href="/wiki/Special:WhatLinksHere/Prescription_drug_prices_in_the_United_States" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j"><span>What links here</span></a></li><li id="t-recentchangeslinked" class="mw-list-item"><a href="/wiki/Special:RecentChangesLinked/Prescription_drug_prices_in_the_United_States" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k"><span>Related changes</span></a></li><li id="t-upload" class="mw-list-item"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u"><span>Upload file</span></a></li><li id="t-specialpages" class="mw-list-item"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q"><span>Special pages</span></a></li><li id="t-permalink" class="mw-list-item"><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;oldid=1192719002" title="Permanent link to this revision of this page"><span>Permanent link</span></a></li><li id="t-info" class="mw-list-item"><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=info" title="More information about this page"><span>Page information</span></a></li><li id="t-cite" class="mw-list-item"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Prescription_drug_prices_in_the_United_States&amp;id=1192719002&amp;wpFormIdentifier=titleform" title="Information on how to cite this page"><span>Cite this page</span></a></li><li id="t-urlshortener" class="mw-list-item"><a href="/w/index.php?title=Special:UrlShortener&amp;url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FPrescription_drug_prices_in_the_United_States"><span>Get shortened URL</span></a></li><li id="t-urlshortener-qrcode" class="mw-list-item"><a href="/w/index.php?title=Special:QrCode&amp;url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FPrescription_drug_prices_in_the_United_States"><span>Download QR code</span></a></li><li id="t-wikibase" class="mw-list-item"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q7240898" title="Structured data on this page hosted by Wikidata [g]" accesskey="g"><span>Wikidata item</span></a></li>
		</ul>
		
	</div>
</div>

<div id="p-coll-print_export" class="vector-menu mw-portlet mw-portlet-coll-print_export"  >
	<div class="vector-menu-heading">
		Print/export
	</div>
	<div class="vector-menu-content">
		
		<ul class="vector-menu-content-list">
			
			<li id="coll-download-as-rl" class="mw-list-item"><a href="/w/index.php?title=Special:DownloadAsPdf&amp;page=Prescription_drug_prices_in_the_United_States&amp;action=show-download-screen" title="Download this page as a PDF file"><span>Download as PDF</span></a></li><li id="t-print" class="mw-list-item"><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;printable=yes" title="Printable version of this page [p]" accesskey="p"><span>Printable version</span></a></li>
		</ul>
		
	</div>
</div>

</div>

									</div>
				
	</div>
</div>

							</nav>
						</div>
					</div>
				</div>
				<div class="vector-column-end">
					<div class="vector-sticky-pinned-container">
						<nav class="vector-page-tools-landmark" aria-label="Page tools">
							<div id="vector-page-tools-pinned-container" class="vector-pinned-container">
				
							</div>
		</nav>
						<nav class="vector-client-prefs-landmark" aria-label="Appearance">
						</nav>
					</div>
				</div>
				<div id="bodyContent" class="vector-body" aria-labelledby="firstHeading" data-mw-ve-target-container>
					<div class="vector-body-before-content">
							<div class="mw-indicators">
		</div>

						<div id="siteSub" class="noprint">From Wikipedia, the free encyclopedia</div>
					</div>
					<div id="contentSub"><div id="mw-content-subtitle"></div></div>
					
					
					<div id="mw-content-text" class="mw-body-content"><div class="mw-content-ltr mw-parser-output" lang="en" dir="ltr"><div class="shortdescription nomobile noexcerpt noprint searchaux" style="display:none">Overview of the cost of medicines in the United States</div>
<table class="box-Tone plainlinks metadata ambox ambox-style ambox-Tone" role="presentation"><tbody><tr><td class="mbox-image"><div class="mbox-image-div"><span typeof="mw:File"><span><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/40px-Edit-clear.svg.png" decoding="async" width="40" height="40" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/60px-Edit-clear.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/80px-Edit-clear.svg.png 2x" data-file-width="48" data-file-height="48" /></span></span></div></td><td class="mbox-text"><div class="mbox-text-span">This article's <b>tone or style may not reflect the <a href="/wiki/Wikipedia:Writing_better_articles#Tone" title="Wikipedia:Writing better articles">encyclopedic tone</a> used on Wikipedia</b>.<span class="hide-when-compact"> See Wikipedia's <a href="/wiki/Wikipedia:Writing_better_articles#Tone" title="Wikipedia:Writing better articles">guide to writing better articles</a> for suggestions.</span>  <span class="date-container"><i>(<span class="date">January 2020</span>)</i></span><span class="hide-when-compact"><i> (<small><a href="/wiki/Help:Maintenance_template_removal" title="Help:Maintenance template removal">Learn how and when to remove this template message</a></small>)</i></span></div></td></tr></tbody></table>
<p><b>Prescription drug list prices in the United States</b> continually are among the highest in the world.<sup id="cite_ref-1" class="reference"><a href="#cite_note-1">&#91;1&#93;</a></sup><sup id="cite_ref-:15_2-0" class="reference"><a href="#cite_note-:15-2">&#91;2&#93;</a></sup> The high <a href="/wiki/Prescription_costs" class="mw-redirect" title="Prescription costs">cost of prescription drugs</a> became a major topic of discussion in the 21st century, leading up to the <a href="/wiki/U.S._health_care_reform" class="mw-redirect" title="U.S. health care reform">American health care reform</a> debate of 2009, and received renewed attention in 2015. One major reason for high <a href="/wiki/Prescription_drug_prices" class="mw-redirect" title="Prescription drug prices">prescription drug prices</a> in the <a href="/wiki/United_States" title="United States">United States</a> relative to other countries is the inability of <a href="/wiki/Government-granted_monopoly" title="Government-granted monopoly">government-granted monopolies</a> in the American health care sector to use their bargaining power to negotiate lower prices, and the American payer ends up subsidizing the world's R&amp;D spending on drugs.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3">&#91;3&#93;</a></sup><sup id="cite_ref-4" class="reference"><a href="#cite_note-4">&#91;4&#93;</a></sup><sup id="cite_ref-5" class="reference"><a href="#cite_note-5">&#91;5&#93;</a></sup>
</p><p>According to a comprehensive 2021 review of the existing literature, the United States had higher prescription drug prices than all 32 comparison countries.<sup id="cite_ref-:15_2-1" class="reference"><a href="#cite_note-:15-2">&#91;2&#93;</a></sup> The United States had 256% higher prescription drug prices than the comparison countries.<sup id="cite_ref-:15_2-2" class="reference"><a href="#cite_note-:15-2">&#91;2&#93;</a></sup>
</p>
<meta property="mw:PageProp/toc" />
<h2><span class="mw-headline" id="History">History</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=1" title="Edit section: History"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h2>
<p><a href="/wiki/Pharmaceutical_drugs" class="mw-redirect" title="Pharmaceutical drugs">Pharmaceutical drugs</a> are the only major health care service in which the producer is able to set prices with little constraint, according to <a href="/wiki/Peter_Bach" title="Peter Bach">Peter Bach</a> from the Health Outcomes Research Group, <a href="/wiki/Memorial_Sloan_Kettering_Cancer_Center" title="Memorial Sloan Kettering Cancer Center">Memorial Sloan Kettering Cancer Center</a>, New York and Steven Pearson from the Institute for Clinical and Economic Review, Boston.<sup id="cite_ref-JAMA2_6-0" class="reference"><a href="#cite_note-JAMA2-6">&#91;6&#93;</a></sup> As of 2004<sup class="plainlinks noexcerpt noprint asof-tag update" style="display:none;"><a class="external text" href="https://en.wikipedia.org/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit">&#91;update&#93;</a></sup>, prices of brand name drugs were significantly higher in the United States (US) than in Canada, India, the UK and other countries, nearly all of which have <a href="/wiki/Price_controls" title="Price controls">price controls</a>, while prices for <a href="/wiki/Generic_drug" title="Generic drug">generic drugs</a> tended to be higher in Canada.<sup id="cite_ref-morgan_7-0" class="reference"><a href="#cite_note-morgan-7">&#91;7&#93;</a></sup>
</p><p>In 2003, a Republican-majority Congress created <a href="/wiki/Medicare_Part_D" title="Medicare Part D">Medicare Part D</a> with the <a href="/wiki/Medicare_Prescription_Drug,_Improvement,_and_Modernization_Act" title="Medicare Prescription Drug, Improvement, and Modernization Act">Medicare Prescription Drug, Improvement, and Modernization Act</a>, which prevented Medicare, the country's largest single-payer health care system, from negotiating drug prices. In effect, drug manufacturers in the US were allowed to set their own prices resulting in the unregulated pricing variation for prescription drugs.<sup id="cite_ref-:5_8-0" class="reference"><a href="#cite_note-:5-8">&#91;8&#93;</a></sup> However, the government does employ drug pricing strategies for other smaller government health programs like the <a href="/wiki/Veterans_Health_Administration" title="Veterans Health Administration">Veterans Health Administration</a>, the <a href="/wiki/United_States_Department_of_Defense" title="United States Department of Defense">Department of Defense</a>, the <a href="/wiki/340B_Drug_Pricing_Program" title="340B Drug Pricing Program">340B Drug Pricing Program</a> (1992), and <a href="/wiki/Medicaid" title="Medicaid">Medicaid</a>.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9">&#91;9&#93;</a></sup>
</p><p>In 2005, the <a href="/wiki/Government_Accountability_Office" title="Government Accountability Office">Government Accountability Office</a> (GAO) examined the change in US drug <a href="/wiki/Retail_price" class="mw-redirect" title="Retail price">retail prices</a> from January 2000 through December 2004 and found the average <a href="/wiki/Usual,_customary_and_reasonable" title="Usual, customary and reasonable">usual and customary</a> (U&amp;C) prices for a 30-day supply of 96 drugs frequently used by people enrolled in <a href="/wiki/BlueCross_BlueShield" class="mw-redirect" title="BlueCross BlueShield">BlueCross BlueShield</a> Federal Employee Programs had increased 24.5%. The average U&amp;C prices for brand prescription drugs increased three times as much as the average for generic drug.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10">&#91;10&#93;</a></sup>
</p><p>In 2007, the <a href="/wiki/AARP" title="AARP">AARP</a> published a series of studies showing that <a href="/wiki/Prescription_drug_prices" class="mw-redirect" title="Prescription drug prices">prescription drug prices</a> have been rising significantly faster than general inflation.<sup id="cite_ref-11" class="reference"><a href="#cite_note-11">&#91;11&#93;</a></sup> The <a href="/wiki/American_Enterprise_Institute" title="American Enterprise Institute">American Enterprise Institute</a>, a conservative <a href="/wiki/Think_tank" title="Think tank">think tank</a>, criticized the methodology as overstating drug price inflation.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12">&#91;12&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Attempts_to_repeal_negotiation_ban">Attempts to repeal negotiation ban</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=2" title="Edit section: Attempts to repeal negotiation ban"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>A February 2019 poll found 86% of Americans in favor of allowing Medicare to negotiate drug prices.<sup id="cite_ref-13" class="reference"><a href="#cite_note-13">&#91;13&#93;</a></sup> A similar survey published in June 2021 found support at 81%, including 67% of Republicans and 97% of Democrats.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14">&#91;14&#93;</a></sup>
</p><p>Twice, a Democrat-controlled House of Representatives passed a repeal of the negotiation ban, but the bill was killed in a Republican-controlled Senate: the <a href="/wiki/Medicare_Prescription_Drug_Price_Negotiation_Act_of_2007" class="mw-redirect" title="Medicare Prescription Drug Price Negotiation Act of 2007">Medicare Prescription Drug Price Negotiation Act of 2007</a>, and the 2019 <a href="/wiki/Elijah_Cummings_Lower_Drug_Costs_Now_Act" title="Elijah Cummings Lower Drug Costs Now Act">Elijah Cummings Lower Drug Costs Now Act</a> (H.R. 3).
</p><p>The Elijah Cummings Lower Drug Costs Now Act was reintroduced in 2021, with Democrats in control of the House, Senate, and Presidency. President Biden supports a repeal of the negotiation ban, but did not include it in his <a href="/wiki/American_Families_Plan" class="mw-redirect" title="American Families Plan">American Families Plan</a>, leading other Democrats to push for it to be added.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">&#91;15&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Affordable_Care_Act">Affordable Care Act</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=3" title="Edit section: Affordable Care Act"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In 2010, the <a href="/wiki/Patient_Protection_and_Affordable_Care_Act" class="mw-redirect" title="Patient Protection and Affordable Care Act">Patient Protection and Affordable Care Act</a>, commonly known as Obamacare or the Affordable Care Act, was created. The goal was to increase the number of people who had healthcare in the United States and reduce the impact that individual healthcare spending had on households, especially since many Americans had lost their health insurance coverage in the <a href="/wiki/Great_Recession" title="Great Recession">Great Recession</a>. Of its many provisions, two aim to reduce the burden of prescription drugs, both relating to the <a href="/wiki/Medicare_Part_D_coverage_gap" title="Medicare Part D coverage gap">Medicare Part D coverage gap</a>. Under 2016 Medicare coverage, people paid the deductible until they reached the limit of $3,310. They then entered the coverage gap where they paid about half the total cost for the drug. Once the yearly <a href="/wiki/Out-of-pocket_expenses" class="mw-redirect" title="Out-of-pocket expenses">out-of-pocket expenses</a> reached $4,850, catastrophic coverage phase begins and the person only pays a very small amount for continued medication.<sup id="cite_ref-16" class="reference"><a href="#cite_note-16">&#91;16&#93;</a></sup> In 2010, the first provision enacted immediately, was a one-year, $250 rebate to those people in the coverage gap to help pay for their medication. The second provision, enacted in January 2011, created a 50% discount on <a href="/wiki/Brand-name" class="mw-redirect" title="Brand-name">brand-name</a> prescription drugs for seniors within the coverage gap. Subsidies were to be provided until 2020,<sup id="cite_ref-17" class="reference"><a href="#cite_note-17">&#91;17&#93;</a></sup> when the coverage gap was closed as of January 1, 2020.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18">&#91;18&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Generic_price_spikes">Generic price spikes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=4" title="Edit section: Generic price spikes"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>A December 2015 <i>New York Times</i> editorial opined that "drug prices have been pushed to astronomical heights for no reason other than the desire of drug makers to maximize profits", pointing in particular to strategies by <a href="/wiki/Turing_Pharmaceuticals" class="mw-redirect" title="Turing Pharmaceuticals">Turing Pharmaceuticals</a> and <a href="/wiki/Valeant_Pharmaceuticals" class="mw-redirect" title="Valeant Pharmaceuticals">Valeant Pharmaceuticals</a> for rights to make and sell generic drugs which had administrative exclusivity<sup class="noprint Inline-Template" style="white-space:nowrap;">&#91;<i><a href="/wiki/Wikipedia:Please_clarify" title="Wikipedia:Please clarify"><span title="The text near this tag needs further explanation. (July 2017)">further explanation needed</span></a></i>&#93;</sup> and then raise the prices dramatically, which were widely condemned in- and outside the pharmaceutical industry.<sup id="cite_ref-NYT-20151219_19-0" class="reference"><a href="#cite_note-NYT-20151219-19">&#91;19&#93;</a></sup> In response, the Department of Health and Human Services and both houses of Congress held a public meeting and hearings respectively to investigate <a href="/wiki/Price_gouging" title="Price gouging">price gouging</a>.<sup id="cite_ref-20" class="reference"><a href="#cite_note-20">&#91;20&#93;</a></sup> In April 2017, Maryland attempted to become the first state to grant the state attorney general the authority to sue drug companies for dramatically increasing drug prices.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21">&#91;21&#93;</a></sup> In April 2018, a divided panel of the <a href="/wiki/United_States_Court_of_Appeals_for_the_Fourth_Circuit" title="United States Court of Appeals for the Fourth Circuit">United States Court of Appeals for the Fourth Circuit</a> found that the Maryland law violated the <a href="/wiki/Dormant_Commerce_Clause" title="Dormant Commerce Clause">Dormant Commerce Clause</a> of the <a href="/wiki/United_States_Constitution" class="mw-redirect" title="United States Constitution">United States Constitution</a>.<sup id="cite_ref-22" class="reference"><a href="#cite_note-22">&#91;22&#93;</a></sup><sup id="cite_ref-23" class="reference"><a href="#cite_note-23">&#91;23&#93;</a></sup>
</p><p>Examples of affected medications include <a href="/wiki/Epinephrine_autoinjector" title="Epinephrine autoinjector">epinephrine auto-injectors</a> and <a href="/wiki/Insulin" title="Insulin">insulin</a>.<sup id="cite_ref-24" class="reference"><a href="#cite_note-24">&#91;24&#93;</a></sup> Between 2011 and 2016, <a href="/wiki/Mylan" title="Mylan">Mylan</a> was the only competitor on the market and raised the price of <a href="/wiki/EpiPen" class="mw-redirect" title="EpiPen">EpiPen</a> by almost 400%, and consumers who were forced to pay the cash prices paid reported amounts of $600 or more for a two pack of EpiPen auto-injectors.<sup id="cite_ref-goodrx.com_25-0" class="reference"><a href="#cite_note-goodrx.com-25">&#91;25&#93;</a></sup> Due to public outcry and demand, <a href="/wiki/Mylan" title="Mylan">Mylan</a> and <a href="/wiki/Teva_Pharmaceuticals" title="Teva Pharmaceuticals">Teva Pharmaceuticals</a> later announced their releases of generics for EpiPen. However prices are still high for patients who need to pay cash price. The cash price of generic epinephrine still averages around $350 for a two pack of auto-injectors, and if a patient's insurance does not cover generic epinephrine they may need their primary physician to submit an appeal letter to their insurance on their behalf.<sup id="cite_ref-goodrx.com_25-1" class="reference"><a href="#cite_note-goodrx.com-25">&#91;25&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Trump_Executive_Orders">Trump Executive Orders</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=5" title="Edit section: Trump Executive Orders"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<figure class="mw-default-size mw-halign-left" typeof="mw:File/Thumb"><a href="/wiki/File:President_Trump_Signs_Executive_Orders_on_Lowering_Drug_Prices_(50159001106).jpg" class="mw-file-description"><img src="//upload.wikimedia.org/wikipedia/commons/thumb/f/f1/President_Trump_Signs_Executive_Orders_on_Lowering_Drug_Prices_%2850159001106%29.jpg/220px-President_Trump_Signs_Executive_Orders_on_Lowering_Drug_Prices_%2850159001106%29.jpg" decoding="async" width="220" height="147" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/f1/President_Trump_Signs_Executive_Orders_on_Lowering_Drug_Prices_%2850159001106%29.jpg/330px-President_Trump_Signs_Executive_Orders_on_Lowering_Drug_Prices_%2850159001106%29.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/f1/President_Trump_Signs_Executive_Orders_on_Lowering_Drug_Prices_%2850159001106%29.jpg/440px-President_Trump_Signs_Executive_Orders_on_Lowering_Drug_Prices_%2850159001106%29.jpg 2x" data-file-width="2400" data-file-height="1600" /></a><figcaption>President Trump signs executive orders on lowering drug prices.</figcaption></figure>
<p>In July 2020, <a href="/wiki/POTUS" class="mw-redirect" title="POTUS">President</a> <a href="/wiki/Donald_Trump" title="Donald Trump">Donald Trump</a> signed four executive orders designed to reduce drug costs. One order permitted certain medications be imported in from <a href="/wiki/Canada" title="Canada">Canada</a> and another order changed the way how discounts for prescription drugs can be negotiated for <a href="/wiki/Medicare_(United_States)" title="Medicare (United States)">Medicare</a> patients. The most radical order mandated Medicare to sell certain medications at the same price in foreign countries. However, this order may not go into effect as the Trump administration plans on negotiating with pharmaceutical companies. Despite the orders, health policy experts have claimed that they will have little or no impact on easing prescription drug costs for patients as they require implementation from the <a href="/wiki/Department_of_Health_and_Human_Services" class="mw-redirect" title="Department of Health and Human Services">Department of Health and Human Services</a> and that is very likely that lawsuits will be filed to stop the order.<sup id="cite_ref-26" class="reference"><a href="#cite_note-26">&#91;26&#93;</a></sup><sup id="cite_ref-27" class="reference"><a href="#cite_note-27">&#91;27&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Drug_expenditures">Drug expenditures</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=6" title="Edit section: Drug expenditures"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Spending on pharmaceuticals can be defined as <a href="/wiki/Expenditure" class="mw-redirect" title="Expenditure">expenditure</a> on prescription medicines and over-the-counter products, excluding pharmaceuticals consumed in hospitals,<sup id="cite_ref-oecd_28-0" class="reference"><a href="#cite_note-oecd-28">&#91;28&#93;</a></sup> This has been mentioned together with drug prices, but is not the same.
</p><p>In 1960, spending on pharmaceuticals accounted for 11.5% of U.S. national healthcare expenses, gradually falling to a low of 5.5% in 1980, before rising back up to 10.4% in 2000 and between 2000 and 2013, it ranged between 10% and 12%.<sup id="cite_ref-29" class="reference"><a href="#cite_note-29">&#91;29&#93;</a></sup>
</p><p>In 2010, prescription drug expenses were 10% of the $2.6 trillion of total <a href="/wiki/Health_care_finance_in_the_United_States" title="Health care finance in the United States">health care spending</a> in the US, and its third largest portion after hospital spending and physician and clinical services.<sup id="cite_ref-30" class="reference"><a href="#cite_note-30">&#91;30&#93;</a></sup>
</p><p>As of 2013, US "pharmaceutical spending", excluding hospital pharmaceutical spending, was $1,034 per capita in the <a href="/wiki/OECD" title="OECD">OECD</a>'s international comparisons.<sup id="cite_ref-oecd_28-1" class="reference"><a href="#cite_note-oecd-28">&#91;28&#93;</a></sup> In 2006, data from the <a href="/wiki/Medical_Expenditure_Panel_Survey" title="Medical Expenditure Panel Survey">Medical Expenditure Panel Survey</a> was analyzed to determine the costs of healthcare for American households. It showed that 19.1% of Americans were considered to have a financial burden due to healthcare spending as they spent more than 10% of their income on it.<sup id="cite_ref-31" class="reference"><a href="#cite_note-31">&#91;31&#93;</a></sup>
</p><p>In 2003, data from the <a href="/wiki/Medical_Expenditure_Panel_Survey" title="Medical Expenditure Panel Survey">Medical Expenditure Panel Survey</a> showed that only 9.5% of Americans with <a href="/wiki/Medicare_(United_States)" title="Medicare (United States)">Medicare</a> coverage had no prescription drug expenses, while 61.6% had prescription drug expenses up to $2,083, and 28.9% of those on Medicare had expenses higher than $2,084.<sup id="cite_ref-:1_32-0" class="reference"><a href="#cite_note-:1-32">&#91;32&#93;</a></sup> low income families tended to have higher prescription drug expenses during the year: 18.9% of poor households paid more than $4,724 compared to 13.2% and 12.5% who had prescription drug expenses between $2,084–$4,723 and $1–2,083, respectively.<sup id="cite_ref-:1_32-1" class="reference"><a href="#cite_note-:1-32">&#91;32&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Specialty_pharmaceuticals_in_the_US">Specialty pharmaceuticals in the US</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=7" title="Edit section: Specialty pharmaceuticals in the US"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3><p>
Prescription drugs known as "specialty" drugs have become integral to the treatment of certain complex diseases including certain cancers and <a href="/wiki/Autoimmune_disease" title="Autoimmune disease">autoimmune diseases</a>. Additionally, some notoriously treatment-resistant infectious diseases such as HIV and hepatitis C have now become manageable (and the latter curable) using so-called "specialty pharmaceuticals". "<a href="/wiki/Specialty_drugs_in_the_United_States" title="Specialty drugs in the United States">Specialty pharmaceuticals</a>" are generally classified as such by possessing one or more of the following characteristics: high cost, high complexity, or <a href="/wiki/High-touch" title="High-touch">high touch</a> (i.e. requiring special monitoring, follow-up, or administration technique or assistance).<sup id="cite_ref-33" class="reference"><a href="#cite_note-33">&#91;33&#93;</a></sup> The number of specialty pharmaceuticals has increased dramatically since 1990 when only ten were available; by 2015, 300 specialty products were available with more than 700 in development (Pew 2016).<sup id="cite_ref-:03_34-0" class="reference"><a href="#cite_note-:03-34">&#91;34&#93;</a></sup> The high costs of specialty pharmaceuticals, in addition to the generally high costs of <a href="/wiki/Prescription_drug" title="Prescription drug">prescription drugs</a> in the United States, have generated a great deal of debate. It is becoming increasingly difficult, at both the individual and societal level, to afford to pay for such medications, as the use of specialty pharmaceuticals continues to increase along with their cost, which had, through 2015, risen faster than inflation for many consecutive years (AARP 2015).<sup id="cite_ref-35" class="reference"><a href="#cite_note-35">&#91;35&#93;</a></sup><sup id="cite_ref-36" class="reference"><a href="#cite_note-36">&#91;36&#93;</a></sup> In 2015, 1-2% of the US population used specialty drugs, but these drugs represented 38% of drug expenditures for that year.<sup id="cite_ref-:03_34-1" class="reference"><a href="#cite_note-:03-34">&#91;34&#93;</a></sup> A path forward must be found that provides specialty drugs to those who need them in an affordable, sustainable manner. A recent policy change by the Centers for Medicare and Medicaid Services will allow Medicare Advantage Plans to utilize formulary management tools used in commercial plans, such as step therapy requirements, in order to manage drug costs, including specialty pharmaceuticals.<sup id="cite_ref-37" class="reference"><a href="#cite_note-37">&#91;37&#93;</a></sup>  Chambers et al. may have identified one path to identifying the value of Specialty Pharmaceuticals using cost-effectiveness analysis:<sup id="cite_ref-38" class="reference"><a href="#cite_note-38">&#91;38&#93;</a></sup></p><blockquote><p>Conducting cost-effectiveness analyses may be desirable to convey the value of a medication relative to a previous standard of care. Even if a new therapy is expensive, its incremental cost-effectiveness may be within a willingness-to-pay threshold, as specialty drugs, though more expensive, often are also associated with the greatest gains in QALYs.</p></blockquote>
<h2><span class="mw-headline" id="Effects">Effects</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=8" title="Edit section: Effects"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h2>
<figure class="mw-default-size" typeof="mw:File/Thumb"><span><video id="mwe_player_0" poster="//upload.wikimedia.org/wikipedia/commons/thumb/5/55/Skipping_Drugs_She_Can%27t_Afford.webm/220px--Skipping_Drugs_She_Can%27t_Afford.webm.jpg" controls="" preload="none" class="mw-file-element" width="220" height="124" data-durationhint="175" data-mwtitle="Skipping_Drugs_She_Can&#39;t_Afford.webm" data-mwprovider="wikimediacommons" resource="/wiki/File:Skipping_Drugs_She_Can%27t_Afford.webm"><source src="//upload.wikimedia.org/wikipedia/commons/transcoded/5/55/Skipping_Drugs_She_Can%27t_Afford.webm/Skipping_Drugs_She_Can%27t_Afford.webm.480p.vp9.webm" type="video/webm; codecs=&quot;vp9, opus&quot;" data-transcodekey="480p.vp9.webm" data-width="854" data-height="480" /><source src="//upload.wikimedia.org/wikipedia/commons/transcoded/5/55/Skipping_Drugs_She_Can%27t_Afford.webm/Skipping_Drugs_She_Can%27t_Afford.webm.720p.vp9.webm" type="video/webm; codecs=&quot;vp9, opus&quot;" data-transcodekey="720p.vp9.webm" data-width="1280" data-height="720" /><source src="//upload.wikimedia.org/wikipedia/commons/5/55/Skipping_Drugs_She_Can%27t_Afford.webm" type="video/webm; codecs=&quot;vp9, opus&quot;" data-width="1920" data-height="1080" /><source src="//upload.wikimedia.org/wikipedia/commons/transcoded/5/55/Skipping_Drugs_She_Can%27t_Afford.webm/Skipping_Drugs_She_Can%27t_Afford.webm.1080p.vp9.webm" type="video/webm; codecs=&quot;vp9, opus&quot;" data-transcodekey="1080p.vp9.webm" data-width="1920" data-height="1080" /><source src="//upload.wikimedia.org/wikipedia/commons/transcoded/5/55/Skipping_Drugs_She_Can%27t_Afford.webm/Skipping_Drugs_She_Can%27t_Afford.webm.m3u8" type="application/vnd.apple.mpegurl" data-transcodekey="m3u8" data-width="0" data-height="0" /><source src="//upload.wikimedia.org/wikipedia/commons/transcoded/5/55/Skipping_Drugs_She_Can%27t_Afford.webm/Skipping_Drugs_She_Can%27t_Afford.webm.240p.vp9.webm" type="video/webm; codecs=&quot;vp9, opus&quot;" data-transcodekey="240p.vp9.webm" data-width="426" data-height="240" /><source src="//upload.wikimedia.org/wikipedia/commons/transcoded/5/55/Skipping_Drugs_She_Can%27t_Afford.webm/Skipping_Drugs_She_Can%27t_Afford.webm.360p.vp9.webm" type="video/webm; codecs=&quot;vp9, opus&quot;" data-transcodekey="360p.vp9.webm" data-width="640" data-height="360" /><source src="//upload.wikimedia.org/wikipedia/commons/transcoded/5/55/Skipping_Drugs_She_Can%27t_Afford.webm/Skipping_Drugs_She_Can%27t_Afford.webm.360p.webm" type="video/webm; codecs=&quot;vp8, vorbis&quot;" data-transcodekey="360p.webm" data-width="640" data-height="360" /><track src="https://commons.wikimedia.org/w/api.php?action=timedtext&amp;title=File%3ASkipping_Drugs_She_Can%27t_Afford.webm&amp;lang=en&amp;trackformat=vtt&amp;origin=%2A" kind="subtitles" type="text/vtt" srclang="en" label="English ‪(en)‬" data-dir="ltr" /></video></span><figcaption>High prices for vital drugs often have deleterious effects for people who have low income.</figcaption></figure>
<p>In 2006, data from the <a href="/wiki/Medical_Expenditure_Panel_Survey" title="Medical Expenditure Panel Survey">Medical Expenditure Panel Survey</a> was analyzed to determine the costs of healthcare for American households. It showed that 19.1% of Americans spent more than 10% of their income on healthcare related expenses. Those Americans were considered to have a financial burden due to their healthcare spending.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39">&#91;39&#93;</a></sup> One example is from a study done in 2018 from the <a href="/wiki/American_Diabetes_Association" title="American Diabetes Association">American Diabetes Association</a> that stated that the cost of insulin devices at a pharmacy can be almost $200 less than at the listed prices by analogs.<sup id="cite_ref-40" class="reference"><a href="#cite_note-40">&#91;40&#93;</a></sup> A November 2020 study by the <a href="/wiki/West_Health" title="West Health">West Health</a> Policy Center stated that more than 1.1 million <a href="/wiki/Senior_citizens" class="mw-redirect" title="Senior citizens">senior citizens</a> in the U.S. <a href="/wiki/Medicare_(United_States)" title="Medicare (United States)">Medicare</a> program are expected to die prematurely over the next decade because they will be unable to afford their prescription medications, requiring an additional $17.7 billion to be spent annually on avoidable medical costs due to health complications.<sup id="cite_ref-41" class="reference"><a href="#cite_note-41">&#91;41&#93;</a></sup> The high cost of prescription drugs has required many Americans to use cost-cutting measures and has also led to reformed healthcare legislation.
</p>
<h3><span class="mw-headline" id="Prescription_non-compliance_and_health_effects">Prescription non-compliance and health effects</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=9" title="Edit section: Prescription non-compliance and health effects"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Another common way that people saved money, was to skip or reduce dosages or fail to fill a prescription entirely due to cost restrictions.
</p><p>One study reported that U.S. consumers pay prescription drug prices anywhere from 4 to 10 times more than other countries, even if they are more advanced or industrialized, and that prescription drug prices have increased twice as much as the inflation rate over the last 12 years.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42">&#91;42&#93;</a></sup> A quarter of Americans taking prescription drugs said in June 2015, they had not filled a prescription in the past 12 months due to cost, and 18 percent reported they "cut pills in half or skipped doses" according to a <a href="/wiki/Kaiser_Family_Foundation" title="Kaiser Family Foundation">Kaiser Family Foundation</a> survey.<sup id="cite_ref-43" class="reference"><a href="#cite_note-43">&#91;43&#93;</a></sup> A 2015 survey by the National Center for Health Statistics found that 8% of Americans did not take their medications as prescribed to save money.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44">&#91;44&#93;</a></sup> Similar studies, done ten years prior, found numbers very similar to the 2015 numbers from the Kasier Family Foundation survey. In 2007, it was estimated that 23.1% of Americans (51 million) had not adhered to their prescription instructions due to the cost of prescription drugs. This is compared to only 8% of Canadians who skipped doses or failed to fill a prescription in the same year because of the cost of prescription medications.<sup id="cite_ref-:2_45-0" class="reference"><a href="#cite_note-:2-45">&#91;45&#93;</a></sup> The number of Americans who reported cost-related non-adherence to their prescriptions was more than double the number of Canadians. The factors that contributed to whether or not a person was more likely to not follow their prescribed medication instructions were age, the number of checkups with a physician, ongoing health problems, income, and insurance coverage.<sup id="cite_ref-:2_45-1" class="reference"><a href="#cite_note-:2-45">&#91;45&#93;</a></sup><sup id="cite_ref-:3_46-0" class="reference"><a href="#cite_note-:3-46">&#91;46&#93;</a></sup> For example, adults between the ages of 18 and 35 were more likely to skip doses or fail to fill a prescription than those 75 years of age or older.<sup id="cite_ref-:3_46-1" class="reference"><a href="#cite_note-:3-46">&#91;46&#93;</a></sup> Those with fewer visits to a physician and those with chronic illnesses or disabilities were also more likely to report noncompliance. The reason for those with ongoing illness or disabilities to skip doses is likely due to the increased complexity and the higher prices of the drugs needed.<sup id="cite_ref-:3_46-2" class="reference"><a href="#cite_note-:3-46">&#91;46&#93;</a></sup> Income and insurance coverage were also major factors determining whether or not a patient would take their medication in the correct doses for the correct duration of time. Those who lacked insurance coverage or were in low-income brackets had very high rates of non-compliance with their medication, even though the United States has drug coverage policies for those with low incomes.<sup id="cite_ref-:3_46-3" class="reference"><a href="#cite_note-:3-46">&#91;46&#93;</a></sup> Those whose healthcare spending is more than 10% of their income and causes a financial burden to the patient, are considered uninsured, whether they actually have health insurance or not.<sup id="cite_ref-:2_45-2" class="reference"><a href="#cite_note-:2-45">&#91;45&#93;</a></sup>
</p><p>One way to examine the potential impact of high drug prices on health outcomes is to look at the effects of having prescription drug insurance and subsequent hospitalizations. Studies have linked obtaining prescription insurance plans to fewer hospitalizations and lower healthcare costs.<sup id="cite_ref-47" class="reference"><a href="#cite_note-47">&#91;47&#93;</a></sup><sup id="cite_ref-48" class="reference"><a href="#cite_note-48">&#91;48&#93;</a></sup> For example, for Medicare beneficiaries between 2002 and 2010, obtaining prescription drug insurance through Medicare Part D was associated with an 8% decrease in the number of hospital admissions, a 7% decrease in Medicare expenditures, and a 12% decrease in total resource use.<sup id="cite_ref-49" class="reference"><a href="#cite_note-49">&#91;49&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Prescriptions_from_other_countries">Prescriptions from other countries</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=10" title="Edit section: Prescriptions from other countries"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Consumer_import_of_prescription_drugs" title="Consumer import of prescription drugs">Consumer import of prescription drugs</a></div>
<p>The <i>Washington Post</i> wrote in 2003 that "<a href="/wiki/U.S._Customs_and_Border_Protection" title="U.S. Customs and Border Protection">U.S. Customs</a> estimated 10 million U.S. citizens brought in medications at land borders each year. An additional 2 million packages of pharmaceuticals arrive annually by international mail from Thailand, India, South Africa and other points".<sup id="cite_ref-50" class="reference"><a href="#cite_note-50">&#91;50&#93;</a></sup> Prescription drugs also entered the country in large quantities through Canada because of the price differential of prescription drugs in the two countries. In 2004, it was estimated that Americans purchased more than $1 billion in US dollars in brand-name drugs per year from Canadian pharmacies to save money.<sup id="cite_ref-51" class="reference"><a href="#cite_note-51">&#91;51&#93;</a></sup>
The United States has some of the highest prices for specialty drugs compared to other developed countries. Within the year of 2014, the cost of prescriptions had increased by at least 11.4% and 58% within the last eight years. The average cost for a month supply of brand-name drugs can run up to a couple of hundred US dollars, whereas in Canada and Great Britain the same medication could cost up to $40 US dollars. In most cases, patients pay less for more.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52">&#91;52&#93;</a></sup>
</p><p>In some cases, U.S. insurance companies will pay consumers of high-cost drugs to personally travel to Mexico to buy the same drugs at a much lower cost there.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53">&#91;53&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Reasons_for_high_prices">Reasons for high prices</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=11" title="Edit section: Reasons for high prices"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Variability_and_non-transparency">Variability and non-transparency</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=12" title="Edit section: Variability and non-transparency"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The price of a pharmaceutical drug can depend on many factors: <a href="/wiki/List_price" title="List price">list price</a>, <a href="/wiki/Wholesale_price" class="mw-redirect" title="Wholesale price">wholesale price</a>, <a href="/wiki/Average_wholesale_price_(pharmaceuticals)" class="mw-redirect" title="Average wholesale price (pharmaceuticals)">average wholesale price (pharmaceuticals)</a>, rebates, supplemental rebates, <a href="/wiki/Markup_(business)" title="Markup (business)">markups</a> from hospitals, markups for physicians, drug price for inpatients versus outpatients, <a href="/wiki/Formulary_(pharmacy)" title="Formulary (pharmacy)">formulary (pharmacy)</a> tiers, mail order price, <a href="/wiki/Biosimilar" title="Biosimilar">biosimilar</a> prices, "patent expirations, compounds, samples, and many other ways that end up obscuring the reality of the price paid, who pays it, and how all of it influences treatment decisions."<sup id="cite_ref-lancet15_54-0" class="reference"><a href="#cite_note-lancet15-54">&#91;54&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Market_exclusivity">Market exclusivity</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=13" title="Edit section: Market exclusivity"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In a market without price controls, competition is key to driving the price of drug products down. However, legal protection in the form of patents results in a government-approved monopoly on the sale of certain drugs. Typically, patents allow for market exclusivity for a maximum period of 20 years after patent approval.<sup id="cite_ref-:4_55-0" class="reference"><a href="#cite_note-:4-55">&#91;55&#93;</a></sup> However, given that FDA approval of a drug can take anywhere from 10 to 12 years, pharmaceutical companies can be granted a patent extension that is valid for a maximum of 14 years after FDA approval of the drug.<sup id="cite_ref-:4_55-1" class="reference"><a href="#cite_note-:4-55">&#91;55&#93;</a></sup>
</p><p>But even as the patent term nears expiration, pharmaceutical manufacturers employ several strategies to delay the entry of generic drugs to market. This could include by obtaining additional patents on other aspects of a drug, such as "its coating, salt moiety, formulation, and method of administration".<sup id="cite_ref-:5_8-1" class="reference"><a href="#cite_note-:5-8">&#91;8&#93;</a></sup> An example of this strategy is the company AstraZeneca PLC ("AstraZeneca") obtaining a patent on the <a href="/wiki/Enantiomer" title="Enantiomer">enantiomer</a> of omeprazole (Prilosec), a heartburn medication. The patent was obtained without significant evidence of the enantiomer's improved efficacy. As a result, AstraZeneca was able to sell its rebranded product esomeprazole (Nexium) at a 600% markup.<sup id="cite_ref-:5_8-2" class="reference"><a href="#cite_note-:5-8">&#91;8&#93;</a></sup>
</p><p>Pharmaceutical companies have also employed the "pay-to-delay" strategy in which they enter into reverse payment agreements with generic companies to delay the generic drug's manufacturer.<sup id="cite_ref-:6_56-0" class="reference"><a href="#cite_note-:6-56">&#91;56&#93;</a></sup> This was the case in 2008, when an agreement between AstraZeneca and <a href="/wiki/Ranbaxy_Laboratories" title="Ranbaxy Laboratories">Ranbaxy Laboratories</a> Ltd. ("Ranbaxy") was reached to delay Ranbaxy's launch of a generic version of <a href="/wiki/AstraZeneca" title="AstraZeneca">AstraZeneca's</a> patented heartburn drug Nexium until 2014.<sup id="cite_ref-:6_56-1" class="reference"><a href="#cite_note-:6-56">&#91;56&#93;</a></sup>
</p><p>Drug companies have also increased the pricing of the drugs during this period of market exclusivity. One study found that oral anticancer drugs introduced in 2014 were six times more expensive at launch, when adjusted for inflation, than drugs introduced in 2010.<sup id="cite_ref-57" class="reference"><a href="#cite_note-57">&#91;57&#93;</a></sup> Once these new drugs are introduced during this period of market exclusivity, these manufactures use patent protection and other exclusivity programs to continue to raise the price of the drug from year to year even though there are no significant improvements to the drug. Between 2014 and 2015 alone over 260 brand name prescription drugs increased in price by an average of 15.5 percent which is 130 times the rate of general inflation.<sup id="cite_ref-58" class="reference"><a href="#cite_note-58">&#91;58&#93;</a></sup> This system creates a natural monopoly for the drug companies meaning that they can drive the price up without facing any punishment from the federal government.
</p><p>Generic drugs typically lower the prices of these brand name drugs as they become direct competitors, however, over 500 drugs have only one marketed generic drug.<sup id="cite_ref-59" class="reference"><a href="#cite_note-59">&#91;59&#93;</a></sup> This is simply not enough competition to drive the price down. The producers of the brand-name drugs have also been known to block the would be producers of the generic drugs from getting the drug samples they would need to be able to conduct bioequivalence studies, which are key to developing new generic drugs. There has also been a drastic increase in the amount of mergers and acquisitions among manufacturers, this leads to much smaller and less competitive markets. For instance, Valeant Pharmaceuticals bought over 100 different companies between 2008 and 2015.<sup id="cite_ref-60" class="reference"><a href="#cite_note-60">&#91;60&#93;</a></sup> This market practice has continued to gain in popularity over the last few decades and remains quite a large issue.
</p>
<h3><span class="mw-headline" id="Drug_company_profits">Drug company profits</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=14" title="Edit section: Drug company profits"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>A Kaiser Family Foundation survey from June 2015 found the public citing "drug company profits" as the number one reason for the high cost of prescription drugs (picked by 77%), followed by the cost of medical research (64%), the cost of marketing and advertising (54%), and the cost of lawsuits against pharmaceutical companies (49%)."<sup id="cite_ref-kaiser_61-0" class="reference"><a href="#cite_note-kaiser-61">&#91;61&#93;</a></sup> <i>CBS MoneyWatch</i> reports that in half of the 16 publicly held drugs companies in its study, profits exceeded R&amp;D cost while in all but one of the companies, "corporate overhead" (which includes sales, administrative, and marketing) exceeded profits.<sup id="cite_ref-62" class="reference"><a href="#cite_note-62">&#91;62&#93;</a></sup>
</p><p>As of 2015, several pharmaceutical companies had developed a new <a href="/wiki/Business_strategy" class="mw-redirect" title="Business strategy">business strategy</a> "of dominating noncompetitive markets for older drugs and then increasing the price substantially".<sup id="cite_ref-greene_63-0" class="reference"><a href="#cite_note-greene-63">&#91;63&#93;</a></sup>
</p><p>In 2019 alone the price of over 3,400 drugs increased.<sup id="cite_ref-64" class="reference"><a href="#cite_note-64">&#91;64&#93;</a></sup> For instance, Allergan raised prices on 51 drugs, just more than half its total medications. Some medications that Allergan manufactures saw a 9.5 percent jump in cost, while others saw a 4.9 percent increase in cost.<sup id="cite_ref-65" class="reference"><a href="#cite_note-65">&#91;65&#93;</a></sup> This helped Allergan make a profit of over $15 million in 2018 alone.<sup id="cite_ref-66" class="reference"><a href="#cite_note-66">&#91;66&#93;</a></sup> This trend is seen all across the healthcare industry, as the price of drugs increase so do the profits of the largest drug companies.
</p><p>Researchers in <i><a href="/wiki/JAMA" title="JAMA">JAMA</a></i> found that between 2000 and 2018, 35 of the largest drug companies in the United States received a combined revenue of $11.5 trillion with a gross profit of $8.6 trillion.<sup id="cite_ref-:14_67-0" class="reference"><a href="#cite_note-:14-67">&#91;67&#93;</a></sup> The key findings of this study relate to the median net income margin which is the percentage of revenue after all the companies expenses have been deducted. The median net income margin for the 35 drug companies was larger than that of the 357 non-pharmaceutical companies in the S&amp;P 500 with the 35 companies having a 13.7 percent median net income margin while the S&amp;P 500 had a 7.7 percent median net income margin.<sup id="cite_ref-:14_67-1" class="reference"><a href="#cite_note-:14-67">&#91;67&#93;</a></sup> The lead author Professor Fred Ledley, who is the Director of the Center for Integration of Science and Industry at Bentley University, stated that "The pharmaceutical companies' profits are really indistinguishable, statistically, from those of technology companies."<sup id="cite_ref-68" class="reference"><a href="#cite_note-68">&#91;68&#93;</a></sup>
</p><p>One of the following programs is the 340B pricing program that allows hospitals and pharmacists to buy drugs at 30–50% off the retail prices.<sup id="cite_ref-:9_69-0" class="reference"><a href="#cite_note-:9-69">&#91;69&#93;</a></sup> Per HRSA's <a href="/wiki/340B_Drug_Pricing_Program" title="340B Drug Pricing Program">340B Drug Pricing Program</a>, drug manufacturers are required to give certain organizations discounted drugs given these organizations fit the eligibility criteria for discounts.<sup id="cite_ref-70" class="reference"><a href="#cite_note-70">&#91;70&#93;</a></sup> A big problem with 340B or similar programs is that pharmacies and hospitals can choose to bill for the discounted drugs at full price, defeating the purpose of the program to control drug prices and maintain affordability for low-income patients.<sup id="cite_ref-:9_69-1" class="reference"><a href="#cite_note-:9-69">&#91;69&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Orphan_drugs">Orphan drugs</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=15" title="Edit section: Orphan drugs"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Drug companies can price new medicines, particularly <a href="/wiki/Orphan_drug" title="Orphan drug">orphan drugs</a>, i.e. drugs that treat rare diseases, defined in the United States as those affecting fewer than 200,000 patients, at a cost that no individual person could pay,<sup id="cite_ref-71" class="reference"><a href="#cite_note-71">&#91;71&#93;</a></sup><sup id="cite_ref-72" class="reference"><a href="#cite_note-72">&#91;72&#93;</a></sup><sup id="cite_ref-73" class="reference"><a href="#cite_note-73">&#91;73&#93;</a></sup> because an insurance company or the government are payors.<sup id="cite_ref-74" class="reference"><a href="#cite_note-74">&#91;74&#93;</a></sup>
Congress passed the <a href="/wiki/Orphan_Drug_Act_of_1983" title="Orphan Drug Act of 1983">Orphan Drug Act (ODA) in 1983</a> to incentivize pharmaceutical companies to research rare disease states like acquired hemophilia A and <a href="/wiki/Glioblastoma" title="Glioblastoma">glioblastomas</a>.<sup id="cite_ref-75" class="reference"><a href="#cite_note-75">&#91;75&#93;</a></sup> Prior to the ODA, the FDA approved 34 orphan drugs. After the passage of the ODA, the FDA approved upwards of 500 orphan drugs in the decade to follow; successfully achieving the goal of increasing FDA approved orphan drugs.<sup id="cite_ref-invivo.pharmaintelligence.informa.com_76-0" class="reference"><a href="#cite_note-invivo.pharmaintelligence.informa.com-76">&#91;76&#93;</a></sup>
An orphan drug may cost as much as $400,000 annually. Monopolizing orphan drugs has proven to be a very profitable strategy for drug companies;<sup id="cite_ref-77" class="reference"><a href="#cite_note-77">&#91;77&#93;</a></sup><sup id="cite_ref-78" class="reference"><a href="#cite_note-78">&#91;78&#93;</a></sup> rare diseases have few patients so heavy investment into marketing is not needed and patients rarely have other options. Furthermore, a majority of orphan drugs (93%) are covered by insurance payers.<sup id="cite_ref-invivo.pharmaintelligence.informa.com_76-1" class="reference"><a href="#cite_note-invivo.pharmaintelligence.informa.com-76">&#91;76&#93;</a></sup> In the face of continued criticism, drug company executives defend this practice by noting that high cost allows the company to produce the drug for the very few patients who need it, and that most patients with very rare disorders rarely require any treatment at all.<sup id="cite_ref-79" class="reference"><a href="#cite_note-79">&#91;79&#93;</a></sup>
</p><p>Targeting orphan drugs may sometimes fail. For example, <a href="/wiki/Glybera" class="mw-redirect" title="Glybera">Glybera</a> was a $1 million injection used to treat a rare metabolic deficiency, but was removed from the market due to lack of demand.<sup id="cite_ref-80" class="reference"><a href="#cite_note-80">&#91;80&#93;</a></sup> However, there are many examples of orphan drug targeting proving to be a very profitable model for pharmaceutical companies. For example, Alexion Pharmaceutical, Inc. released <a href="/wiki/Soliris" class="mw-redirect" title="Soliris">Soliris</a> in 2007 with an indication for a rare blood disorder. Treatment with Soliris costs roughly $410,000 per year, and has led to $2.8 billion in total sales in 2016, even with a patient base of only 9,000 people.<sup id="cite_ref-81" class="reference"><a href="#cite_note-81">&#91;81&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="FDA_backlog_in_generic_drug_application_review">FDA backlog in generic drug application review</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=16" title="Edit section: FDA backlog in generic drug application review"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<table class="box-POV plainlinks metadata ambox ambox-content ambox-POV" role="presentation"><tbody><tr><td class="mbox-image"><div class="mbox-image-div"><span typeof="mw:File"><span><img src="//upload.wikimedia.org/wikipedia/commons/thumb/f/fe/Unbalanced_scales.svg/45px-Unbalanced_scales.svg.png" decoding="async" width="45" height="40" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/fe/Unbalanced_scales.svg/68px-Unbalanced_scales.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/fe/Unbalanced_scales.svg/90px-Unbalanced_scales.svg.png 2x" data-file-width="400" data-file-height="354" /></span></span></div></td><td class="mbox-text"><div class="mbox-text-span">The <b><a href="/wiki/Wikipedia:Neutral_point_of_view" title="Wikipedia:Neutral point of view">neutrality</a> of this section is <a href="/wiki/Wikipedia:NPOV_dispute" title="Wikipedia:NPOV dispute">disputed</a></b>.<span class="hide-when-compact"> Relevant discussion may be found on the <a href="/wiki/Talk:Prescription_drug_prices_in_the_United_States##" title="Talk:Prescription drug prices in the United States">talk page</a>. Please do not remove this message until <a href="/wiki/Template:POV#When_to_remove" title="Template:POV">conditions to do so are met</a>.</span>  <span class="date-container"><i>(<span class="date">September 2016</span>)</i></span><span class="hide-when-compact"><i> (<small><a href="/wiki/Help:Maintenance_template_removal" title="Help:Maintenance template removal">Learn how and when to remove this template message</a></small>)</i></span></div></td></tr></tbody></table>
<p>The national debate over the rising cost of prescription medicines drew attention to the huge backlog of generic drug applications at the <a href="/wiki/US_Food_and_Drug_Administration" class="mw-redirect" title="US Food and Drug Administration">US Food and Drug Administration</a> (FDA).<sup id="cite_ref-82" class="reference"><a href="#cite_note-82">&#91;82&#93;</a></sup>
</p><p>Usually, when enough generic drug products are introduced to the market, the cost to buy prescription medications decreases for both the insurer and the patient.<sup id="cite_ref-83" class="reference"><a href="#cite_note-83">&#91;83&#93;</a></sup><sup id="cite_ref-84" class="reference"><a href="#cite_note-84">&#91;84&#93;</a></sup> Generic drugs have been shown to reduce healthcare costs in multiple ways, among them increasing competition which, in most cases, helps drive prices down.<sup id="cite_ref-85" class="reference"><a href="#cite_note-85">&#91;85&#93;</a></sup>
</p><p>Companies that want to manufacture generic drugs must show in their applications to the FDA that they guarantee quality and <a href="/wiki/Bioequivalence" title="Bioequivalence">bioequivalence</a>. In July 2016, the FDA generic drug application backlog comprised 4,036 generics. On the other hand, the European Medicine Agency (EMA), Europe's equivalent to the FDA, had only 24 generics drug applications awaiting approval. This count includes biologically based biosimilars awaiting approval. The FDA's generic count does not include biosimilars, which are more complicated medicines to review. According to Generic Pharmaceutical Association, the median time it takes for the FDA to approve a generic is 47 months.<sup id="cite_ref-86" class="reference"><a href="#cite_note-86">&#91;86&#93;</a></sup>
</p><p>On July 9, 2012, Generic Drug User Fee Amendments of 2012 (GDUFA) was signed into law.<sup id="cite_ref-:8_87-0" class="reference"><a href="#cite_note-:8-87">&#91;87&#93;</a></sup> The GDUFA was designed to build upon the 20-year-old Prescription Drug Fee Act and improve the generic drug review and<sup id="cite_ref-:8_87-1" class="reference"><a href="#cite_note-:8-87">&#91;87&#93;</a></sup> approval process.<sup id="cite_ref-:7_88-0" class="reference"><a href="#cite_note-:7-88">&#91;88&#93;</a></sup> According to the FDA website, the GDUFA enables the FDA to levy user fees "to fund critical and measurable enhancements to the performance of FDA's generic drugs program, bringing greater predictability and timeliness to the review of generic drug applications".<sup id="cite_ref-:8_87-2" class="reference"><a href="#cite_note-:8-87">&#91;87&#93;</a></sup> The hiring of over 1,000 employees and the upgrade of the office's information technology were among the improvements generated by these funds.<sup id="cite_ref-:7_88-1" class="reference"><a href="#cite_note-:7-88">&#91;88&#93;</a></sup>
</p><p>The EMA along with the European Commission, which handles approval of marketing materials, are approving generics and brand-name drugs in about a year on average, according to the EMA. In fiscal year 2014, the FDA had not approved any of about 1500 such applications by the end of 2014.<sup id="cite_ref-89" class="reference"><a href="#cite_note-89">&#91;89&#93;</a></sup> The slow pace of the FDA review (6–12 months even for a priority review) has not allowed the market to correct itself in a timely manner, i.e. not allowed manufacturers to begin to produce and offer a product, when a price is too high. The following suggestions have been made: prioritize review of applications for essential drugs, i.e. move them up in the queue. If the FDA felt unable to make this largely economic evaluation about priority, the Department of Health and Human Services (DHHS) Office of the Assistant Secretary for Planning and Evaluation could do this. Second, the FDA could temporarily permit compounding. And third, the FDA could "temporarily permit the importation of drug products reviewed/approved by competent regulatory authorities outside the United States".<sup id="cite_ref-greene_63-1" class="reference"><a href="#cite_note-greene-63">&#91;63&#93;</a></sup>
</p><p>In a January 2016 senate hearing, the director of the FDA's <a href="/wiki/Center_for_Drug_Evaluation_and_Research" title="Center for Drug Evaluation and Research">Center for Drug Evaluation and Research</a> said that increasing numbers of generic drug applications had "overwhelmed the FDA staff and created unpredictability and delay for industry",<sup id="cite_ref-wood_90-0" class="reference"><a href="#cite_note-wood-90">&#91;90&#93;</a></sup><sup class="reference nowrap"><span title="Page / location: 2">&#58;&#8202;2&#8202;</span></sup> but that the FDA is ahead of schedule in reducing the backlog since then.<sup id="cite_ref-wood_90-1" class="reference"><a href="#cite_note-wood-90">&#91;90&#93;</a></sup><sup class="reference nowrap"><span title="Page / location: 11">&#58;&#8202;11&#8202;</span></sup>
</p>
<h3><span class="mw-headline" id="Research_and_development">Research and development</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=17" title="Edit section: Research and development"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Pharmaceutical companies argue that the prices they set for a drug are necessary to fund research. High drug prices can sometimes be a necessity to finance the high-risk and high-cost nature of pharmaceutical R&amp;D.<sup id="cite_ref-91" class="reference"><a href="#cite_note-91">&#91;91&#93;</a></sup>11% of drug candidates that enter clinical trials are successful and receive approval for sale.<sup id="cite_ref-92" class="reference"><a href="#cite_note-92">&#91;92&#93;</a></sup> Although the cost of manufacturing is relatively low, the cost of <a href="/wiki/Drug_development" title="Drug development">developing a new drug</a> is relatively high.<sup id="cite_ref-SmithandODonnell_93-0" class="reference"><a href="#cite_note-SmithandODonnell-93">&#91;93&#93;</a></sup><sup class="reference nowrap"><span title="Page / location: 422">&#58;&#8202;422&#8202;</span></sup> In 2011, "a single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion."<sup id="cite_ref-94" class="reference"><a href="#cite_note-94">&#91;94&#93;</a></sup> It has been stated that the U.S. pharmaceutical industry is able to invent drugs that would not be profitable in countries with lower prices, because of the high drug prices in the United States.<sup id="cite_ref-SmithandODonnell_93-1" class="reference"><a href="#cite_note-SmithandODonnell-93">&#91;93&#93;</a></sup>
</p><p>Critics of pharmaceutical companies point out that only a small portion of the drug companies' expenditures are used for research and development, with the majority of their money being spent in the areas of marketing and administration.<sup id="cite_ref-95" class="reference"><a href="#cite_note-95">&#91;95&#93;</a></sup>
</p><p>European pharmaceutical companies are potentially as innovative as their U.S. counterparts, despite price controls. In addition, some countries, such as the United Kingdom and Germany, encourage <a href="/wiki/Comparative_effectiveness_research" title="Comparative effectiveness research">comparative effectiveness reviews</a>, whereby <a href="/wiki/Cost%E2%80%93benefit_analyses" class="mw-redirect" title="Cost–benefit analyses">cost–benefit analyses</a> of rival drugs determine which perform best.<sup id="cite_ref-:0_96-0" class="reference"><a href="#cite_note-:0-96">&#91;96&#93;</a></sup><sup class="noprint Inline-Template" style="white-space:nowrap;">&#91;<i><a href="/wiki/Wikipedia:Citing_sources" title="Wikipedia:Citing sources"><span title="This citation requires a reference to the specific page or range of pages in which the material appears. (February 2016)">page&#160;needed</span></a></i>&#93;</sup>
</p><p>Charles L. Hooper and <a href="/wiki/David_R._Henderson" title="David R. Henderson">David R. Henderson</a> wrote in a 2016 publication of the <a href="/wiki/Cato_Institute" title="Cato Institute">Cato Institute</a> that drug company's pricing correlates with the per capita income of foreign countries and they opined, that in some cases foreign governments drive such hard bargains to the point that they do not contribute to the cost of R&amp;D, leaving "Americans to subsidize the R&amp;D costs".<sup id="cite_ref-97" class="reference"><a href="#cite_note-97">&#91;97&#93;</a></sup> Jeanne Whalen wrote in the Wall Street Journal in 2015, "The upshot is Americans fund much of the global drug industry's earnings, and its efforts to find new medicines." and that the U.S. market was "responsible for the majority of profits for most large pharmaceutical companies."<sup id="cite_ref-98" class="reference"><a href="#cite_note-98">&#91;98&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Intermediaries">Intermediaries</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=18" title="Edit section: Intermediaries"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Intermediaries are estimated to absorb about 41% of the revenue in pharmaceutical industry transactions.<sup id="cite_ref-99" class="reference"><a href="#cite_note-99">&#91;99&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Pharmacy_benefit_managers">Pharmacy benefit managers</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=19" title="Edit section: Pharmacy benefit managers"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h4>
<p><a href="/wiki/Pharmacy_benefit_manager" class="mw-redirect" title="Pharmacy benefit manager">Pharmacy benefit managers</a> (PBMs) may increase drug prices they charge to their clients, in order to increase their profits. For example, they may classify generic drugs as brand name drugs, because their contract does not contain a definition, or only an ambiguous, or a variable definition. This allows PBM's to classify drugs "for one purpose in one way, and for another purpose in another way", and to change the classification at different points during the life of a contract. This, as of 2010 un-litigated freedom, affects "drug coverage, making contract terms, and the reporting about the satisfaction of contract terms".<sup id="cite_ref-Cahn_100-0" class="reference"><a href="#cite_note-Cahn-100">&#91;100&#93;</a></sup>
</p><p>PBM's can make confidential business agreements with pharmaceutical companies, which PBM's have called <a href="/wiki/Collective_buying_power" title="Collective buying power">collective buying power</a>, then set a (lower) reimbursement maximum amounts to drugstores for generic drugs and set (higher) charges to insurers. This practice is also known as "spread pricing".<sup id="cite_ref-usa14_101-0" class="reference"><a href="#cite_note-usa14-101">&#91;101&#93;</a></sup> There are examples where PBMs can double drug costs.<sup id="cite_ref-usa14_101-1" class="reference"><a href="#cite_note-usa14-101">&#91;101&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Drug_rebates">Drug rebates</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=20" title="Edit section: Drug rebates"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Drug manufacturers may offer to pay an insurance company a <a href="/wiki/Rebate_(marketing)" title="Rebate (marketing)">rebate</a> after they have sold them a drug for full price. This is largely invisible to the consumer, because a drug company does not report how much money it returns to the payer. In 2012, the aggregate in the US has been estimated at $40 billion per year.<sup id="cite_ref-forbes_102-0" class="reference"><a href="#cite_note-forbes-102">&#91;102&#93;</a></sup> Many people are concerned that pharmaceutical rebates increase out-of-posts and overall insurance costs. Other critics also argue that drug manufactures may use rebates to incentivize insurance companies to get preferred tiered placement on drug formularies.<sup id="cite_ref-103" class="reference"><a href="#cite_note-103">&#91;103&#93;</a></sup> The actual rebate amount can be influenced by many factors such as size of insurance clientele or the amount of insurance coverage provided for that drug. As solution to high medication costs as a result of drug rebates, the Trump administration have proposed allocating a portion of the drug rebate directly to Medicare patients at the time of purchase in order to offset growing out-of-pocket costs.<sup id="cite_ref-104" class="reference"><a href="#cite_note-104">&#91;104&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Solutions">Solutions</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=21" title="Edit section: Solutions"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Discounts_and_drug_coupons">Discounts and drug coupons</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=22" title="Edit section: Discounts and drug coupons"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>With the rising cost of prescriptions, affordability becomes one of the biggest reasons people in the United States don't take prescriptions the correct way (i.e. cutting pills in half to extend the life of the prescription or opting for an over-the-counter alternative instead).<sup id="cite_ref-105" class="reference"><a href="#cite_note-105">&#91;105&#93;</a></sup> However, there are programs and strategies available to cut prescription drug costs.<sup id="cite_ref-106" class="reference"><a href="#cite_note-106">&#91;106&#93;</a></sup> Programs like <a href="/wiki/GoodRx" title="GoodRx">GoodRx</a> and <a href="/w/index.php?title=RxSaver&amp;action=edit&amp;redlink=1" class="new" title="RxSaver (page does not exist)">RxSaver</a> help the consumer navigate prescription drug costs in order to obtain affordable drugs.<sup id="cite_ref-107" class="reference"><a href="#cite_note-107">&#91;107&#93;</a></sup>
</p><p>Patients can obtain coupons online or at their doctor's office and use them to reduce their co-pays for a given prescription medication. For certain specialty drugs (most injectables and biologic agents), drug coupons have been found to save patients as much as $6 of every $10 they are asked to pay out-of-pocket.<sup id="cite_ref-108" class="reference"><a href="#cite_note-108">&#91;108&#93;</a></sup> According to a 2017 study, for <a href="/wiki/Statin" title="Statin">statin</a> drugs, coupon users had higher drug utilization rates and lower rates of discontinuation than for non coupon users.<sup id="cite_ref-109" class="reference"><a href="#cite_note-109">&#91;109&#93;</a></sup>
</p><p>Prices vary from one pharmacy to another as listed prices determine what the insurance companies will have to pay for the drug. While this approach has been praised for lowering out-of-pocket costs and consequently reducing cost-related nonadherence,<sup id="cite_ref-110" class="reference"><a href="#cite_note-110">&#91;110&#93;</a></sup> some argue that coupons simply incentivize patients to initiate expensive brand-name drugs, ultimately leading to more expensive premiums that cancel out any previous cost-saving effects of the coupons.<sup id="cite_ref-111" class="reference"><a href="#cite_note-111">&#91;111&#93;</a></sup>
</p><p>According to the 2017 consumer reports, it is important to compare prices of various retail pharmacies to get the best deal.<sup id="cite_ref-:10_112-0" class="reference"><a href="#cite_note-:10-112">&#91;112&#93;</a></sup> Other tips include seeking 90-day prescription when possible, asking for the lowest price when deciding to pay for a medication, asking for generics (refer to "Generics versus Brand-name Products" for more details regarding generic drugs vs. brand-name drugs), comparing insurance plans and talking to your doctor about costs in order to find cheaper alternative(s).<sup id="cite_ref-113" class="reference"><a href="#cite_note-113">&#91;113&#93;</a></sup><sup id="cite_ref-:10_112-1" class="reference"><a href="#cite_note-:10-112">&#91;112&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Generics_versus_brand-name_products">Generics versus brand-name products</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=23" title="Edit section: Generics versus brand-name products"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Although branded drugs represent a small minority of the total volume of drugs prescribed in the US, they are responsible for the majority of drug spending.<sup id="cite_ref-Kang_114-0" class="reference"><a href="#cite_note-Kang-114">&#91;114&#93;</a></sup> A generic drug is a chemically equivalent, cheaper version of a brand-name drug. A generic drug form is required to have the same dose, strength and active ingredient(s) as the brand name drug; thus, they carry the same risks and benefits. To ensure compliance, the FDA Generic Drugs Program conducts stringent reviews (3,500 inspections of manufacturing plants per year).<sup id="cite_ref-:11_115-0" class="reference"><a href="#cite_note-:11-115">&#91;115&#93;</a></sup> Generic medicines can only be sold after the patents of the brand name versions end.<sup id="cite_ref-:11_115-1" class="reference"><a href="#cite_note-:11-115">&#91;115&#93;</a></sup> Due to this mandatory period of exclusivity for many brand-name drugs (a period in which generic medicines cannot be sold), delay of generic drugs reaching the market is expected. The high cost of upfront research that brand-name products have to go through to ensure safety and efficacy largely account for the high discrepancy in pricing between the two groups.<sup id="cite_ref-116" class="reference"><a href="#cite_note-116">&#91;116&#93;</a></sup> Branded drugs may have marketing budgets that meet or exceed the cost of research and development.<sup id="cite_ref-Kang_114-1" class="reference"><a href="#cite_note-Kang-114">&#91;114&#93;</a></sup> Generic drug manufacturers determine price based on what the name-brand equivalent is sold for. If multiple generic drug companies manufacture the same drug, price is often driven down towards production costs. If only a few generic drug manufacturers make the product, the price remains close to that of the branded drug. In some cases, <a href="/wiki/Price_fixing" title="Price fixing">price fixing</a> occurs among the generic drug companies—instead of trying to beat competitors by lowering prices, the companies agree to maintain similar prices.<sup id="cite_ref-Kang_114-2" class="reference"><a href="#cite_note-Kang-114">&#91;114&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Value-based_prices">Value-based prices</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=24" title="Edit section: Value-based prices"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>An effort is being made to determine if the value of a drug justifies its price. Such measures include cost-minimization, cost-benefit, cost-effectiveness, and cost-utility analysis.<sup id="cite_ref-:02_117-0" class="reference"><a href="#cite_note-:02-117">&#91;117&#93;</a></sup> They take into account the total costs, including hospital stays, repeated dosages, etc. and, comparing it to a similar treatment, determines whether a drug will actually minimize costs and whether it is more effective in curing the patient. These cost analyses can all be calculated from the point of view of the hospital, the healthcare system, the government, and the patient, so what is best for one party may not be best for another in terms of cost, making the value of a drug in terms of its price, sometimes a difficult thing to measure.
</p><p><a href="/wiki/Quality-adjusted_life_year" title="Quality-adjusted life year">Quality-Adjusted Life Years</a> (QALY) is a cost-effective measure that determines the value of a drug in terms of the quality of life achieved after taking a prescription drug, rather than the number of years the medication extends a patient's life.<sup id="cite_ref-:02_117-1" class="reference"><a href="#cite_note-:02-117">&#91;117&#93;</a></sup> However, QALY is subjective to each patient and brings up moral dilemmas such as whether or not it is cost-effective to do a life-saving operation for someone who is elderly or has other complications. The subjectiveness of QALY is apparent on a case-by-case basis as it takes into account both the quality and quantity of life lived by an individual, with quality of life being the primary subjective factor. QALY does not completely reflect an individual's personal preferences in a particular clinical situation as their value based perspective of life is completely subjective.<sup id="cite_ref-118" class="reference"><a href="#cite_note-118">&#91;118&#93;</a></sup>
</p><p>In <a href="/wiki/Oncology" title="Oncology">oncology</a>, the <a href="/wiki/American_Society_of_Clinical_Oncology" title="American Society of Clinical Oncology">American Society of Clinical Oncology</a> and the <a href="/wiki/European_Society_for_Medical_Oncology" title="European Society for Medical Oncology">European Society for Medical Oncology</a> both developed specific tools in 2015 to grade the value of new drugs.<sup id="cite_ref-119" class="reference"><a href="#cite_note-119">&#91;119&#93;</a></sup><sup id="cite_ref-:12_120-0" class="reference"><a href="#cite_note-:12-120">&#91;120&#93;</a></sup><sup id="cite_ref-121" class="reference"><a href="#cite_note-121">&#91;121&#93;</a></sup> to discuss the price/value ratio of anti-cancer drugs between physicians and patients and on a societal level.<sup id="cite_ref-:12_120-1" class="reference"><a href="#cite_note-:12-120">&#91;120&#93;</a></sup><sup id="cite_ref-:13_122-0" class="reference"><a href="#cite_note-:13-122">&#91;122&#93;</a></sup> A 2017 review of anti-cancer drugs approved by the FDA between 2000 and 2015 found no relationship between their price and their value as measured by the scales of the ASCO and the ESMO.<sup id="cite_ref-123" class="reference"><a href="#cite_note-123">&#91;123&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Policy_makers">Policy makers</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=25" title="Edit section: Policy makers"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The FDA has a "priority review process" for drugs which compete with another drug whose price exceeds its value-based price. Congress could also grant the FDA the ability to change the exclusivity period for new drugs.<sup id="cite_ref-JAMA2_6-1" class="reference"><a href="#cite_note-JAMA2-6">&#91;6&#93;</a></sup> The FDA could also temporarily allow the import of drugs approved for sale outside the United States.<sup id="cite_ref-greene_63-2" class="reference"><a href="#cite_note-greene-63">&#91;63&#93;</a></sup>
</p><p>In December 2015, the DHHS held a public meeting and both houses of Congress had hearings on off-patent drugs with limited or no competition.<sup id="cite_ref-124" class="reference"><a href="#cite_note-124">&#91;124&#93;</a></sup>
</p><p>In 2017, Democratic party leaders announced a plan to enforce limits on how much pharmaceutical companies could raise drug prices. Under the plan, drugs with a "significant price increase" would have to explain the price rise to the HHS a minimum of 30 days before implementing the price hike. Although Turing Pharmaceuticals' <a href="/wiki/Daraprim" class="mw-redirect" title="Daraprim">Daraprim</a> price rise of 5000% overnight would meet the proposal's definition of a "significant price increase," under the proposed plan, Mylan's well-publicized price increase for EpiPen would fall below the thresholds in the plan's criteria for enforcement.<sup id="cite_ref-125" class="reference"><a href="#cite_note-125">&#91;125&#93;</a></sup><sup id="cite_ref-Senate_Bill_17_126-0" class="reference"><a href="#cite_note-Senate_Bill_17-126">&#91;126&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="New_legislation">New legislation</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=26" title="Edit section: New legislation"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>On October 9, 2017, Governor <a href="/wiki/Jerry_Brown" title="Jerry Brown">Jerry Brown</a> of <a href="/wiki/California" title="California">California</a> passed Senate Bill 17 (SB-17) Health care: prescription drug costs. This bill focuses on transparency regarding pharmaceutical companies. This bill mainly focuses on two aspects. The first being that drug companies must give prior notice of price increases for prescription drugs. Drug Manufacturers must notify state purchasers such as <a href="/wiki/CalPERS" title="CalPERS">CalPERS</a>, Medi-Cal etc. 90 days prior to the planned effective date. The second focus is on the transparency of spending trends. This means that health plans and insurers have to annually report the following for all covered drugs (categorized by generic drugs, brand names, and specialty drugs):<sup id="cite_ref-Senate_Bill_17_126-1" class="reference"><a href="#cite_note-Senate_Bill_17-126">&#91;126&#93;</a></sup><sup id="cite_ref-127" class="reference"><a href="#cite_note-127">&#91;127&#93;</a></sup>
</p>
<ul><li>the 25 most prescribed drugs</li>
<li>the 25 most costly drugs</li>
<li>the 25 drugs with the highest year-over-year increase in total annual spending.<sup id="cite_ref-Senate_Bill_17_126-2" class="reference"><a href="#cite_note-Senate_Bill_17-126">&#91;126&#93;</a></sup></li></ul>
<p>This information was intended to help the public and policy makers see and understand pharmaceutical spending trends.
</p>
<h3><span id="Canada.27s_model"></span><span class="mw-headline" id="Canada's_model">Canada's model</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=27" title="Edit section: Canada&#039;s model"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In Canada, the <a href="/wiki/Patented_Medicine_Prices_Review_Board" title="Patented Medicine Prices Review Board">Patented Medicine Prices Review Board</a> (PMPRB) determines a maximum price for all drugs. In 1987, Bill C-22 established an extended period of protection for patents prior to licensing, which would allow for generics to enter the market. It also created the PMPRB, an independent semi-judicial body, which had the purpose of establishing review guidelines of individual drug prices, conduct investigations for allegations of excessive pricing, and negotiations to a voluntary compliance agreement. These efforts are to ensure that manufacturer prices are within justification, and not excessive. Excessive is interpreted based on the following criteria:<sup id="cite_ref-128" class="reference"><a href="#cite_note-128">&#91;128&#93;</a></sup>
</p>
<blockquote>
<ol><li>The price of an existing patented drug cannot increase by more than the Consumer Price Index (CPI)</li>
<li>The price of a new drug (in most cases) is limited so that the cost of therapy with the new drug is in the range of the costs of therapy with existing drugs in the same therapeutic class.</li>
<li>The price of a breakthrough drug is limited to the median of its prices in France, Germany, Italy, Sweden, Switzerland, Britain, and the United States. In addition, no patented drug can be priced above the highest price in this group of countries.</li></ol>
</blockquote>
<p>Low levels of drug spending in Canada are not solely attributable to the regulatory activities of the government, but also the actions of provincial and private insurance plans. These plans prevents price inflation through formulary management, independent clinical review of new products, reference-based pricing, the LCA, and limited use program.<sup id="cite_ref-129" class="reference"><a href="#cite_note-129">&#91;129&#93;</a></sup>
In reviewing formularies, the drug program reviews the therapeutic advantage of one product over the existing formulary, and only adds new drugs if program costs are unchanged. The reference-based pricing entails having a "reference product" for each category that is the baseline price, and utilizes an independent panel of pharmacists and doctors the University of British Columbia to evaluate the therapeutic discrepancies between drugs. The LCA, or low-cost alternative program establishes the price of generics for payment regardless if brand or genetics are used. The limited use program requires prior authorization for specific drugs, and restricts reimbursements to the approved rationale of prior authorizations (i.e. patients who have failed previous agents for the same indication).
</p><p>The government is purchasing drugs similar to how the United States purchases medications for military personnel, but on a much wider scale.<sup id="cite_ref-:0_96-1" class="reference"><a href="#cite_note-:0-96">&#91;96&#93;</a></sup><sup class="reference nowrap"><span title="Page / location: 280">&#58;&#8202;280&#8202;</span></sup>
</p><p>Gail Wilensky, former director of Medicare and Medicaid, said that because most other countries' governments set prices and the U.S. does not, the United States is effectively subsidizing drug development for other countries. She believes if the United States started setting prices, it would disproportionately impact new drug development. She predicted that the tradeoff if prices were set too low, would be fewer new treatments coming to market in about a decade (due to the long development lifecycle).<sup id="cite_ref-onpoint_130-0" class="reference"><a href="#cite_note-onpoint-130">&#91;130&#93;</a></sup> David Mitchell of the advocacy group <a href="/wiki/Patients_for_Affordable_Drugs_Now" title="Patients for Affordable Drugs Now">Patients for Affordable Drugs</a> argues that in the face of reduced pharmaceutical company profits, <a href="/wiki/Medical_research#Funding" title="Medical research">government-funded research</a> could provide an ongoing pipeline of new treatments.<sup id="cite_ref-onpoint_130-1" class="reference"><a href="#cite_note-onpoint-130">&#91;130&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Healthcare_providers">Healthcare providers</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=28" title="Edit section: Healthcare providers"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Healthcare providers can help lower drug prices by helping patients navigate the medication formulary, prescribing drugs covered by formularies, and participating in formulary development through <a href="/wiki/Pharmacy_and_Therapeutics" title="Pharmacy and Therapeutics">Pharmacy and Therapeutics</a> committees. The formulary system's effectiveness is directly correlated to the education of physicians, pharmacists and patients in understanding the justification of formulary compositions. This education includes drug information monographs to provide adequate resources to physicians in making clinical prescribing decisions, pharmacy education regarding any changes in the formulary, and patient education within the managed care system.<sup id="cite_ref-131" class="reference"><a href="#cite_note-131">&#91;131&#93;</a></sup>
</p><p>Formularies should be easily accessible for patient access as well, such as the online <a rel="nofollow" class="external text" href="https://www.medicare.gov/find-a-plan/questions/home.aspx/">Medicare Planfinder</a>, which is part of the Medicare Part D Plan.
</p><p>Healthcare providers can substitute three-month for one-month supplies of medicines. A three-month supply represented a 29% decrease in out-of-pocket costs and an 18% decrease in total prescription costs in one study.<sup id="cite_ref-132" class="reference"><a href="#cite_note-132">&#91;132&#93;</a></sup>
</p><p>Prescribing combination drugs instead of two separate medications can also potentially reduce monthly copays.<sup id="cite_ref-133" class="reference"><a href="#cite_note-133">&#91;133&#93;</a></sup>
</p><p>Because the FDA has no regulations on drug companies in providing evidence that a new drug has a therapeutic advantage over an older drug, many physicians have a tendency to write prescriptions for drugs they are most familiar with. Oftentimes, these prescribing practices are influenced by manufacturer marketing to private practices or hospitals.<sup id="cite_ref-134" class="reference"><a href="#cite_note-134">&#91;134&#93;</a></sup> Prescriber monitoring programs should be implemented to help physicians make cost-effective, evidence-based prescribing decisions, and foundation protocols should be established. This is important to ensure that the most clinically effective drugs are selected, and if a more expensive drug is selected, that appropriate therapeutic equivalence is evaluated with research supporting this decision. However, some organizations believe that if the federal government modified reimportation laws, the FDA could conduct a comprehensive assessment on manufacturing standards in other countries, and allow importation of drugs that meet or exceed U.S. safety standards for drug manufacturing.<sup id="cite_ref-American_Hospital_Association:_Drug_Policy_Recommendations_135-0" class="reference"><a href="#cite_note-American_Hospital_Association:_Drug_Policy_Recommendations-135">&#91;135&#93;</a></sup>
</p><p>Individual importation of lower cost prescription drugs from foreign countries – as done by 2% of U.S. consumers in 2011 and 2012 – is likely not an effective public health solution.<sup id="cite_ref-136" class="reference"><a href="#cite_note-136">&#91;136&#93;</a></sup> However, if the federal government modified reimportation laws, the FDA could conduct a comprehensive assessment on manufacturing standards in other countries, and allow importation of drugs that meet or exceed U.S. safety standards for drug manufacturing.
</p>
<h3><span class="mw-headline" id="Medicare_for_All">Medicare for All</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=29" title="Edit section: Medicare for All"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h3>
<div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Medicare_for_All_Act" title="Medicare for All Act">Medicare for All Act</a></div>
<p>H.R.3,<sup id="cite_ref-137" class="reference"><a href="#cite_note-137">&#91;137&#93;</a></sup> <a href="/wiki/Elijah_E._Cummings_Lower_Drug_Costs_Now_Act" class="mw-redirect" title="Elijah E. Cummings Lower Drug Costs Now Act">Elijah E. Cummings Lower Drug Costs Now Act</a>, is a 2019 House of Representatives approved bill that would allow the <a href="/wiki/United_States_Secretary_of_Health_and_Human_Services" title="United States Secretary of Health and Human Services">Secretary of Health and Human Services</a> (HSS) to negotiate with pharmaceutical companies for some of the most expensive drugs covered by <a href="/wiki/Medicare_Part_D" title="Medicare Part D">Medicare Part D</a>. This negotiation would manifest as a price ceiling, ensuring the Medicare Part D would pay no more than the negotiated price for the expensive drugs.<sup id="cite_ref-138" class="reference"><a href="#cite_note-138">&#91;138&#93;</a></sup> This proposal received support from President Biden during his campaign.<sup id="cite_ref-139" class="reference"><a href="#cite_note-139">&#91;139&#93;</a></sup> <a href="/wiki/Bernie_Sanders" title="Bernie Sanders">Bernie Sanders</a>' 2019 Medicare for All proposal expands upon this bill proposal by requiring a universal health care system instead of private insurance.<sup id="cite_ref-140" class="reference"><a href="#cite_note-140">&#91;140&#93;</a></sup> With this universal health care system, the negotiation style from H.R.3 would apply to everyone under <a href="/wiki/Medicare_for_All_Act" title="Medicare for All Act">Medicare for All</a>, rather than just the current recipients of Medicare.
</p><p>Price controls on the pharmaceutical industry have some empirical evidence to support the policy. The United States’ <a href="/wiki/International_Trade_Administration" title="International Trade Administration">International Trade Administration</a> reports the OECD companies with price controls drug prices range from 18 to 67 percent lower than the US's, depending on the drug.<sup id="cite_ref-141" class="reference"><a href="#cite_note-141">&#91;141&#93;</a></sup>
</p><p>There are several reasons why some experts believe that price controls on the pharmaceutical industry have some serious downsides. The <a href="/wiki/National_Bureau_of_Economic_Research" title="National Bureau of Economic Research">National Bureau of Economic Research</a> conducted a study in 2014 that found that price regulations significantly delayed the launch of new drugs.<sup id="cite_ref-142" class="reference"><a href="#cite_note-142">&#91;142&#93;</a></sup> Moreover, a study done by Dr. David Stewart found that 260 life-years are lost per hour of delay for drug approval.<sup id="cite_ref-143" class="reference"><a href="#cite_note-143">&#91;143&#93;</a></sup> Sanders’ proposal may mitigate delays with the inclusion of an inability to negotiate section, which states if the negotiation is unable to conclude, the HSS may price the drug at no more than the amount of one of three different prices. These prices include the price the Secretary of Veterans Affairs pays, the price of the drug under section 8126 of title 38, United States Code, and the price paid under a section of Social Security.
</p>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=30" title="Edit section: See also"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h2>
<ul><li><a href="/wiki/Medicare_Prescription_Drug,_Improvement,_and_Modernization_Act" title="Medicare Prescription Drug, Improvement, and Modernization Act">Medicare Prescription Drug, Improvement, and Modernization Act</a></li>
<li><a href="/wiki/Essential_medicines_policies" title="Essential medicines policies">Essential medicines policies</a></li>
<li><a href="/wiki/Prescription_costs" class="mw-redirect" title="Prescription costs">Prescription costs</a></li>
<li><a href="/wiki/Prescription_charges" title="Prescription charges">Prescription charges</a></li>
<li><a href="/wiki/Sri_Lanka_National_Pharmaceuticals_Policy" title="Sri Lanka National Pharmaceuticals Policy">Sri Lanka National Pharmaceuticals Policy</a></li></ul>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=31" title="Edit section: References"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist reflist-columns references-column-width" style="column-width: 30em;">
<ol class="references">
<li id="cite_note-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-1">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.commonwealthfund.org/sites/default/files/documents/___media_files_publications_issue_brief_2017_oct_sarnak_paying_for_rx_ib_v2.pdf">"Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier?"</a> <span class="cs1-format">(PDF)</span>. <i>www.commonwealthfund.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">Aug 13,</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.commonwealthfund.org&amp;rft.atitle=Paying+for+Prescription+Drugs+Around+the+World%3A+Why+Is+the+U.S.+an+Outlier%3F&amp;rft_id=https%3A%2F%2Fwww.commonwealthfund.org%2Fsites%2Fdefault%2Ffiles%2Fdocuments%2F&#95;__media_files_publications_issue_brief_2017_oct_sarnak_paying_for_rx_ib_v2.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:15-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-:15_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:15_2-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:15_2-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFMulcahyWhaleyTebekaSchwam2021" class="citation journal cs1">Mulcahy, Andrew W.; Whaley, Christopher M.; Tebeka, Mahlet G.; Schwam, Daniel; Edenfield, Nathaniel; Becerra-Ornelas, Alejandro U. (2021-01-28). <a rel="nofollow" class="external text" href="https://www.rand.org/pubs/research_reports/RR2956.html">"International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies"</a>. <i>RAND Corporation</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=RAND+Corporation&amp;rft.atitle=International+Prescription+Drug+Price+Comparisons%3A+Current+Empirical+Estimates+and+Comparisons+with+Previous+Studies&amp;rft.date=2021-01-28&amp;rft.aulast=Mulcahy&amp;rft.aufirst=Andrew+W.&amp;rft.au=Whaley%2C+Christopher+M.&amp;rft.au=Tebeka%2C+Mahlet+G.&amp;rft.au=Schwam%2C+Daniel&amp;rft.au=Edenfield%2C+Nathaniel&amp;rft.au=Becerra-Ornelas%2C+Alejandro+U.&amp;rft_id=https%3A%2F%2Fwww.rand.org%2Fpubs%2Fresearch_reports%2FRR2956.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-3">^</a></b></span> <span class="reference-text"><cite id="CITEREFKesselheimAvornSarpatwari2016" class="citation journal cs1">Kesselheim, Aaron S.; Avorn, Jerry; Sarpatwari, Ameet (23 August 2016). "The High Cost of Prescription Drugs in the United States". <i>JAMA</i>. <b>316</b> (8): 858–71. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjama.2016.11237">10.1001/jama.2016.11237</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/27552619">27552619</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:19317308">19317308</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=The+High+Cost+of+Prescription+Drugs+in+the+United+States&amp;rft.volume=316&amp;rft.issue=8&amp;rft.pages=858-71&amp;rft.date=2016-08-23&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A19317308%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F27552619&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2016.11237&amp;rft.aulast=Kesselheim&amp;rft.aufirst=Aaron+S.&amp;rft.au=Avorn%2C+Jerry&amp;rft.au=Sarpatwari%2C+Ameet&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-4">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cbo.gov/publication/57126">"Research and Development in the Pharmaceutical Industry | Congressional Budget Office"</a>. <i>www.cbo.gov</i>. 8 April 2021<span class="reference-accessdate">. Retrieved <span class="nowrap">2021-07-15</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cbo.gov&amp;rft.atitle=Research+and+Development+in+the+Pharmaceutical+Industry+%7C+Congressional+Budget+Office&amp;rft.date=2021-04-08&amp;rft_id=https%3A%2F%2Fwww.cbo.gov%2Fpublication%2F57126&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><cite id="CITEREFKennedy2019" class="citation journal cs1">Kennedy, Joe (2019-09-09). <a rel="nofollow" class="external text" href="https://itif.org/publications/2019/09/09/link-between-drug-prices-and-research-next-generation-cures">"The Link Between Drug Prices and Research on the Next Generation of Cures"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+Link+Between+Drug+Prices+and+Research+on+the+Next+Generation+of+Cures&amp;rft.date=2019-09-09&amp;rft.aulast=Kennedy&amp;rft.aufirst=Joe&amp;rft_id=https%3A%2F%2Fitif.org%2Fpublications%2F2019%2F09%2F09%2Flink-between-drug-prices-and-research-next-generation-cures&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span> <span class="cs1-visible-error citation-comment"><code class="cs1-code">{{<a href="/wiki/Template:Cite_journal" title="Template:Cite journal">cite journal</a>}}</code>: </span><span class="cs1-visible-error citation-comment">Cite journal requires <code class="cs1-code">&#124;journal=</code> (<a href="/wiki/Help:CS1_errors#missing_periodical" title="Help:CS1 errors">help</a>)</span></span>
</li>
<li id="cite_note-JAMA2-6"><span class="mw-cite-backlink">^ <a href="#cite_ref-JAMA2_6-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-JAMA2_6-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFBachPearson2015" class="citation journal cs1">Bach, Peter B.; Pearson, Steven D. (2015-12-15). "Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs". <i>JAMA</i>. <b>314</b> (23): 2503–2504. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjama.2015.16843">10.1001/jama.2015.16843</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/1538-3598">1538-3598</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/26619354">26619354</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=Payer+and+Policy+Maker+Steps+to+Support+Value-Based+Pricing+for+Drugs&amp;rft.volume=314&amp;rft.issue=23&amp;rft.pages=2503-2504&amp;rft.date=2015-12-15&amp;rft.issn=1538-3598&amp;rft_id=info%3Apmid%2F26619354&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2015.16843&amp;rft.aulast=Bach&amp;rft.aufirst=Peter+B.&amp;rft.au=Pearson%2C+Steven+D.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-morgan-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-morgan_7-0">^</a></b></span> <span class="reference-text"><cite id="CITEREFMorgan,_StevenHurley,_Jeremiah2004" class="citation journal cs1">Morgan, Steven &amp; Hurley, Jeremiah (2004-03-16). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC359422">"Internet pharmacy: prices on the up-and-up"</a>. <i>CMAJ</i>. <b>170</b> (6): 945–946. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1503%2Fcmaj.104001">10.1503/cmaj.104001</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC359422">359422</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/15023915">15023915</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CMAJ&amp;rft.atitle=Internet+pharmacy%3A+prices+on+the+up-and-up&amp;rft.volume=170&amp;rft.issue=6&amp;rft.pages=945-946&amp;rft.date=2004-03-16&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC359422%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F15023915&amp;rft_id=info%3Adoi%2F10.1503%2Fcmaj.104001&amp;rft.au=Morgan%2C+Steven&amp;rft.au=Hurley%2C+Jeremiah&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC359422&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:5-8"><span class="mw-cite-backlink">^ <a href="#cite_ref-:5_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:5_8-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:5_8-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFKesselheimAvornSarpatwari2016" class="citation journal cs1">Kesselheim, Aaron S.; Avorn, Jerry; Sarpatwari, Ameet (2016-08-23). "The High Cost of Prescription Drugs in the United States". <i>JAMA</i>. <b>316</b> (8): 858–71. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjama.2016.11237">10.1001/jama.2016.11237</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0098-7484">0098-7484</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/27552619">27552619</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:19317308">19317308</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=The+High+Cost+of+Prescription+Drugs+in+the+United+States&amp;rft.volume=316&amp;rft.issue=8&amp;rft.pages=858-71&amp;rft.date=2016-08-23&amp;rft.issn=0098-7484&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A19317308%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F27552619&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2016.11237&amp;rft.aulast=Kesselheim&amp;rft.aufirst=Aaron+S.&amp;rft.au=Avorn%2C+Jerry&amp;rft.au=Sarpatwari%2C+Ameet&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-9">^</a></b></span> <span class="reference-text"><cite id="CITEREFBlumenthalSquires2016" class="citation journal cs1">Blumenthal, David; Squires, David (2016). <a rel="nofollow" class="external text" href="http://www.commonwealthfund.org/publications/blog/2016/may/drug-price-control-how-some-government-programs-do-it">"Drug Price Control: How Some Government Programs Do It"</a>. <i>www.commonwealthfund.org</i>. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.26099%2FF58J-XW81">10.26099/F58J-XW81</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2017-05-01</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=www.commonwealthfund.org&amp;rft.atitle=Drug+Price+Control%3A+How+Some+Government+Programs+Do+It&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.26099%2FF58J-XW81&amp;rft.aulast=Blumenthal&amp;rft.aufirst=David&amp;rft.au=Squires%2C+David&amp;rft_id=http%3A%2F%2Fwww.commonwealthfund.org%2Fpublications%2Fblog%2F2016%2Fmay%2Fdrug-price-control-how-some-government-programs-do-it&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-10">^</a></b></span> <span class="reference-text">US Government Accountability Office (GAO) <a rel="nofollow" class="external text" href="http://www.gao.gov/products/GAO-05-779">Prescription Drugs: Price Trends for Frequently Used Brand and Generic Drugs from 2000 through 2004.</a> Report to Congressional Requesters. GAO-05-779. 15 August 2005.</span>
</li>
<li id="cite_note-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-11">^</a></b></span> <span class="reference-text"><cite id="CITEREFDavid_Gross,_Leigh_Gross_Purvis_and_Stephen_W._Schondelmeyer2007" class="citation web cs1">David Gross, Leigh Gross Purvis and Stephen W. Schondelmeyer (March 2007). <a rel="nofollow" class="external text" href="http://www.aarp.org/research/health/drugs/aresearch-import-869-2004-06--IB69.html">"Trends in Manufacturer Prices of Prescription Drugs Used by Older Americans"</a>. <a href="/wiki/AARP" title="AARP">AARP</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Trends+in+Manufacturer+Prices+of+Prescription+Drugs+Used+by+Older+Americans&amp;rft.pub=AARP&amp;rft.date=2007-03&amp;rft.au=David+Gross%2C+Leigh+Gross+Purvis+and+Stephen+W.+Schondelmeyer&amp;rft_id=http%3A%2F%2Fwww.aarp.org%2Fresearch%2Fhealth%2Fdrugs%2Faresearch-import-869-2004-06--IB69.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text">Joseph Antos and Thomas F. Wildsmith, <a rel="nofollow" class="external text" href="http://www.aei.org/outlook/22818">"Inflated Claims about Drug Prices"</a> <a rel="nofollow" class="external text" href="https://web.archive.org/web/20090714051407/http://www.aei.org/outlook/22818">Archived</a> 2009-07-14 at the <a href="/wiki/Wayback_Machine" title="Wayback Machine">Wayback Machine</a>, <a href="/wiki/American_Enterprise_Institute" title="American Enterprise Institute">American Enterprise Institute</a>, 8 July 2005</span>
</li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text"><cite id="CITEREFAshley_KirzingerLunna_LopesBryan_WuMollyann_Brodie2019" class="citation web cs1">Ashley Kirzinger; Lunna Lopes; Bryan Wu; Mollyann Brodie (1 March 2019). <a rel="nofollow" class="external text" href="https://www.kff.org/report-section/kff-health-tracking-poll-february-2019-prescription-drugs-findings/">"KFF Health Tracking Poll – February 2019: Prescription Drugs"</a>. <a href="/wiki/Kaiser_Family_Foundation" title="Kaiser Family Foundation">Kaiser Family Foundation</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=KFF+Health+Tracking+Poll+%E2%80%93+February+2019%3A+Prescription+Drugs&amp;rft.pub=Kaiser+Family+Foundation&amp;rft.date=2019-03-01&amp;rft.au=Ashley+Kirzinger&amp;rft.au=Lunna+Lopes&amp;rft.au=Bryan+Wu&amp;rft.au=Mollyann+Brodie&amp;rft_id=https%3A%2F%2Fwww.kff.org%2Freport-section%2Fkff-health-tracking-poll-february-2019-prescription-drugs-findings%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><cite id="CITEREFJustine_Coleman2021" class="citation web cs1">Justine Coleman (3 June 2021). <a rel="nofollow" class="external text" href="https://www.msn.com/en-us/news/politics/poll-majority-of-republicans-support-medicare-negotiations-for-prescription-drug-prices/ar-AAKGn8b">"Poll: Majority of Republicans support Medicare negotiations for prescription drug prices"</a>. <i><a href="/wiki/MSN" title="MSN">MSN</a></i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=MSN&amp;rft.atitle=Poll%3A+Majority+of+Republicans+support+Medicare+negotiations+for+prescription+drug+prices&amp;rft.date=2021-06-03&amp;rft.au=Justine+Coleman&amp;rft_id=https%3A%2F%2Fwww.msn.com%2Fen-us%2Fnews%2Fpolitics%2Fpoll-majority-of-republicans-support-medicare-negotiations-for-prescription-drug-prices%2Far-AAKGn8b&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><cite id="CITEREFSullivan2021" class="citation web cs1">Sullivan, Peter (Apr 30, 2021). <a rel="nofollow" class="external text" href="https://thehill.com/homenews/house/551091-democrats-push-to-add-drug-pricing-medicare-measures-to-biden-plan/">"Democrats push to add drug pricing, Medicare measures to Biden plan"</a>. <i>thehill.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">Aug 13,</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=thehill.com&amp;rft.atitle=Democrats+push+to+add+drug+pricing%2C+Medicare+measures+to+Biden+plan&amp;rft.date=2021-04-30&amp;rft.aulast=Sullivan&amp;rft.aufirst=Peter&amp;rft_id=https%3A%2F%2Fthehill.com%2Fhomenews%2Fhouse%2F551091-democrats-push-to-add-drug-pricing-medicare-measures-to-biden-plan%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-16">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://medicare.com/medicare-part-d/coverage-gap-donut-hole-made-simple/">"Medicare Part D Coverage Gap ("Donut Hole")"</a>. <i>medicare.com</i>. 2014-11-13<span class="reference-accessdate">. Retrieved <span class="nowrap">2016-10-22</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=medicare.com&amp;rft.atitle=Medicare+Part+D+Coverage+Gap+%28%22Donut+Hole%22%29&amp;rft.date=2014-11-13&amp;rft_id=https%3A%2F%2Fmedicare.com%2Fmedicare-part-d%2Fcoverage-gap-donut-hole-made-simple%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-17">^</a></b></span> <span class="reference-text"><cite id="CITEREFManchikantiCarawayParrFellows2011" class="citation journal cs1">Manchikanti, Laxmaiah; Caraway, David; Parr, Allan; Fellows, Bert; Hirsch, Joshua (2011). <a rel="nofollow" class="external text" href="https://doi.org/10.36076%2Fppj.2011%2F14%2FE35">"Patient Protection and Affordable Care Act of 2010: Reforming the Health Care Reform for the New Decade"</a>. <i>Pain Physician</i>. <b>14</b> (1): E35-67. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.36076%2Fppj.2011%2F14%2FE35">10.36076/ppj.2011/14/E35</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/21267047">21267047</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pain+Physician&amp;rft.atitle=Patient+Protection+and+Affordable+Care+Act+of+2010%3A+Reforming+the+Health+Care+Reform+for+the+New+Decade&amp;rft.volume=14&amp;rft.issue=1&amp;rft.pages=E35-67&amp;rft.date=2011&amp;rft_id=info%3Adoi%2F10.36076%2Fppj.2011%2F14%2FE35&amp;rft_id=info%3Apmid%2F21267047&amp;rft.aulast=Manchikanti&amp;rft.aufirst=Laxmaiah&amp;rft.au=Caraway%2C+David&amp;rft.au=Parr%2C+Allan&amp;rft.au=Fellows%2C+Bert&amp;rft.au=Hirsch%2C+Joshua&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.36076%252Fppj.2011%252F14%252FE35&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-18">^</a></b></span> <span class="reference-text"><cite id="CITEREFSpan2020" class="citation news cs1">Span, Paula (2020-01-17). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2020/01/17/health/medicare-drug-costs.html">"Medicare's Part D Doughnut Hole Has Closed! Mostly. Sorta"</a>. <i>The New York Times</i>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0362-4331">0362-4331</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2021-08-24</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Medicare%27s+Part+D+Doughnut+Hole+Has+Closed%21+Mostly.+Sorta.&amp;rft.date=2020-01-17&amp;rft.issn=0362-4331&amp;rft.aulast=Span&amp;rft.aufirst=Paula&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2020%2F01%2F17%2Fhealth%2Fmedicare-drug-costs.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-NYT-20151219-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-NYT-20151219_19-0">^</a></b></span> <span class="reference-text"><cite id="CITEREFThe_Editorial_Board2015" class="citation news cs1">The Editorial Board (19 December 2015). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2015/12/20/opinion/sunday/no-justification-for-high-drug-prices.html">"No Justification for High Drug Prices"</a>. <i>New York Times</i><span class="reference-accessdate">. Retrieved <span class="nowrap">20 December</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+York+Times&amp;rft.atitle=No+Justification+for+High+Drug+Prices&amp;rft.date=2015-12-19&amp;rft.au=The+Editorial+Board&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2015%2F12%2F20%2Fopinion%2Fsunday%2Fno-justification-for-high-drug-prices.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text">US Senate Special Committee on Aging. <a rel="nofollow" class="external text" href="http://www.aging.senate.gov/press-releases/collins-mccaskill-open-senate-investigation-into-rx-drug-pricing-announce-intention-to-hold-hearings">Collins, McCaskill open Senate investigation into Rx drug pricing, announce intention to hold hearings. November 4, 2015. Accessed 4 January 2016.</a></span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><cite id="CITEREFDuncan" class="citation news cs1">Duncan, Ian. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20190410124630/https://www.baltimoresun.com/news/maryland/politics/bs-md-drug-price-gouging-20170410-story.html">"Maryland General Assembly passes bill aimed at drug 'price gouging'<span class="cs1-kern-right"></span>"</a>. <i>baltimoresun.com</i>. Archived from <a rel="nofollow" class="external text" href="http://www.baltimoresun.com/news/maryland/politics/bs-md-drug-price-gouging-20170410-story.html">the original</a> on 2019-04-10<span class="reference-accessdate">. Retrieved <span class="nowrap">2017-05-01</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=baltimoresun.com&amp;rft.atitle=Maryland+General+Assembly+passes+bill+aimed+at+drug+%27price+gouging%27&amp;rft.aulast=Duncan&amp;rft.aufirst=Ian&amp;rft_id=http%3A%2F%2Fwww.baltimoresun.com%2Fnews%2Fmaryland%2Fpolitics%2Fbs-md-drug-price-gouging-20170410-story.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><cite id="CITEREFNote2019"> Note, <span class="bluebook-title bluebook-lock-none" title=""><a rel="nofollow" class="external text" href="https://harvardlawreview.org/wp-content/uploads/2019/04/1748-1755_Online.pdf">Recent Case: Fourth Circuit Invalidates Maryland Statute Regulating Price Gouging in the Sale of Generic Drugs</a></span>, 132 <a href="/wiki/Harvard_Law_Review" title="Harvard Law Review">Harv. L. Rev.</a> 1748 (2019).</cite></span>
</li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><cite><i>Association for Accessible Medicines v. Frosh</i></cite>,&#32;<a rel="nofollow" class="external text" href="https://scholar.google.com/scholar_case?case=17880672085993330281">887&#32;F.3d&#32;664</a>&#32;(4th Cir.&#32;2018).</span>
</li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.statnews.com/2019/02/19/no-generic-insulin-who-is-to-blame/">"<span class="cs1-kern-left"></span>'Everyone is at fault': With insulin prices skyrocketing, there's plenty of blame to go around"</a>. <i>www.statnews.com</i>. Feb 19, 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">Aug 13,</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.statnews.com&amp;rft.atitle=%27Everyone+is+at+fault%27%3A+With+insulin+prices+skyrocketing%2C+there%27s+plenty+of+blame+to+go+around&amp;rft.date=2019-02-19&amp;rft_id=https%3A%2F%2Fwww.statnews.com%2F2019%2F02%2F19%2Fno-generic-insulin-who-is-to-blame%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-goodrx.com-25"><span class="mw-cite-backlink">^ <a href="#cite_ref-goodrx.com_25-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-goodrx.com_25-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="https://www.goodrx.com/blog/generic-epipen-is-still-expensive-heres-how-you-can-save/">"Generic EpiPen Is Still Expensive – Here's How You Can Save – GoodRx"</a>. <i>The GoodRx Prescription Savings Blog</i>. 2019-05-24<span class="reference-accessdate">. Retrieved <span class="nowrap">2019-10-23</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+GoodRx+Prescription+Savings+Blog&amp;rft.atitle=Generic+EpiPen+Is+Still+Expensive+%E2%80%93+Here%27s+How+You+Can+Save+%E2%80%93+GoodRx&amp;rft.date=2019-05-24&amp;rft_id=https%3A%2F%2Fwww.goodrx.com%2Fblog%2Fgeneric-epipen-is-still-expensive-heres-how-you-can-save%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><cite id="CITEREFLupkin2020" class="citation web cs1">Lupkin, Sydney (24 July 2020). <a rel="nofollow" class="external text" href="https://www.npr.org/2020/07/24/895290378/trump-signs-executive-orders-on-drug-prices">"Trump Signs Executive Orders on Drug Prices"</a>. <i>NPR</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NPR&amp;rft.atitle=Trump+Signs+Executive+Orders+on+Drug+Prices&amp;rft.date=2020-07-24&amp;rft.aulast=Lupkin&amp;rft.aufirst=Sydney&amp;rft_id=https%3A%2F%2Fwww.npr.org%2F2020%2F07%2F24%2F895290378%2Ftrump-signs-executive-orders-on-drug-prices&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.eastidahonews.com/2020/07/trump-signs-executive-order-to-lower-drug-prices/">"Trump signs executive order to lower drug prices"</a>. 26 July 2020.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Trump+signs+executive+order+to+lower+drug+prices&amp;rft.date=2020-07-26&amp;rft_id=https%3A%2F%2Fwww.eastidahonews.com%2F2020%2F07%2Ftrump-signs-executive-order-to-lower-drug-prices%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-oecd-28"><span class="mw-cite-backlink">^ <a href="#cite_ref-oecd_28-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-oecd_28-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://data.oecd.org/healthres/pharmaceutical-spending.htm">Pharmaceutical spending (indicator)</a>. OECD Data, Health resources. 2013 doi: 10.1787/998febf6-en, accessed 27 November 2015</span>
</li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cdc.gov/nchs/data/hus/2014/103.pdf">"National health expenditures, average annual percent change, and percent distribution, by type of expenditure: United States, selected years 1960–2013"</a> <span class="cs1-format">(Table)</span>. <i>CDC</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 December</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=CDC&amp;rft.atitle=National+health+expenditures%2C+average+annual+percent+change%2C+and+percent+distribution%2C+by+type+of+expenditure%3A+United+States%2C+selected+years+1960%E2%80%932013&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fdata%2Fhus%2F2014%2F103.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><cite id="CITEREFMartinLassmanWashingtonthe_National_Health_Expenditure_Accounts2012" class="citation journal cs1">Martin, Anne B.; Lassman, David; Washington, Benjamin; the National Health Expenditure Accounts; et&#160;al. (2012-01-01). <a rel="nofollow" class="external text" href="https://doi.org/10.1377%2Fhlthaff.2011.1135">"Growth In US Health Spending Remained Slow In 2010; Health Share Of Gross Domestic Product Was Unchanged From 2009"</a>. <i>Health Affairs</i>. <b>31</b> (1): 208–219. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1377%2Fhlthaff.2011.1135">10.1377/hlthaff.2011.1135</a></span>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0278-2715">0278-2715</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/22232112">22232112</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Affairs&amp;rft.atitle=Growth+In+US+Health+Spending+Remained+Slow+In+2010%3B+Health+Share+Of+Gross+Domestic+Product+Was+Unchanged+From+2009&amp;rft.volume=31&amp;rft.issue=1&amp;rft.pages=208-219&amp;rft.date=2012-01-01&amp;rft.issn=0278-2715&amp;rft_id=info%3Apmid%2F22232112&amp;rft_id=info%3Adoi%2F10.1377%2Fhlthaff.2011.1135&amp;rft.aulast=Martin&amp;rft.aufirst=Anne+B.&amp;rft.au=Lassman%2C+David&amp;rft.au=Washington%2C+Benjamin&amp;rft.au=the+National+Health+Expenditure+Accounts&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1377%252Fhlthaff.2011.1135&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><cite id="CITEREFCunningham2010" class="citation journal cs1">Cunningham, Peter J. (2010-05-01). "The Growing Financial Burden Of Health Care: National And State Trends, 2001–2006". <i>Health Affairs</i>. <b>29</b> (5): 1037–1044. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1377%2Fhlthaff.2009.0493">10.1377/hlthaff.2009.0493</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0278-2715">0278-2715</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/20338908">20338908</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:500824">500824</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Affairs&amp;rft.atitle=The+Growing+Financial+Burden+Of+Health+Care%3A+National+And+State+Trends%2C+2001%E2%80%932006&amp;rft.volume=29&amp;rft.issue=5&amp;rft.pages=1037-1044&amp;rft.date=2010-05-01&amp;rft.issn=0278-2715&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A500824%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F20338908&amp;rft_id=info%3Adoi%2F10.1377%2Fhlthaff.2009.0493&amp;rft.aulast=Cunningham&amp;rft.aufirst=Peter+J.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:1-32"><span class="mw-cite-backlink">^ <a href="#cite_ref-:1_32-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:1_32-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Stagnitti, Marie N. Population Characteristics of Medicare Beneficiaries in the U.S. Civilian Noninstitutionalized Population, by Level of Annual Prescribed Medicines Expenses, 2003. Statistical Brief #138. September 2006. Agency for Healthcare Research and Quality, Rockville, MD. Web. 17 Sept. 2016.</span>
</li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://magellanrx.com/member/external/commercial/common/doc/en-us/MRx_Formulary_Specialty.pdf">"Specialty Pharmacy Drug List"</a> <span class="cs1-format">(PDF)</span><span class="reference-accessdate">. Retrieved <span class="nowrap">Aug 13,</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Specialty+Pharmacy+Drug+List&amp;rft_id=https%3A%2F%2Fmagellanrx.com%2Fmember%2Fexternal%2Fcommercial%2Fcommon%2Fdoc%2Fen-us%2FMRx_Formulary_Specialty.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:03-34"><span class="mw-cite-backlink">^ <a href="#cite_ref-:03_34-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:03_34-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://pew.org/1MRtwwM">"Specialty Drugs and Health Care Costs"</a>. <i>pew.org</i>. 16 November 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">Aug 13,</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=pew.org&amp;rft.atitle=Specialty+Drugs+and+Health+Care+Costs&amp;rft.date=2015-11-16&amp;rft_id=http%3A%2F%2Fpew.org%2F1MRtwwM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.aarp.org/content/dam/aarp/ppi/2017/11/full-report-trends-in-retail-prices-of-specialty-prescription-drugs-widely-used-by-older-americans.pdf">"Trends in Retail Prices of Specialty Prescription Drugs Widely Used by Older Americans, 2006 to 2015"</a> <span class="cs1-format">(PDF)</span><span class="reference-accessdate">. Retrieved <span class="nowrap">Aug 13,</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Trends+in+Retail+Prices+of+Specialty+Prescription+Drugs+Widely+Used+by+Older+Americans%2C+2006+to+2015&amp;rft_id=https%3A%2F%2Fwww.aarp.org%2Fcontent%2Fdam%2Faarp%2Fppi%2F2017%2F11%2Ffull-report-trends-in-retail-prices-of-specialty-prescription-drugs-widely-used-by-older-americans.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text"><cite id="CITEREFT.2017" class="citation book cs1">T., Folland, Sherman (2017). <i>The economics of health and health care</i>. Goodman, Allen C. 1947–, Stano, Miron (Eighth international&#160;ed.). London; New York. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9781138208049" title="Special:BookSources/9781138208049"><bdi>9781138208049</bdi></a>. <a href="/wiki/OCLC_(identifier)" class="mw-redirect" title="OCLC (identifier)">OCLC</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/oclc/1002226694">1002226694</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=The+economics+of+health+and+health+care.&amp;rft.place=London%3B+New+York&amp;rft.edition=Eighth+international&amp;rft.date=2017&amp;rft_id=info%3Aoclcnum%2F1002226694&amp;rft.isbn=9781138208049&amp;rft.aulast=T.&amp;rft.aufirst=Folland%2C+Sherman&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span><span class="cs1-maint citation-comment"><code class="cs1-code">{{<a href="/wiki/Template:Cite_book" title="Template:Cite book">cite book</a>}}</code>:  CS1 maint: location missing publisher (<a href="/wiki/Category:CS1_maint:_location_missing_publisher" title="Category:CS1 maint: location missing publisher">link</a>) CS1 maint: multiple names: authors list (<a href="/wiki/Category:CS1_maint:_multiple_names:_authors_list" title="Category:CS1 maint: multiple names: authors list">link</a>)</span></span>
</li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cms.gov/Medicare/Health-Plans/HealthPlansGenInfo/Downloads/MA_Step_Therapy_HPMS_Memo_8_7_2018.pdf">"Prior Authorization and Step Therapy for Part B Drugs in Medicare Advantage"</a> <span class="cs1-format">(PDF)</span><span class="reference-accessdate">. Retrieved <span class="nowrap">Aug 13,</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Prior+Authorization+and+Step+Therapy+for+Part+B+Drugs+in+Medicare+Advantage&amp;rft_id=https%3A%2F%2Fwww.cms.gov%2FMedicare%2FHealth-Plans%2FHealthPlansGenInfo%2FDownloads%2FMA_Step_Therapy_HPMS_Memo_8_7_2018.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-38">^</a></b></span> <span class="reference-text"><cite id="CITEREFChambersThoratPyoChenoweth2014" class="citation journal cs1">Chambers, James D.; Thorat, Teja; Pyo, Junhee; Chenoweth, Matthew; Neumann, Peter J. (October 2014). <a rel="nofollow" class="external text" href="https://doi.org/10.1377%2Fhlthaff.2014.0574">"Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional Drugs"</a>. <i>Health Affairs</i>. <b>33</b> (10): 1751–1760. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1377%2Fhlthaff.2014.0574">10.1377/hlthaff.2014.0574</a></span>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0278-2715">0278-2715</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/25288419">25288419</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Affairs&amp;rft.atitle=Despite+High+Costs%2C+Specialty+Drugs+May+Offer+Value+For+Money+Comparable+To+That+Of+Traditional+Drugs&amp;rft.volume=33&amp;rft.issue=10&amp;rft.pages=1751-1760&amp;rft.date=2014-10&amp;rft.issn=0278-2715&amp;rft_id=info%3Apmid%2F25288419&amp;rft_id=info%3Adoi%2F10.1377%2Fhlthaff.2014.0574&amp;rft.aulast=Chambers&amp;rft.aufirst=James+D.&amp;rft.au=Thorat%2C+Teja&amp;rft.au=Pyo%2C+Junhee&amp;rft.au=Chenoweth%2C+Matthew&amp;rft.au=Neumann%2C+Peter+J.&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1377%252Fhlthaff.2014.0574&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><cite id="CITEREFCunningham2010" class="citation journal cs1">Cunningham, Peter J. (2010-05-01). "The Growing Financial Burden Of Health Care: National And State Trends, 2001–2006". <i>Health Affairs</i>. <b>29</b> (5): 1037–1044. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1377%2Fhlthaff.2009.0493">10.1377/hlthaff.2009.0493</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0278-2715">0278-2715</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/20338908">20338908</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:500824">500824</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Affairs&amp;rft.atitle=The+Growing+Financial+Burden+Of+Health+Care%3A+National+And+State+Trends%2C+2001%E2%80%932006&amp;rft.volume=29&amp;rft.issue=5&amp;rft.pages=1037-1044&amp;rft.date=2010-05-01&amp;rft.issn=0278-2715&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A500824%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F20338908&amp;rft_id=info%3Adoi%2F10.1377%2Fhlthaff.2009.0493&amp;rft.aulast=Cunningham&amp;rft.aufirst=Peter+J.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-40">^</a></b></span> <span class="reference-text"><cite id="CITEREFCefalu2018" class="citation journal cs1">Cefalu, William (2018). <a rel="nofollow" class="external text" href="https://care.diabetesjournals.org/content/diacare/early/2018/05/03/dci18-0019.full.pdf">"Insulin Access and Affordability Work Group: Conclusions and Recommendations"</a> <span class="cs1-format">(PDF)</span>. <i>Diabetes Care</i>. <b>6</b> (41): 1299–1311. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.2337%2Fdci18-0019">10.2337/dci18-0019</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/29739814">29739814</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Diabetes+Care&amp;rft.atitle=Insulin+Access+and+Affordability+Work+Group%3A+Conclusions+and+Recommendations&amp;rft.volume=6&amp;rft.issue=41&amp;rft.pages=1299-1311&amp;rft.date=2018&amp;rft_id=info%3Adoi%2F10.2337%2Fdci18-0019&amp;rft_id=info%3Apmid%2F29739814&amp;rft.aulast=Cefalu&amp;rft.aufirst=William&amp;rft_id=https%3A%2F%2Fcare.diabetesjournals.org%2Fcontent%2Fdiacare%2Fearly%2F2018%2F05%2F03%2Fdci18-0019.full.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cidsa.org/publications/xcenda-summary">"High Drug Prices and Patient Costs: Millions of Lives and Billions of Dollars Lost"</a>. <i>www.cidsa.org</i>. West Health Council for Informed Drug Spending Analysis. November 18, 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">2023-02-20</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cidsa.org&amp;rft.atitle=High+Drug+Prices+and+Patient+Costs%3A+Millions+of+Lives+and+Billions+of+Dollars+Lost&amp;rft.date=2020-11-18&amp;rft_id=https%3A%2F%2Fwww.cidsa.org%2Fpublications%2Fxcenda-summary&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="https://www.washingtontimes.com/news/2019/oct/29/getting-skyrocketing-drug-prices-back-down-to-eart/">"Getting skyrocketing drug prices back down to earth"</a>. <i>The Washington Times</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2019-10-31</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Washington+Times&amp;rft.atitle=Getting+skyrocketing+drug+prices+back+down+to+earth&amp;rft_id=https%3A%2F%2Fwww.washingtontimes.com%2Fnews%2F2019%2Foct%2F29%2Fgetting-skyrocketing-drug-prices-back-down-to-eart%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-43">^</a></b></span> <span class="reference-text"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="http://kff.org/health-costs/press-release/poll-finds-nearly-three-quarters-of-americans-say-prescription-drug-costs-are-unreasonable-and-most-blame-drug-makers-rather-than-insurers-for-the-problem/">"Poll Finds Nearly Three Quarters of Americans Say Prescription Drug Costs Are Unreasonable, and Most Blame Drug Makers Rather Than Insurers for the Problem"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2015-11-27</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Poll+Finds+Nearly+Three+Quarters+of+Americans+Say+Prescription+Drug+Costs+Are+Unreasonable%2C+and+Most+Blame+Drug+Makers+Rather+Than+Insurers+for+the+Problem&amp;rft_id=http%3A%2F%2Fkff.org%2Fhealth-costs%2Fpress-release%2Fpoll-finds-nearly-three-quarters-of-americans-say-prescription-drug-costs-are-unreasonable-and-most-blame-drug-makers-rather-than-insurers-for-the-problem%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-44">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cdc.gov/nchs/data/databriefs/db184.htm">"Products – Data Briefs – Number 184 – January 2015"</a>. <i>www.cdc.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2018-04-10</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=Products+%E2%80%93+Data+Briefs+%E2%80%93+Number+184+%E2%80%93+January+2015&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fdata%2Fdatabriefs%2Fdb184.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:2-45"><span class="mw-cite-backlink">^ <a href="#cite_ref-:2_45-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:2_45-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:2_45-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFKennedyMorgan2009" class="citation journal cs1">Kennedy, Jae; Morgan, Steve (2009). "Cost-related prescription nonadherence in the united states and Canada: A system-level comparison using the 2007 international health policy survey in seven countries". <i>Clinical Therapeutics</i>. <b>31</b> (1): 213–219. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.clinthera.2009.01.006">10.1016/j.clinthera.2009.01.006</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/19243719">19243719</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Therapeutics&amp;rft.atitle=Cost-related+prescription+nonadherence+in+the+united+states+and+Canada%3A+A+system-level+comparison+using+the+2007+international+health+policy+survey+in+seven+countries&amp;rft.volume=31&amp;rft.issue=1&amp;rft.pages=213-219&amp;rft.date=2009&amp;rft_id=info%3Adoi%2F10.1016%2Fj.clinthera.2009.01.006&amp;rft_id=info%3Apmid%2F19243719&amp;rft.aulast=Kennedy&amp;rft.aufirst=Jae&amp;rft.au=Morgan%2C+Steve&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:3-46"><span class="mw-cite-backlink">^ <a href="#cite_ref-:3_46-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:3_46-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:3_46-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-:3_46-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFKennedyMorgan2006" class="citation journal cs1">Kennedy, Jae; Morgan, Steve (2006). "A cross-national study of prescription nonadherence due to cost: Data from the joint Canada-United States survey of health". <i>Clinical Therapeutics</i>. <b>28</b> (8): 1217–1224. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.clinthera.2006.07.009">10.1016/j.clinthera.2006.07.009</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/16982299">16982299</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Therapeutics&amp;rft.atitle=A+cross-national+study+of+prescription+nonadherence+due+to+cost%3A+Data+from+the+joint+Canada-United+States+survey+of+health&amp;rft.volume=28&amp;rft.issue=8&amp;rft.pages=1217-1224&amp;rft.date=2006&amp;rft_id=info%3Adoi%2F10.1016%2Fj.clinthera.2006.07.009&amp;rft_id=info%3Apmid%2F16982299&amp;rft.aulast=Kennedy&amp;rft.aufirst=Jae&amp;rft.au=Morgan%2C+Steve&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text"><cite id="CITEREFHsuPriceHuangBrand2006" class="citation journal cs1">Hsu, John; Price, Mary; Huang, Jie; Brand, Richard; Fung, Vicki; Hui, Rita; Fireman, Bruce; Newhouse, Joseph P.; Selby, Joseph V. (2006-06-01). "Unintended Consequences of Caps on Medicare Drug Benefits". <i>New England Journal of Medicine</i>. <b>354</b> (22): 2349–2359. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1056%2Fnejmsa054436">10.1056/nejmsa054436</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0028-4793">0028-4793</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/16738271">16738271</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:20145849">20145849</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.atitle=Unintended+Consequences+of+Caps+on+Medicare+Drug+Benefits&amp;rft.volume=354&amp;rft.issue=22&amp;rft.pages=2349-2359&amp;rft.date=2006-06-01&amp;rft.issn=0028-4793&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A20145849%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F16738271&amp;rft_id=info%3Adoi%2F10.1056%2Fnejmsa054436&amp;rft.aulast=Hsu&amp;rft.aufirst=John&amp;rft.au=Price%2C+Mary&amp;rft.au=Huang%2C+Jie&amp;rft.au=Brand%2C+Richard&amp;rft.au=Fung%2C+Vicki&amp;rft.au=Hui%2C+Rita&amp;rft.au=Fireman%2C+Bruce&amp;rft.au=Newhouse%2C+Joseph+P.&amp;rft.au=Selby%2C+Joseph+V.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-48">^</a></b></span> <span class="reference-text"><cite id="CITEREFChandraGruberMcKnight2010" class="citation journal cs1">Chandra, Amitabh; Gruber, Jonathan; McKnight, Robin (2010). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982192">"Patient Cost-Sharing and Hospitalization Offsets in the Elderly"</a>. <i>The American Economic Review</i>. <b>100</b> (1): 193–213. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1257%2Faer.100.1.193">10.1257/aer.100.1.193</a>. <a href="/wiki/JSTOR_(identifier)" class="mw-redirect" title="JSTOR (identifier)">JSTOR</a>&#160;<a rel="nofollow" class="external text" href="https://www.jstor.org/stable/27804926">27804926</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982192">2982192</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/21103385">21103385</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+American+Economic+Review&amp;rft.atitle=Patient+Cost-Sharing+and+Hospitalization+Offsets+in+the+Elderly&amp;rft.volume=100&amp;rft.issue=1&amp;rft.pages=193-213&amp;rft.date=2010&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2982192%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F21103385&amp;rft_id=https%3A%2F%2Fwww.jstor.org%2Fstable%2F27804926%23id-name%3DJSTOR&amp;rft_id=info%3Adoi%2F10.1257%2Faer.100.1.193&amp;rft.aulast=Chandra&amp;rft.aufirst=Amitabh&amp;rft.au=Gruber%2C+Jonathan&amp;rft.au=McKnight%2C+Robin&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2982192&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><cite id="CITEREFAlexanderLongKaestner2016" class="citation journal cs1">Alexander GC, Long C, Kaestner R (December 1, 2016). "Association Between Prescription Drug Insurance and Hospitalization Among Medicare Beneficiaries". <i>Medical Care Research and Review</i>. <b>75</b>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Medical+Care+Research+and+Review&amp;rft.atitle=Association+Between+Prescription+Drug+Insurance+and+Hospitalization+Among+Medicare+Beneficiaries&amp;rft.volume=75&amp;rft.date=2016-12-01&amp;rft.aulast=Alexander&amp;rft.aufirst=GC&amp;rft.au=Long%2C+C&amp;rft.au=Kaestner%2C+R&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-50">^</a></b></span> <span class="reference-text"><cite id="CITEREFFlahertyGaul2003" class="citation news cs1">Flaherty, Mary Pat; Gaul, Gilbert M. (2003-10-23). <a rel="nofollow" class="external text" href="https://www.washingtonpost.com/archive/politics/2003/10/23/millions-of-americans-look-outside-us-for-drugs/8bfeb294-b1b2-4be5-bb4b-0764d1e899d3/">"Millions of Americans Look Outside U.S. for Drugs"</a>. <i>The Washington Post</i>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0190-8286">0190-8286</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Washington+Post&amp;rft.atitle=Millions+of+Americans+Look+Outside+U.S.+for+Drugs&amp;rft.date=2003-10-23&amp;rft.issn=0190-8286&amp;rft.aulast=Flaherty&amp;rft.aufirst=Mary+Pat&amp;rft.au=Gaul%2C+Gilbert+M.&amp;rft_id=https%3A%2F%2Fwww.washingtonpost.com%2Farchive%2Fpolitics%2F2003%2F10%2F23%2Fmillions-of-americans-look-outside-us-for-drugs%2F8bfeb294-b1b2-4be5-bb4b-0764d1e899d3%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-51">^</a></b></span> <span class="reference-text"><cite id="CITEREFMorganHurley2004" class="citation journal cs1">Morgan, Steven; Hurley, Jeremiah (2004-03-16). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC359422">"Internet pharmacy: prices on the up-and-up"</a>. <i>Canadian Medical Association Journal</i>. <b>170</b> (6): 945–946. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1503%2Fcmaj.104001">10.1503/cmaj.104001</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0820-3946">0820-3946</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC359422">359422</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/15023915">15023915</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Canadian+Medical+Association+Journal&amp;rft.atitle=Internet+pharmacy%3A+prices+on+the+up-and-up&amp;rft.volume=170&amp;rft.issue=6&amp;rft.pages=945-946&amp;rft.date=2004-03-16&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC359422%23id-name%3DPMC&amp;rft.issn=0820-3946&amp;rft_id=info%3Apmid%2F15023915&amp;rft_id=info%3Adoi%2F10.1503%2Fcmaj.104001&amp;rft.aulast=Morgan&amp;rft.aufirst=Steven&amp;rft.au=Hurley%2C+Jeremiah&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC359422&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text"><cite id="CITEREFCoxKamalJankiewiczRousseau2016" class="citation journal cs1">Cox, Cynthia; Kamal, Rabah; Jankiewicz, Anne; Rousseau, David (Apr 5, 2016). <a rel="nofollow" class="external text" href="https://doi.org/10.1001/jama.2016.2646">"Recent Trends in Prescription Drug Costs"</a>. <i>JAMA</i>. <b>315</b> (13): 1326. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjama.2016.2646">10.1001/jama.2016.2646</a><span class="reference-accessdate">. Retrieved <span class="nowrap">Aug 13,</span> 2022</span> &#8211; via Silverchair.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=Recent+Trends+in+Prescription+Drug+Costs&amp;rft.volume=315&amp;rft.issue=13&amp;rft.pages=1326&amp;rft.date=2016-04-05&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2016.2646&amp;rft.aulast=Cox&amp;rft.aufirst=Cynthia&amp;rft.au=Kamal%2C+Rabah&amp;rft.au=Jankiewicz%2C+Anne&amp;rft.au=Rousseau%2C+David&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1001%2Fjama.2016.2646&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-53">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.wbur.org/onpoint/2021/09/23/medicine-america-broken-prescription-drug-system">"Steps To Fix America's Broken Prescription Drug System"</a>. <i>www.wbur.org</i>. 23 September 2021<span class="reference-accessdate">. Retrieved <span class="nowrap">Aug 13,</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.wbur.org&amp;rft.atitle=Steps+To+Fix+America%27s+Broken+Prescription+Drug+System&amp;rft.date=2021-09-23&amp;rft_id=https%3A%2F%2Fwww.wbur.org%2Fonpoint%2F2021%2F09%2F23%2Fmedicine-america-broken-prescription-drug-system&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-lancet15-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-lancet15_54-0">^</a></b></span> <span class="reference-text"><cite id="CITEREFJaffe2015" class="citation journal cs1">Jaffe, Susan (28 November 2015). <a rel="nofollow" class="external text" href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2901098-3/fulltext">"USA grapples with high drug costs"</a>. <i>The Lancet</i>. <b>386</b> (10009): 2127–2128. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2FS0140-6736%2815%2901098-3">10.1016/S0140-6736(15)01098-3</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/26638951">26638951</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:29538953">29538953</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Lancet&amp;rft.atitle=USA+grapples+with+high+drug+costs&amp;rft.volume=386&amp;rft.issue=10009&amp;rft.pages=2127-2128&amp;rft.date=2015-11-28&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A29538953%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F26638951&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2815%2901098-3&amp;rft.aulast=Jaffe&amp;rft.aufirst=Susan&amp;rft_id=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%252815%252901098-3%2Ffulltext&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:4-55"><span class="mw-cite-backlink">^ <a href="#cite_ref-:4_55-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:4_55-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20200217225944/http://www.iphandbook.org/handbook/ch10/p09/">"The Interface of Patents with the Regulatory Drug Approval Process and How Resulting Interplay Can Affect Market Entry"</a>. <i>www.iphandbook.org</i>. Archived from <a rel="nofollow" class="external text" href="http://www.iphandbook.org/handbook/ch10/p09/">the original</a> on 2020-02-17<span class="reference-accessdate">. Retrieved <span class="nowrap">2017-05-01</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.iphandbook.org&amp;rft.atitle=The+Interface+of+Patents+with+the+Regulatory+Drug+Approval+Process+and+How+Resulting+Interplay+Can+Affect+Market+Entry&amp;rft_id=http%3A%2F%2Fwww.iphandbook.org%2Fhandbook%2Fch10%2Fp09%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:6-56"><span class="mw-cite-backlink">^ <a href="#cite_ref-:6_56-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:6_56-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFUlwik2015" class="citation web cs1">Ulwik, James (2015). <a rel="nofollow" class="external text" href="http://www.luc.edu/media/lucedu/law/centers/antitrust/pdfs/publications/newsviews/Ulwick%20Pay-to-Delay%20-%20Antitrust%20NewsViews%20-%20JAU%20Edits%204%2023%202015.pdf">"Pay-to-Delay: How to Prevent Competition and Get Away With It"</a> <span class="cs1-format">(PDF)</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Pay-to-Delay%3A+How+to+Prevent+Competition+and+Get+Away+With+It&amp;rft.date=2015&amp;rft.aulast=Ulwik&amp;rft.aufirst=James&amp;rft_id=http%3A%2F%2Fwww.luc.edu%2Fmedia%2Flucedu%2Flaw%2Fcenters%2Fantitrust%2Fpdfs%2Fpublications%2Fnewsviews%2FUlwick%2520Pay-to-Delay%2520-%2520Antitrust%2520NewsViews%2520-%2520JAU%2520Edits%25204%252023%25202015.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-57"><span class="mw-cite-backlink"><b><a href="#cite_ref-57">^</a></b></span> <span class="reference-text"><cite id="CITEREFDusetzina2016" class="citation journal cs1">Dusetzina, Stacie B (July 2016). <a rel="nofollow" class="external text" href="https://jamanetwork.com/journals/jamaoncology/article-abstract/2517398">"Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000–2014"</a>. <i>JAMA Oncology</i>. <b>2</b> (7): 960–61. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjamaoncol.2016.0648">10.1001/jamaoncol.2016.0648</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/27123993">27123993</a> &#8211; via JAMA Network.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA+Oncology&amp;rft.atitle=Drug+Pricing+Trends+for+Orally+Administered+Anticancer+Medications+Reimbursed+by+Commercial+Health+Plans%2C+2000%E2%80%932014&amp;rft.volume=2&amp;rft.issue=7&amp;rft.pages=960-61&amp;rft.date=2016-07&amp;rft_id=info%3Adoi%2F10.1001%2Fjamaoncol.2016.0648&amp;rft_id=info%3Apmid%2F27123993&amp;rft.aulast=Dusetzina&amp;rft.aufirst=Stacie+B&amp;rft_id=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamaoncology%2Farticle-abstract%2F2517398&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-58">^</a></b></span> <span class="reference-text"><cite id="CITEREFSchondelmeyerPurvis2016" class="citation web cs1">Schondelmeyer, Stephen W; Purvis, Leigh (December 2016). <a rel="nofollow" class="external text" href="https://www.aarp.org/content/dam/aarp/ppi/2016-12/trends-in-retail-prices-dec-2016.pdf">"Trends in Retail Prices of Brand Name Prescription Drugs Widely Used by Older Americans, 2006 to 2015"</a> <span class="cs1-format">(PDF)</span>. <i>AARP Public Policy Institute</i><span class="reference-accessdate">. Retrieved <span class="nowrap">7 December</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=AARP+Public+Policy+Institute&amp;rft.atitle=Trends+in+Retail+Prices+of+Brand+Name+Prescription+Drugs+Widely+Used+by+Older+Americans%2C+2006+to+2015&amp;rft.date=2016-12&amp;rft.aulast=Schondelmeyer&amp;rft.aufirst=Stephen+W&amp;rft.au=Purvis%2C+Leigh&amp;rft_id=https%3A%2F%2Fwww.aarp.org%2Fcontent%2Fdam%2Faarp%2Fppi%2F2016-12%2Ftrends-in-retail-prices-dec-2016.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-59">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20210325213610/https://energycommerce.house.gov/committee-activity/hearings/hearing-on-examining-fda-s-generic-drug-and-biosimilar-user-fee-programs">"Hearing on "Examining FDA's Generic Drug and Biosimilar User Fee Programs," Subcommittee on Health (March 2, 2017)"</a>. <i>Democrats, Energy and Commerce Committee</i>. 2017-03-02. Archived from <a rel="nofollow" class="external text" href="https://energycommerce.house.gov/committee-activity/hearings/hearing-on-examining-fda-s-generic-drug-and-biosimilar-user-fee-programs">the original</a> on 2021-03-25<span class="reference-accessdate">. Retrieved <span class="nowrap">2020-12-07</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Democrats%2C+Energy+and+Commerce+Committee&amp;rft.atitle=Hearing+on+%22Examining+FDA%27s+Generic+Drug+and+Biosimilar+User+Fee+Programs%2C%22+Subcommittee+on+Health+%28March+2%2C+2017%29&amp;rft.date=2017-03-02&amp;rft_id=https%3A%2F%2Fenergycommerce.house.gov%2Fcommittee-activity%2Fhearings%2Fhearing-on-examining-fda-s-generic-drug-and-biosimilar-user-fee-programs&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-60"><span class="mw-cite-backlink"><b><a href="#cite_ref-60">^</a></b></span> <span class="reference-text">For instance, Valeant Pharmaceuticals’ acquisition strategy acquired 100 companies, and part of this strategy was to increase prices as the market was consolidated. See S. M. Collins and C. McCaskill, <i>Sudden Price Spikes in Off-Patent Prescription Drugs: The Monopoly Business Model that Harms Patients, Taxpayers, and the U.S. Health Care System</i> (U.S. Senate, Special Committee on Aging, Dec. 2016).</span>
</li>
<li id="cite_note-kaiser-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-kaiser_61-0">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://kff.org/health-costs/press-release/poll-finds-nearly-three-quarters-of-americans-say-prescription-drug-costs-are-unreasonable-and-most-blame-drug-makers-rather-than-insurers-for-the-problem/">Poll Finds Nearly Three Quarters of Americans Say Prescription Drug Costs Are Unreasonable, and Most Blame Drug Makers Rather Than Insurers for the Problem</a> Kaiser Family Foundation. 16 June 2015, accessed 27 November 2015</span>
</li>
<li id="cite_note-62"><span class="mw-cite-backlink"><b><a href="#cite_ref-62">^</a></b></span> <span class="reference-text"><cite id="CITEREFErik_Sherman2015" class="citation news cs1">Erik Sherman (October 7, 2015). <a rel="nofollow" class="external text" href="http://www.cbsnews.com/news/higher-drug-prices-support-profits-not-research/">"The real reason U.S. drug prices are so high"</a>. <i>CBS news</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CBS+news&amp;rft.atitle=The+real+reason+U.S.+drug+prices+are+so+high&amp;rft.date=2015-10-07&amp;rft.au=Erik+Sherman&amp;rft_id=http%3A%2F%2Fwww.cbsnews.com%2Fnews%2Fhigher-drug-prices-support-profits-not-research%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-greene-63"><span class="mw-cite-backlink">^ <a href="#cite_ref-greene_63-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-greene_63-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-greene_63-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFGreeneAndersonSharfstein2016" class="citation journal cs1">Greene, Jeremy A.; Anderson, Gerard; Sharfstein, Joshua M. (2016). "Role of the FDA in Affordability of Off-Patent Pharmaceuticals". <i>Journal of the American Medical Association</i>. <b>31</b> (5): 461–462. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjama.2015.18720">10.1001/jama.2015.18720</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/26747694">26747694</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+the+American+Medical+Association&amp;rft.atitle=Role+of+the+FDA+in+Affordability+of+Off-Patent+Pharmaceuticals&amp;rft.volume=31&amp;rft.issue=5&amp;rft.pages=461-462&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2015.18720&amp;rft_id=info%3Apmid%2F26747694&amp;rft.aulast=Greene&amp;rft.aufirst=Jeremy+A.&amp;rft.au=Anderson%2C+Gerard&amp;rft.au=Sharfstein%2C+Joshua+M.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span> <span style="font-size:0.95em; font-size:95%; color: var( --color-subtle, #555 )">(subscription required)</span></span>
</li>
<li id="cite_note-64"><span class="mw-cite-backlink"><b><a href="#cite_ref-64">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cbsnews.com/news/drug-prices-in-2019-are-surging-with-hikes-at-5-times-inflation/">"Drug prices in 2019 are surging, with hikes at 5 times inflation"</a>. <i>www.cbsnews.com</i>. July 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">2020-12-07</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cbsnews.com&amp;rft.atitle=Drug+prices+in+2019+are+surging%2C+with+hikes+at+5+times+inflation&amp;rft.date=2019-07&amp;rft_id=https%3A%2F%2Fwww.cbsnews.com%2Fnews%2Fdrug-prices-in-2019-are-surging-with-hikes-at-5-times-inflation%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-65"><span class="mw-cite-backlink"><b><a href="#cite_ref-65">^</a></b></span> <span class="reference-text"><cite id="CITEREFTami_Luhby2019" class="citation web cs1">Tami Luhby (3 January 2019). <a rel="nofollow" class="external text" href="https://www.cnn.com/2019/01/03/politics/drug-prices-trump/index.html">"Drug makers resist pressure from Washington on prices"</a>. <i>CNN</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2020-12-07</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=CNN&amp;rft.atitle=Drug+makers+resist+pressure+from+Washington+on+prices&amp;rft.date=2019-01-03&amp;rft.au=Tami+Luhby&amp;rft_id=https%3A%2F%2Fwww.cnn.com%2F2019%2F01%2F03%2Fpolitics%2Fdrug-prices-trump%2Findex.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-66"><span class="mw-cite-backlink"><b><a href="#cite_ref-66">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://www.allergan.com/investors/news/thomson-reuters/allergan-reports-fourth-quarter-and-full-year-2018">Allergan, “Allergan Reports Fourth Quarter and Full-Year 2018 Financial Results,” January 29, 2019</a></span>
</li>
<li id="cite_note-:14-67"><span class="mw-cite-backlink">^ <a href="#cite_ref-:14_67-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:14_67-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFLedleyMcCoyVaughanCleary2020" class="citation journal cs1">Ledley, Fred D.; McCoy, Sarah Shonka; Vaughan, Gregory; Cleary, Ekaterina Galkina (2020-03-03). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054843">"Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies"</a>. <i>JAMA</i>. <b>323</b> (9): 834–843. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjama.2020.0442">10.1001/jama.2020.0442</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0098-7484">0098-7484</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054843">7054843</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/32125401">32125401</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=Profitability+of+Large+Pharmaceutical+Companies+Compared+With+Other+Large+Public+Companies&amp;rft.volume=323&amp;rft.issue=9&amp;rft.pages=834-843&amp;rft.date=2020-03-03&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7054843%23id-name%3DPMC&amp;rft.issn=0098-7484&amp;rft_id=info%3Apmid%2F32125401&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2020.0442&amp;rft.aulast=Ledley&amp;rft.aufirst=Fred+D.&amp;rft.au=McCoy%2C+Sarah+Shonka&amp;rft.au=Vaughan%2C+Gregory&amp;rft.au=Cleary%2C+Ekaterina+Galkina&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7054843&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-68">^</a></b></span> <span class="reference-text"><cite id="CITEREFEST2020" class="citation web cs1">EST, Rosie McCall On 3/4/20 at 6:01 AM (2020-03-04). <a rel="nofollow" class="external text" href="https://www.newsweek.com/big-pharma-companies-profits-industries-study-1490407">"Big pharma companies earn more profits than most other industries, study suggests"</a>. <i>Newsweek</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2020-12-07</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Newsweek&amp;rft.atitle=Big+pharma+companies+earn+more+profits+than+most+other+industries%2C+study+suggests&amp;rft.date=2020-03-04&amp;rft.aulast=EST&amp;rft.aufirst=Rosie+McCall+On+3%2F4%2F20+at+6%3A01+AM&amp;rft_id=https%3A%2F%2Fwww.newsweek.com%2Fbig-pharma-companies-profits-industries-study-1490407&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span><span class="cs1-maint citation-comment"><code class="cs1-code">{{<a href="/wiki/Template:Cite_web" title="Template:Cite web">cite web</a>}}</code>:  CS1 maint: numeric names: authors list (<a href="/wiki/Category:CS1_maint:_numeric_names:_authors_list" title="Category:CS1 maint: numeric names: authors list">link</a>)</span></span>
</li>
<li id="cite_note-:9-69"><span class="mw-cite-backlink">^ <a href="#cite_ref-:9_69-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:9_69-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="https://catalyst.nejm.org/who-has-the-power-to-cut-drug-prices/">"Who Has the Power to Cut Drug Prices? – NEJM Catalyst"</a>. <i>NEJM Catalyst</i>. 2016-01-13<span class="reference-accessdate">. Retrieved <span class="nowrap">2017-10-30</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=NEJM+Catalyst&amp;rft.atitle=Who+Has+the+Power+to+Cut+Drug+Prices%3F+%E2%80%93+NEJM+Catalyst&amp;rft.date=2016-01-13&amp;rft_id=https%3A%2F%2Fcatalyst.nejm.org%2Fwho-has-the-power-to-cut-drug-prices%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-70">^</a></b></span> <span class="reference-text"><cite id="CITEREFOffice_of_Pharmacy_Affairsn.d." class="citation web cs1">Office of Pharmacy Affairs (n.d.). <a rel="nofollow" class="external text" href="https://www.hrsa.gov/opa/">"340B Drug Pricing Program"</a>. Health Resources and Services Administration<span class="reference-accessdate">. Retrieved <span class="nowrap">2 December</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=340B+Drug+Pricing+Program&amp;rft.pub=Health+Resources+and+Services+Administration&amp;rft.au=Office+of+Pharmacy+Affairs&amp;rft_id=http%3A%2F%2Fwww.hrsa.gov%2Fopa%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-71"><span class="mw-cite-backlink"><b><a href="#cite_ref-71">^</a></b></span> <span class="reference-text"><cite id="CITEREFMichaeliJürgesMichaeli2023" class="citation journal cs1">Michaeli, Thomas; Jürges, Hendrik; Michaeli, Daniel Tobias (2023-05-09). <a rel="nofollow" class="external text" href="https://www.bmj.com/content/381/bmj-2022-073242">"FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis"</a>. <i>BMJ</i>. <b>381</b>: e073242. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1136%2Fbmj-2022-073242">10.1136/bmj-2022-073242</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/1756-1833">1756-1833</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167557">10167557</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/37160306">37160306</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BMJ&amp;rft.atitle=FDA+approval%2C+clinical+trial+evidence%2C+efficacy%2C+epidemiology%2C+and+price+for+non-orphan+and+ultra-rare%2C+rare%2C+and+common+orphan+cancer+drug+indications%3A+cross+sectional+analysis&amp;rft.volume=381&amp;rft.pages=e073242&amp;rft.date=2023-05-09&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10167557%23id-name%3DPMC&amp;rft.issn=1756-1833&amp;rft_id=info%3Apmid%2F37160306&amp;rft_id=info%3Adoi%2F10.1136%2Fbmj-2022-073242&amp;rft.aulast=Michaeli&amp;rft.aufirst=Thomas&amp;rft.au=J%C3%BCrges%2C+Hendrik&amp;rft.au=Michaeli%2C+Daniel+Tobias&amp;rft_id=https%3A%2F%2Fwww.bmj.com%2Fcontent%2F381%2Fbmj-2022-073242&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-72"><span class="mw-cite-backlink"><b><a href="#cite_ref-72">^</a></b></span> <span class="reference-text"><cite id="CITEREFMichaeliMichaeli2023" class="citation journal cs1">Michaeli, Daniel Tobias; Michaeli, Thomas (2023-10-19). <a rel="nofollow" class="external text" href="https://doi.org/10.1007/s40273-023-01320-4">"Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition"</a>. <i>PharmacoEconomics</i>. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs40273-023-01320-4">10.1007/s40273-023-01320-4</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/1179-2027">1179-2027</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/37855850">37855850</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PharmacoEconomics&amp;rft.atitle=Launch+and+Post-Launch+Prices+of+Injectable+Cancer+Drugs+in+the+US%3A+Clinical+Benefit%2C+Innovation%2C+Epidemiology%2C+and+Competition&amp;rft.date=2023-10-19&amp;rft.issn=1179-2027&amp;rft_id=info%3Apmid%2F37855850&amp;rft_id=info%3Adoi%2F10.1007%2Fs40273-023-01320-4&amp;rft.aulast=Michaeli&amp;rft.aufirst=Daniel+Tobias&amp;rft.au=Michaeli%2C+Thomas&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1007%2Fs40273-023-01320-4&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-73"><span class="mw-cite-backlink"><b><a href="#cite_ref-73">^</a></b></span> <span class="reference-text"><cite id="CITEREFMichaeliMichaeli2023" class="citation journal cs1">Michaeli, Daniel Tobias; Michaeli, Thomas (November 2023). <a rel="nofollow" class="external text" href="https://doi.org/10.1016/j.jval.2023.06.020">"Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology"</a>. <i>Value in Health</i>. <b>26</b> (11): 1590–1600. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.jval.2023.06.020">10.1016/j.jval.2023.06.020</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/1098-3015">1098-3015</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/37516196">37516196</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Value+in+Health&amp;rft.atitle=Cancer+Drug+Prices+in+the+United+States%3A+Efficacy%2C+Innovation%2C+Clinical+Trial+Evidence%2C+and+Epidemiology&amp;rft.volume=26&amp;rft.issue=11&amp;rft.pages=1590-1600&amp;rft.date=2023-11&amp;rft.issn=1098-3015&amp;rft_id=info%3Apmid%2F37516196&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jval.2023.06.020&amp;rft.aulast=Michaeli&amp;rft.aufirst=Daniel+Tobias&amp;rft.au=Michaeli%2C+Thomas&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1016%2Fj.jval.2023.06.020&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-74">^</a></b></span> <span class="reference-text">Matthew Herper <a rel="nofollow" class="external text" href="https://www.forbes.com/sites/matthewherper/2012/03/19/how-to-charge-1-6-million-for-a-new-drug-and-get-away-with-it/">How To Charge $1.6 Million For a New Drug And Get Away With It. Forbes, Mar 19, 2012, accessed 2 December 2015</a></span>
</li>
<li id="cite_note-75"><span class="mw-cite-backlink"><b><a href="#cite_ref-75">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20210318003736/https://rarediseases.info.nih.gov/diseases/fda-orphan-drugs">"List of FDA Orphan Drugs | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program"</a>. <i>rarediseases.info.nih.gov</i>. Archived from <a rel="nofollow" class="external text" href="https://rarediseases.info.nih.gov/diseases/fda-orphan-drugs">the original</a> on 2021-03-18<span class="reference-accessdate">. Retrieved <span class="nowrap">2019-10-23</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=rarediseases.info.nih.gov&amp;rft.atitle=List+of+FDA+Orphan+Drugs+%7C+Genetic+and+Rare+Diseases+Information+Center+%28GARD%29+%E2%80%93+an+NCATS+Program&amp;rft_id=https%3A%2F%2Frarediseases.info.nih.gov%2Fdiseases%2Ffda-orphan-drugs&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-invivo.pharmaintelligence.informa.com-76"><span class="mw-cite-backlink">^ <a href="#cite_ref-invivo.pharmaintelligence.informa.com_76-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-invivo.pharmaintelligence.informa.com_76-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://invivo.pharmaintelligence.informa.com/IV005214/Orphan-Drug-Pricing-And-Reimbursement-Challenges-To-Patient-Access">"Orphan Drug Pricing and Reimbursement: Challenges to Patient Access"</a>. 2017-11-15.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Orphan+Drug+Pricing+and+Reimbursement%3A+Challenges+to+Patient+Access&amp;rft.date=2017-11-15&amp;rft_id=https%3A%2F%2Finvivo.pharmaintelligence.informa.com%2FIV005214%2FOrphan-Drug-Pricing-And-Reimbursement-Challenges-To-Patient-Access&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-77"><span class="mw-cite-backlink"><b><a href="#cite_ref-77">^</a></b></span> <span class="reference-text"><cite id="CITEREFMichaeliYagmurAchmadeevMichaeli2022" class="citation journal cs1">Michaeli, Daniel Tobias; Yagmur, Hasan Basri; Achmadeev, Timur; Michaeli, Thomas (2022-11-01). <a rel="nofollow" class="external text" href="https://doi.org/10.1007/s10198-021-01427-5">"Value drivers of development stage biopharma companies"</a>. <i>The European Journal of Health Economics</i>. <b>23</b> (8): 1287–1296. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs10198-021-01427-5">10.1007/s10198-021-01427-5</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/1618-7601">1618-7601</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550717">9550717</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/35038054">35038054</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+European+Journal+of+Health+Economics&amp;rft.atitle=Value+drivers+of+development+stage+biopharma+companies&amp;rft.volume=23&amp;rft.issue=8&amp;rft.pages=1287-1296&amp;rft.date=2022-11-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9550717%23id-name%3DPMC&amp;rft.issn=1618-7601&amp;rft_id=info%3Apmid%2F35038054&amp;rft_id=info%3Adoi%2F10.1007%2Fs10198-021-01427-5&amp;rft.aulast=Michaeli&amp;rft.aufirst=Daniel+Tobias&amp;rft.au=Yagmur%2C+Hasan+Basri&amp;rft.au=Achmadeev%2C+Timur&amp;rft.au=Michaeli%2C+Thomas&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1007%2Fs10198-021-01427-5&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-78"><span class="mw-cite-backlink"><b><a href="#cite_ref-78">^</a></b></span> <span class="reference-text"><cite id="CITEREFMichaeliYagmurAchmadeevMichaeli2022" class="citation journal cs1">Michaeli, Daniel Tobias; Yagmur, Hasan Basri; Achmadeev, Timur; Michaeli, Thomas (2022-03-01). <a rel="nofollow" class="external text" href="https://doi.org/10.1007/s43441-021-00364-y">"Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors"</a>. <i>Therapeutic Innovation &amp; Regulatory Science</i>. <b>56</b> (2): 313–322. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs43441-021-00364-y">10.1007/s43441-021-00364-y</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/2168-4804">2168-4804</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854317">8854317</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/35018622">35018622</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Therapeutic+Innovation+%26+Regulatory+Science&amp;rft.atitle=Valuation+and+Returns+of+Drug+Development+Companies%3A+Lessons+for+Bioentrepreneurs+and+Investors&amp;rft.volume=56&amp;rft.issue=2&amp;rft.pages=313-322&amp;rft.date=2022-03-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8854317%23id-name%3DPMC&amp;rft.issn=2168-4804&amp;rft_id=info%3Apmid%2F35018622&amp;rft_id=info%3Adoi%2F10.1007%2Fs43441-021-00364-y&amp;rft.aulast=Michaeli&amp;rft.aufirst=Daniel+Tobias&amp;rft.au=Yagmur%2C+Hasan+Basri&amp;rft.au=Achmadeev%2C+Timur&amp;rft.au=Michaeli%2C+Thomas&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1007%2Fs43441-021-00364-y&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-79"><span class="mw-cite-backlink"><b><a href="#cite_ref-79">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.forbes.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html#462e45fc5e10">"The World's Most Expensive Drugs"</a>. <i><a href="/wiki/Forbes" title="Forbes">Forbes</a></i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Forbes&amp;rft.atitle=The+World%27s+Most+Expensive+Drugs&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2F2010%2F02%2F19%2Fexpensive-drugs-cost-business-healthcare-rare-diseases.html%23462e45fc5e10&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-80"><span class="mw-cite-backlink"><b><a href="#cite_ref-80">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.the-scientist.com/features/how-orphan-drugs-became-a-highly-profitable-industry-64278">"How Orphan Drugs Became a Highly Profitable Industry"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=How+Orphan+Drugs+Became+a+Highly+Profitable+Industry&amp;rft_id=https%3A%2F%2Fwww.the-scientist.com%2Ffeatures%2Fhow-orphan-drugs-became-a-highly-profitable-industry-64278&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-81"><span class="mw-cite-backlink"><b><a href="#cite_ref-81">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.biopharmadive.com/news/pricing-rare-disease-drugs-orphan-act/439808/">"The orphan drug dilemma: How to price for a tiny market"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=The+orphan+drug+dilemma%3A+How+to+price+for+a+tiny+market&amp;rft_id=https%3A%2F%2Fwww.biopharmadive.com%2Fnews%2Fpricing-rare-disease-drugs-orphan-act%2F439808%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-82"><span class="mw-cite-backlink"><b><a href="#cite_ref-82">^</a></b></span> <span class="reference-text"><cite id="CITEREFSilverman2016" class="citation news cs1">Silverman, Ed (2 March 2016). <a rel="nofollow" class="external text" href="https://www.statnews.com/pharmalot/2016/03/02/fda-generic-drugs/">"FDA still struggling with backlog of generic drug applications"</a>. <a href="/wiki/Stat_(website)" title="Stat (website)">Stat</a><span class="reference-accessdate">. Retrieved <span class="nowrap">17 August</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=FDA+still+struggling+with+backlog+of+generic+drug+applications&amp;rft.date=2016-03-02&amp;rft.aulast=Silverman&amp;rft.aufirst=Ed&amp;rft_id=https%3A%2F%2Fwww.statnews.com%2Fpharmalot%2F2016%2F03%2F02%2Ffda-generic-drugs%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-83"><span class="mw-cite-backlink"><b><a href="#cite_ref-83">^</a></b></span> <span class="reference-text"><cite id="CITEREFLeeChenRomanelliSegal2016" class="citation journal cs1">Lee, Chia-Ying; Chen, Xiaohan; Romanelli, Robert J.; Segal, Jodi B. (2016-01-01). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034442">"Forces influencing generic drug development in the United States: a narrative review"</a>. <i>Journal of Pharmaceutical Policy and Practice</i>. <b>9</b>: 26. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1186%2Fs40545-016-0079-1">10.1186/s40545-016-0079-1</a></span>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/2052-3211">2052-3211</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034442">5034442</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/27688886">27688886</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Pharmaceutical+Policy+and+Practice&amp;rft.atitle=Forces+influencing+generic+drug+development+in+the+United+States%3A+a+narrative+review&amp;rft.volume=9&amp;rft.pages=26&amp;rft.date=2016-01-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5034442%23id-name%3DPMC&amp;rft.issn=2052-3211&amp;rft_id=info%3Apmid%2F27688886&amp;rft_id=info%3Adoi%2F10.1186%2Fs40545-016-0079-1&amp;rft.aulast=Lee&amp;rft.aufirst=Chia-Ying&amp;rft.au=Chen%2C+Xiaohan&amp;rft.au=Romanelli%2C+Robert+J.&amp;rft.au=Segal%2C+Jodi+B.&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5034442&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-84"><span class="mw-cite-backlink"><b><a href="#cite_ref-84">^</a></b></span> <span class="reference-text"><cite id="CITEREFMorgenson2017" class="citation news cs1">Morgenson, Gretchen (2017-04-14). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2017/04/14/business/lannett-drug-price-hike-bedrosian.html">"Defiant, Generic Drug Maker Continues to Raise Prices"</a>. <i>The New York Times</i>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0362-4331">0362-4331</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2017-05-01</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Defiant%2C+Generic+Drug+Maker+Continues+to+Raise+Prices&amp;rft.date=2017-04-14&amp;rft.issn=0362-4331&amp;rft.aulast=Morgenson&amp;rft.aufirst=Gretchen&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2017%2F04%2F14%2Fbusiness%2Flannett-drug-price-hike-bedrosian.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-85"><span class="mw-cite-backlink"><b><a href="#cite_ref-85">^</a></b></span> <span class="reference-text"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="https://aspe.hhs.gov/basic-report/expanding-use-generic-drugs">"Expanding the Use of Generic Drugs"</a>. <i>ASPE</i>. 2015-06-13<span class="reference-accessdate">. Retrieved <span class="nowrap">2017-05-01</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=ASPE&amp;rft.atitle=Expanding+the+Use+of+Generic+Drugs&amp;rft.date=2015-06-13&amp;rft_id=https%3A%2F%2Faspe.hhs.gov%2Fbasic-report%2Fexpanding-use-generic-drugs&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-86"><span class="mw-cite-backlink"><b><a href="#cite_ref-86">^</a></b></span> <span class="reference-text"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="https://www.npr.org/sections/health-shots/2016/09/01/492235796/fda-fees-on-industry-havent-fixed-delays-in-generic-drug-approvals">"FDA Fees On Industry Haven't Fixed Delays In Generic Drug Approvals"</a>. <i>NPR.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2017-05-01</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=NPR.org&amp;rft.atitle=FDA+Fees+On+Industry+Haven%27t+Fixed+Delays+In+Generic+Drug+Approvals&amp;rft_id=https%3A%2F%2Fwww.npr.org%2Fsections%2Fhealth-shots%2F2016%2F09%2F01%2F492235796%2Ffda-fees-on-industry-havent-fixed-delays-in-generic-drug-approvals&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:8-87"><span class="mw-cite-backlink">^ <a href="#cite_ref-:8_87-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:8_87-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:8_87-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFResearch" class="citation web cs1">Research, Center for Drug Evaluation and. <a rel="nofollow" class="external text" href="https://www.fda.gov/forindustry/userfees/genericdruguserfees/default.htm">"Generic Drug User Fee Amendments of 2012"</a>. <i>www.fda.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2017-05-01</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fda.gov&amp;rft.atitle=Generic+Drug+User+Fee+Amendments+of+2012&amp;rft.aulast=Research&amp;rft.aufirst=Center+for+Drug+Evaluation+and&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2Fforindustry%2Fuserfees%2Fgenericdruguserfees%2Fdefault.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:7-88"><span class="mw-cite-backlink">^ <a href="#cite_ref-:7_88-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:7_88-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="http://www.cbsnews.com/news/epipen-price-hike-controversy-mylan-ceo-heather-bresch-speaks-out/">"Mylan CEO on EpiPen drug price controversy: "I get the outrage"<span class="cs1-kern-right"></span>"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2017-05-01</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mylan+CEO+on+EpiPen+drug+price+controversy%3A+%22I+get+the+outrage%22&amp;rft_id=http%3A%2F%2Fwww.cbsnews.com%2Fnews%2Fepipen-price-hike-controversy-mylan-ceo-heather-bresch-speaks-out%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-89"><span class="mw-cite-backlink"><b><a href="#cite_ref-89">^</a></b></span> <span class="reference-text">FDA. <a rel="nofollow" class="external text" href="https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/UCM451179.pdf.">FY 2014 Performance Report to the President and Congress for the Generic Drug User Fee Amendments.</a> FDA User Fee Reports, Accessed 4 January 2015.</span>
</li>
<li id="cite_note-wood-90"><span class="mw-cite-backlink">^ <a href="#cite_ref-wood_90-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-wood_90-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://1.usa.gov/1POUpcB">Implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA) Testimony of Janet Woodcock, M.D.Director, Center for Drug Evaluation and Research U.S. Food and Drug Administration</a><sup class="noprint Inline-Template"><span style="white-space: nowrap;">&#91;<i><a href="/wiki/Wikipedia:Link_rot" title="Wikipedia:Link rot"><span title="&#160;Dead link tagged October 2023">permanent dead link</span></a></i>&#93;</span></sup> Before the Committee on Health, Education, Labor and Pensions. United States Senate, 18 pages, January 28, 2016.</span>
</li>
<li id="cite_note-91"><span class="mw-cite-backlink"><b><a href="#cite_ref-91">^</a></b></span> <span class="reference-text"><cite id="CITEREFMorenoEpstein2019" class="citation journal cs1">Moreno, Santiago G.; Epstein, David (2019-01-01). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442120">"The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework"</a>. <i>Journal of Market Access &amp; Health Policy</i>. <b>7</b> (1): 1583536. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1080%2F20016689.2019.1583536">10.1080/20016689.2019.1583536</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/2001-6689">2001-6689</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442120">6442120</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/30956782">30956782</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Market+Access+%26+Health+Policy&amp;rft.atitle=The+price+of+innovation+-+the+role+of+drug+pricing+in+financing+pharmaceutical+innovation.+A+conceptual+framework&amp;rft.volume=7&amp;rft.issue=1&amp;rft.pages=1583536&amp;rft.date=2019-01-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6442120%23id-name%3DPMC&amp;rft.issn=2001-6689&amp;rft_id=info%3Apmid%2F30956782&amp;rft_id=info%3Adoi%2F10.1080%2F20016689.2019.1583536&amp;rft.aulast=Moreno&amp;rft.aufirst=Santiago+G.&amp;rft.au=Epstein%2C+David&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6442120&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-92"><span class="mw-cite-backlink"><b><a href="#cite_ref-92">^</a></b></span> <span class="reference-text">Nature Reviews Drug Discovery, 2004 (3), 711–716.</span>
</li>
<li id="cite_note-SmithandODonnell-93"><span class="mw-cite-backlink">^ <a href="#cite_ref-SmithandODonnell_93-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-SmithandODonnell_93-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://books.google.com/books?id=-DgAe57FAGcC&amp;dq=%22united+states%22+canada+drug+development&amp;pg=PA422">The Process of New Drug Discovery and Development</a> Second Edition, Charles G. Smith and James T. O'Donnell, Taylor &amp; Francis, 2006, <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0849327792" title="Special:BookSources/0849327792">0849327792</a>, 9780849327797 688 pages, published by Informa Healthcare</span>
</li>
<li id="cite_note-94"><span class="mw-cite-backlink"><b><a href="#cite_ref-94">^</a></b></span> <span class="reference-text"><cite id="CITEREFHerper" class="citation news cs1">Herper, Matthew. <a rel="nofollow" class="external text" href="https://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/">"The Truly Staggering Cost Of Inventing New Drugs"</a>. <i>Forbes</i><span class="reference-accessdate">. Retrieved <span class="nowrap">29 March</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Forbes&amp;rft.atitle=The+Truly+Staggering+Cost+Of+Inventing+New+Drugs&amp;rft.aulast=Herper&amp;rft.aufirst=Matthew&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fmatthewherper%2F2012%2F02%2F10%2Fthe-truly-staggering-cost-of-inventing-new-drugs%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-95"><span class="mw-cite-backlink"><b><a href="#cite_ref-95">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://archive.psc-cuny.org/drugprices.htm">Why Are Drug Prices So High?</a>, PSC/<a href="/wiki/City_University_of_New_York" title="City University of New York">City University of New York</a></span>
</li>
<li id="cite_note-:0-96"><span class="mw-cite-backlink">^ <a href="#cite_ref-:0_96-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:0_96-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Brandon Kramer and Michael Shally-Jensen. <a rel="nofollow" class="external text" href="https://books.google.com/books?id=BjKWfAz0tx4C&amp;dq=Prescription+Drug+costs+Brandon+Kramer++and+Michael+Shally-Jensen&amp;pg=PA273">Prescription Drug costs</a>. pp 273–283. in: Encyclopedia of Contemporary American Social Issues 4 volumes, ABC-CLIO, December 22, 2010, Social Science, 1707 pages, Santa Barbara</span>
</li>
<li id="cite_note-97"><span class="mw-cite-backlink"><b><a href="#cite_ref-97">^</a></b></span> <span class="reference-text"><cite id="CITEREFCharles_L._HooperDavid_R._Henderson2016" class="citation web cs1">Charles L. Hooper; David R. Henderson (2016). <a rel="nofollow" class="external text" href="https://object.cato.org/sites/cato.org/files/serials/files/regulation/2016/4/regulation-v39n1-2.pdf">"Want Cheaper Drugs"</a> <span class="cs1-format">(PDF)</span>. <i>Regulation</i>. Cato Institute.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Regulation&amp;rft.atitle=Want+Cheaper+Drugs&amp;rft.date=2016&amp;rft.au=Charles+L.+Hooper&amp;rft.au=David+R.+Henderson&amp;rft_id=https%3A%2F%2Fobject.cato.org%2Fsites%2Fcato.org%2Ffiles%2Fserials%2Ffiles%2Fregulation%2F2016%2F4%2Fregulation-v39n1-2.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-98"><span class="mw-cite-backlink"><b><a href="#cite_ref-98">^</a></b></span> <span class="reference-text"><cite id="CITEREFJeanne_Whalen2015" class="citation news cs1">Jeanne Whalen (December 1, 2015). <a rel="nofollow" class="external text" href="https://www.wsj.com/articles/why-the-u-s-pays-more-than-other-countries-for-drugs-1448939481">"Why the U.S. Pays More than Other Countries for Drugs"</a>. <i>Wall Street Journal</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Wall+Street+Journal&amp;rft.atitle=Why+the+U.S.+Pays+More+than+Other+Countries+for+Drugs&amp;rft.date=2015-12-01&amp;rft.au=Jeanne+Whalen&amp;rft_id=https%3A%2F%2Fwww.wsj.com%2Farticles%2Fwhy-the-u-s-pays-more-than-other-countries-for-drugs-1448939481&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-99"><span class="mw-cite-backlink"><b><a href="#cite_ref-99">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.thepharmaletter.com/article/intermediaries-capture-41-of-price-paid-for-drugs-in-usa-study-shows">"Intermediaries capture 41% of price paid for drugs in USA, study shows"</a>. <i>www.thepharmaletter.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2019-12-29</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.thepharmaletter.com&amp;rft.atitle=Intermediaries+capture+41%25+of+price+paid+for+drugs+in+USA%2C+study+shows&amp;rft_id=https%3A%2F%2Fwww.thepharmaletter.com%2Farticle%2Fintermediaries-capture-41-of-price-paid-for-drugs-in-usa-study-shows&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-Cahn-100"><span class="mw-cite-backlink"><b><a href="#cite_ref-Cahn_100-0">^</a></b></span> <span class="reference-text">Linda Cahn <a rel="nofollow" class="external text" href="http://www.managedcaremag.com/archives/1009/1009.cahn_generic.html">When Is a Brand a Generic? In a Contract With a PBM</a> Managed Care, September 2010. accessed 2 December 2015.</span>
</li>
<li id="cite_note-usa14-101"><span class="mw-cite-backlink">^ <a href="#cite_ref-usa14_101-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-usa14_101-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFJayne_O&#39;Donnell2014" class="citation news cs1">Jayne O'Donnell (3 March 2014). <a rel="nofollow" class="external text" href="https://www.usatoday.com/story/money/personalfinance/2014/03/03/pharmacy-benefit-managers-healthcare-costs-savings/5495317/">"Do drug benefit managers reduce health costs?"</a>. <i>USA Today</i><span class="reference-accessdate">. Retrieved <span class="nowrap">1 August</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=USA+Today&amp;rft.atitle=Do+drug+benefit+managers+reduce+health+costs%3F&amp;rft.date=2014-03-03&amp;rft.au=Jayne+O%27Donnell&amp;rft_id=https%3A%2F%2Fwww.usatoday.com%2Fstory%2Fmoney%2Fpersonalfinance%2F2014%2F03%2F03%2Fpharmacy-benefit-managers-healthcare-costs-savings%2F5495317%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-forbes-102"><span class="mw-cite-backlink"><b><a href="#cite_ref-forbes_102-0">^</a></b></span> <span class="reference-text"><cite id="CITEREFMatthew_Herper2012" class="citation news cs1">Matthew Herper (10 May 2012). <a rel="nofollow" class="external text" href="https://www.forbes.com/sites/matthewherper/2012/05/10/why-astrazeneca-gives-insurers-60-discounts-on-nexiums-list-price/">"Inside The Secret World Of Drug Company Rebates"</a>. <i>Forbes</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 December</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Forbes&amp;rft.atitle=Inside+The+Secret+World+Of+Drug+Company+Rebates&amp;rft.date=2012-05-10&amp;rft.au=Matthew+Herper&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fmatthewherper%2F2012%2F05%2F10%2Fwhy-astrazeneca-gives-insurers-60-discounts-on-nexiums-list-price%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-103"><span class="mw-cite-backlink"><b><a href="#cite_ref-103">^</a></b></span> <span class="reference-text"><cite id="CITEREFDusetzinaContiYuBach2017" class="citation journal cs1">Dusetzina, Stacie B.; Conti, Rena M.; Yu, Nancy L.; Bach, Peter B. (2017-08-01). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722464">"Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending"</a>. <i>JAMA Internal Medicine</i>. <b>177</b> (8): 1185–1188. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjamainternmed.2017.1885">10.1001/jamainternmed.2017.1885</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/2168-6106">2168-6106</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722464">5722464</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/28558108">28558108</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA+Internal+Medicine&amp;rft.atitle=Association+of+Prescription+Drug+Price+Rebates+in+Medicare+Part+D+With+Patient+Out-of-Pocket+and+Federal+Spending&amp;rft.volume=177&amp;rft.issue=8&amp;rft.pages=1185-1188&amp;rft.date=2017-08-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5722464%23id-name%3DPMC&amp;rft.issn=2168-6106&amp;rft_id=info%3Apmid%2F28558108&amp;rft_id=info%3Adoi%2F10.1001%2Fjamainternmed.2017.1885&amp;rft.aulast=Dusetzina&amp;rft.aufirst=Stacie+B.&amp;rft.au=Conti%2C+Rena+M.&amp;rft.au=Yu%2C+Nancy+L.&amp;rft.au=Bach%2C+Peter+B.&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5722464&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-104"><span class="mw-cite-backlink"><b><a href="#cite_ref-104">^</a></b></span> <span class="reference-text"><cite id="CITEREFThomas2018" class="citation news cs1">Thomas, Katie (2018-07-27). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2018/07/27/health/rebates-high-drug-prices-trump.html">"Meet the Rebate, the New Villain of High Drug Prices | The New York Times"</a>. <i>The New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Meet+the+Rebate%2C+the+New+Villain+of+High+Drug+Prices+%7C+The+New+York+Times&amp;rft.date=2018-07-27&amp;rft.aulast=Thomas&amp;rft.aufirst=Katie&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2018%2F07%2F27%2Fhealth%2Frebates-high-drug-prices-trump.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-105"><span class="mw-cite-backlink"><b><a href="#cite_ref-105">^</a></b></span> <span class="reference-text"><cite id="CITEREFLopesWu2019" class="citation web cs1">Lopes, Lunna; Wu, Bryan (2019-03-01). <a rel="nofollow" class="external text" href="https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-february-2019-prescription-drugs/">"KFF Health Tracking Poll – February 2019: Prescription Drugs"</a>. <i>KFF</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2021-08-24</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=KFF&amp;rft.atitle=KFF+Health+Tracking+Poll+%E2%80%93+February+2019%3A+Prescription+Drugs&amp;rft.date=2019-03-01&amp;rft.aulast=Lopes&amp;rft.aufirst=Lunna&amp;rft.au=Wu%2C+Bryan&amp;rft_id=https%3A%2F%2Fwww.kff.org%2Fhealth-costs%2Fpoll-finding%2Fkff-health-tracking-poll-february-2019-prescription-drugs%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-106"><span class="mw-cite-backlink"><b><a href="#cite_ref-106">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.medicalnewstoday.com/articles/save-money-on-prescriptions">"How to save money on prescription medication: 13 tips"</a>. <i>www.medicalnewstoday.com</i>. 2021-07-30<span class="reference-accessdate">. Retrieved <span class="nowrap">2021-08-24</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.medicalnewstoday.com&amp;rft.atitle=How+to+save+money+on+prescription+medication%3A+13+tips&amp;rft.date=2021-07-30&amp;rft_id=https%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2Fsave-money-on-prescriptions&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-107"><span class="mw-cite-backlink"><b><a href="#cite_ref-107">^</a></b></span> <span class="reference-text"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="https://www.komando.com/tech-tips/3-ways-to-save-money-on-prescriptions-2/567361/">"3 little-known ways to save money on prescriptions GoodRx, RetailMeNot, Blink Health"</a>. <i>Komando.com</i>. 2020-08-12<span class="reference-accessdate">. Retrieved <span class="nowrap">2020-10-08</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Komando.com&amp;rft.atitle=3+little-known+ways+to+save+money+on+prescriptions+GoodRx%2C+RetailMeNot%2C+Blink+Health&amp;rft.date=2020-08-12&amp;rft_id=https%3A%2F%2Fwww.komando.com%2Ftech-tips%2F3-ways-to-save-money-on-prescriptions-2%2F567361%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-108"><span class="mw-cite-backlink"><b><a href="#cite_ref-108">^</a></b></span> <span class="reference-text"><cite id="CITEREFStarnerAlexanderBowenQui2014" class="citation journal cs1">Starner CI, Alexander GC, Bowen K, Qui Y, Wickersham P, Gleason PP (Oct 2014). <a rel="nofollow" class="external text" href="https://doi.org/10.1377%2Fhlthaff.2014.0497">"Specialty Drug Coupons Lower Out-of-pocket Costs and May Improve Adherence at the Risk of Increasing Premiums"</a>. <i>Health Affairs</i>. <b>33</b> (10): 1761–1769. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1377%2Fhlthaff.2014.0497">10.1377/hlthaff.2014.0497</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/25288420">25288420</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Affairs&amp;rft.atitle=Specialty+Drug+Coupons+Lower+Out-of-pocket+Costs+and+May+Improve+Adherence+at+the+Risk+of+Increasing+Premiums&amp;rft.volume=33&amp;rft.issue=10&amp;rft.pages=1761-1769&amp;rft.date=2014-10&amp;rft_id=info%3Adoi%2F10.1377%2Fhlthaff.2014.0497&amp;rft_id=info%3Apmid%2F25288420&amp;rft.aulast=Starner&amp;rft.aufirst=CI&amp;rft.au=Alexander%2C+GC&amp;rft.au=Bowen%2C+K&amp;rft.au=Qui%2C+Y&amp;rft.au=Wickersham%2C+P&amp;rft.au=Gleason%2C+PP&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1377%252Fhlthaff.2014.0497&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-109"><span class="mw-cite-backlink"><b><a href="#cite_ref-109">^</a></b></span> <span class="reference-text"><cite id="CITEREFDaubresseAndersenRiggsAlexander2017" class="citation journal cs1">Daubresse, Matthew; Andersen, Martin; Riggs, Kevin R.; Alexander, G. Caleb (2017-01-01). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243177">"Effect of Prescription Drug Coupons on Statin Utilization and Expenditures: A Retrospective Cohort Study"</a>. <i>Pharmacotherapy</i>. <b>37</b> (1): 12–24. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1002%2Fphar.1802">10.1002/phar.1802</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/1875-9114">1875-9114</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243177">5243177</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/27455456">27455456</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmacotherapy&amp;rft.atitle=Effect+of+Prescription+Drug+Coupons+on+Statin+Utilization+and+Expenditures%3A+A+Retrospective+Cohort+Study&amp;rft.volume=37&amp;rft.issue=1&amp;rft.pages=12-24&amp;rft.date=2017-01-01&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5243177%23id-name%3DPMC&amp;rft.issn=1875-9114&amp;rft_id=info%3Apmid%2F27455456&amp;rft_id=info%3Adoi%2F10.1002%2Fphar.1802&amp;rft.aulast=Daubresse&amp;rft.aufirst=Matthew&amp;rft.au=Andersen%2C+Martin&amp;rft.au=Riggs%2C+Kevin+R.&amp;rft.au=Alexander%2C+G.+Caleb&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5243177&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-110"><span class="mw-cite-backlink"><b><a href="#cite_ref-110">^</a></b></span> <span class="reference-text"><cite id="CITEREFGrande2012" class="citation journal cs1">Grande, David (2012-06-13). "The Cost of Drug Coupons". <i>JAMA</i>. <b>307</b> (22): 2375–2376. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1001%2Fjama.2012.5603">10.1001/jama.2012.5603</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0098-7484">0098-7484</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/22692167">22692167</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=The+Cost+of+Drug+Coupons&amp;rft.volume=307&amp;rft.issue=22&amp;rft.pages=2375-2376&amp;rft.date=2012-06-13&amp;rft.issn=0098-7484&amp;rft_id=info%3Apmid%2F22692167&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2012.5603&amp;rft.aulast=Grande&amp;rft.aufirst=David&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-111"><span class="mw-cite-backlink"><b><a href="#cite_ref-111">^</a></b></span> <span class="reference-text"><cite id="CITEREFRossKesselheim2013" class="citation journal cs1">Ross, Joseph S.; Kesselheim, Aaron S. (2013-09-25). "Prescription-Drug Coupons — No Such Thing as a Free Lunch". <i>New England Journal of Medicine</i>. <b>369</b> (13): 1188–1189. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1056%2Fnejmp1301993">10.1056/nejmp1301993</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/23984672">23984672</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:205109358">205109358</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.atitle=Prescription-Drug+Coupons+%E2%80%94+No+Such+Thing+as+a+Free+Lunch&amp;rft.volume=369&amp;rft.issue=13&amp;rft.pages=1188-1189&amp;rft.date=2013-09-25&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A205109358%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F23984672&amp;rft_id=info%3Adoi%2F10.1056%2Fnejmp1301993&amp;rft.aulast=Ross&amp;rft.aufirst=Joseph+S.&amp;rft.au=Kesselheim%2C+Aaron+S.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:10-112"><span class="mw-cite-backlink">^ <a href="#cite_ref-:10_112-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:10_112-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="https://www.consumerreports.org/drugs/6-tips-for-finding-the-best-prescription-drug-prices/">"Save Money on Meds: 9 Tips for Finding the Best Prescription Drug Prices"</a>. <i>Consumer Reports</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2017-10-30</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Consumer+Reports&amp;rft.atitle=Save+Money+on+Meds%3A+9+Tips+for+Finding+the+Best+Prescription+Drug+Prices&amp;rft_id=https%3A%2F%2Fwww.consumerreports.org%2Fdrugs%2F6-tips-for-finding-the-best-prescription-drug-prices%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-113"><span class="mw-cite-backlink"><b><a href="#cite_ref-113">^</a></b></span> <span class="reference-text"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="https://www.npr.org/sections/health-shots/2015/09/16/440612238/how-to-save-money-on-prescription-drugs-insured-or-not">"How To Save Money On Prescription Drugs, Insured Or Not"</a>. <i>NPR.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2017-10-30</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=NPR.org&amp;rft.atitle=How+To+Save+Money+On+Prescription+Drugs%2C+Insured+Or+Not&amp;rft_id=https%3A%2F%2Fwww.npr.org%2Fsections%2Fhealth-shots%2F2015%2F09%2F16%2F440612238%2Fhow-to-save-money-on-prescription-drugs-insured-or-not&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-Kang-114"><span class="mw-cite-backlink">^ <a href="#cite_ref-Kang_114-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Kang_114-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Kang_114-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFKangBaiDiStefanoSocal2020" class="citation journal cs1">Kang, So-Yeon; Bai, Ge; DiStefano, Michael J.; Socal, Mariana P.; Yehia, Farah; Anderson, Gerard F. (2020-04-02). <a rel="nofollow" class="external text" href="https://doi.org/10.1146%2Fannurev-publhealth-040119-094305">"Comparative Approaches to Drug Pricing"</a>. <i>Annual Review of Public Health</i>. <b>41</b> (1): 499–512. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1146%2Fannurev-publhealth-040119-094305">10.1146/annurev-publhealth-040119-094305</a></span>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0163-7525">0163-7525</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/31874070">31874070</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annual+Review+of+Public+Health&amp;rft.atitle=Comparative+Approaches+to+Drug+Pricing&amp;rft.volume=41&amp;rft.issue=1&amp;rft.pages=499-512&amp;rft.date=2020-04-02&amp;rft.issn=0163-7525&amp;rft_id=info%3Apmid%2F31874070&amp;rft_id=info%3Adoi%2F10.1146%2Fannurev-publhealth-040119-094305&amp;rft.aulast=Kang&amp;rft.aufirst=So-Yeon&amp;rft.au=Bai%2C+Ge&amp;rft.au=DiStefano%2C+Michael+J.&amp;rft.au=Socal%2C+Mariana+P.&amp;rft.au=Yehia%2C+Farah&amp;rft.au=Anderson%2C+Gerard+F.&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1146%252Fannurev-publhealth-040119-094305&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:11-115"><span class="mw-cite-backlink">^ <a href="#cite_ref-:11_115-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:11_115-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFResearch" class="citation web cs1">Research, Center for Drug Evaluation and. <a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/genericdrugs/UCM167991.htm">"Generic Drugs – Generic Drug Facts"</a>. <i>www.fda.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2017-10-30</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fda.gov&amp;rft.atitle=Generic+Drugs+%E2%80%93+Generic+Drug+Facts&amp;rft.aulast=Research&amp;rft.aufirst=Center+for+Drug+Evaluation+and&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresourcesforyou%2Fconsumers%2Fbuyingusingmedicinesafely%2Fgenericdrugs%2FUCM167991.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-116"><span class="mw-cite-backlink"><b><a href="#cite_ref-116">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.medicalnewstoday.com/articles/brand-and-generic-drugs">"Brand-name vs. generic drugs: Which is better?"</a>. <i>www.medicalnewstoday.com</i>. 2021-06-28<span class="reference-accessdate">. Retrieved <span class="nowrap">2021-09-07</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.medicalnewstoday.com&amp;rft.atitle=Brand-name+vs.+generic+drugs%3A+Which+is+better%3F&amp;rft.date=2021-06-28&amp;rft_id=https%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2Fbrand-and-generic-drugs&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:02-117"><span class="mw-cite-backlink">^ <a href="#cite_ref-:02_117-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:02_117-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFSchoonveld2015" class="citation book cs1">Schoonveld, Ed (2015). <i>The Price of Global Health: Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation</i>. Gower Publishing, Ltd. pp.&#160;73–86. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-1472438829" title="Special:BookSources/978-1472438829"><bdi>978-1472438829</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=The+Price+of+Global+Health%3A+Drug+Pricing+Strategies+to+Balance+Patient+Access+and+the+Funding+of+Innovation&amp;rft.pages=73-86&amp;rft.pub=Gower+Publishing%2C+Ltd&amp;rft.date=2015&amp;rft.isbn=978-1472438829&amp;rft.aulast=Schoonveld&amp;rft.aufirst=Ed&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-118"><span class="mw-cite-backlink"><b><a href="#cite_ref-118">^</a></b></span> <span class="reference-text"><cite id="CITEREFMehrezGafni1989" class="citation journal cs1">Mehrez, Abraham; Gafni, Amiram (1989). "Quality-adjusted Life Years, Utility Theory, and Healthy-years Equivalents". <i>Medical Decision Making</i>. <b>9</b> (2): 142–149. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F0272989x8900900209">10.1177/0272989x8900900209</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/2501627">2501627</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:21035216">21035216</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Medical+Decision+Making&amp;rft.atitle=Quality-adjusted+Life+Years%2C+Utility+Theory%2C+and+Healthy-years+Equivalents&amp;rft.volume=9&amp;rft.issue=2&amp;rft.pages=142-149&amp;rft.date=1989&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A21035216%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F2501627&amp;rft_id=info%3Adoi%2F10.1177%2F0272989x8900900209&amp;rft.aulast=Mehrez&amp;rft.aufirst=Abraham&amp;rft.au=Gafni%2C+Amiram&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-119"><span class="mw-cite-backlink"><b><a href="#cite_ref-119">^</a></b></span> <span class="reference-text"><cite id="CITEREFSchnipperDavidsonWollinsBlayney2016" class="citation journal cs1">Schnipper, Lowell E.; Davidson, Nancy E.; Wollins, Dana S.; Blayney, Douglas W.; Dicker, Adam P.; Ganz, Patricia A.; Hoverman, J. Russell; Langdon, Robert; Lyman, Gary H. (2016-08-20). "Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received". <i>Journal of Clinical Oncology</i>. <b>34</b> (24): 2925–2934. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1200%2FJCO.2016.68.2518">10.1200/JCO.2016.68.2518</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0732-183X">0732-183X</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/27247218">27247218</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:20877575">20877575</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Clinical+Oncology&amp;rft.atitle=Updating+the+American+Society+of+Clinical+Oncology+Value+Framework%3A+Revisions+and+Reflections+in+Response+to+Comments+Received&amp;rft.volume=34&amp;rft.issue=24&amp;rft.pages=2925-2934&amp;rft.date=2016-08-20&amp;rft.issn=0732-183X&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A20877575%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F27247218&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2016.68.2518&amp;rft.aulast=Schnipper&amp;rft.aufirst=Lowell+E.&amp;rft.au=Davidson%2C+Nancy+E.&amp;rft.au=Wollins%2C+Dana+S.&amp;rft.au=Blayney%2C+Douglas+W.&amp;rft.au=Dicker%2C+Adam+P.&amp;rft.au=Ganz%2C+Patricia+A.&amp;rft.au=Hoverman%2C+J.+Russell&amp;rft.au=Langdon%2C+Robert&amp;rft.au=Lyman%2C+Gary+H.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:12-120"><span class="mw-cite-backlink">^ <a href="#cite_ref-:12_120-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:12_120-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite id="CITEREFSchnipperDavidsonWollinsTyne2015" class="citation journal cs1">Schnipper, Lowell E.; Davidson, Nancy E.; Wollins, Dana S.; Tyne, Courtney; Blayney, Douglas W.; Blum, Diane; Dicker, Adam P.; Ganz, Patricia A.; Hoverman, J. Russell (2015-08-10). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015427">"American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options"</a>. <i>Journal of Clinical Oncology</i>. <b>33</b> (23): 2563–2577. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1200%2FJCO.2015.61.6706">10.1200/JCO.2015.61.6706</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015427">5015427</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/26101248">26101248</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Clinical+Oncology&amp;rft.atitle=American+Society+of+Clinical+Oncology+Statement%3A+A+Conceptual+Framework+to+Assess+the+Value+of+Cancer+Treatment+Options&amp;rft.volume=33&amp;rft.issue=23&amp;rft.pages=2563-2577&amp;rft.date=2015-08-10&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5015427%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F26101248&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2015.61.6706&amp;rft.aulast=Schnipper&amp;rft.aufirst=Lowell+E.&amp;rft.au=Davidson%2C+Nancy+E.&amp;rft.au=Wollins%2C+Dana+S.&amp;rft.au=Tyne%2C+Courtney&amp;rft.au=Blayney%2C+Douglas+W.&amp;rft.au=Blum%2C+Diane&amp;rft.au=Dicker%2C+Adam+P.&amp;rft.au=Ganz%2C+Patricia+A.&amp;rft.au=Hoverman%2C+J.+Russell&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5015427&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-121"><span class="mw-cite-backlink"><b><a href="#cite_ref-121">^</a></b></span> <span class="reference-text"><cite id="CITEREFChernyDafniBogaertsLatino2017" class="citation journal cs1">Cherny, N. I.; Dafni, U.; Bogaerts, J.; Latino, N. J.; Pentheroudakis, G.; Douillard, J.-Y.; Tabernero, J.; Zielinski, C.; Piccart, M. J. (2017-09-04). <a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Fannonc%2Fmdx310">"ESMO-Magnitude of Clinical Benefit Scale version 1.1"</a>. <i>Annals of Oncology</i>. <b>28</b> (10): 2340–2366. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Fannonc%2Fmdx310">10.1093/annonc/mdx310</a></span>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0923-7534">0923-7534</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/28945867">28945867</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annals+of+Oncology&amp;rft.atitle=ESMO-Magnitude+of+Clinical+Benefit+Scale+version+1.1&amp;rft.volume=28&amp;rft.issue=10&amp;rft.pages=2340-2366&amp;rft.date=2017-09-04&amp;rft.issn=0923-7534&amp;rft_id=info%3Apmid%2F28945867&amp;rft_id=info%3Adoi%2F10.1093%2Fannonc%2Fmdx310&amp;rft.aulast=Cherny&amp;rft.aufirst=N.+I.&amp;rft.au=Dafni%2C+U.&amp;rft.au=Bogaerts%2C+J.&amp;rft.au=Latino%2C+N.+J.&amp;rft.au=Pentheroudakis%2C+G.&amp;rft.au=Douillard%2C+J.-Y.&amp;rft.au=Tabernero%2C+J.&amp;rft.au=Zielinski%2C+C.&amp;rft.au=Piccart%2C+M.+J.&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1093%252Fannonc%252Fmdx310&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-:13-122"><span class="mw-cite-backlink"><b><a href="#cite_ref-:13_122-0">^</a></b></span> <span class="reference-text"><cite id="CITEREFChernySullivanDafniKerst2017" class="citation journal cs1">Cherny, N. I.; Sullivan, R.; Dafni, U.; Kerst, J. M.; Sobrero, A.; Zielinski, C.; Vries, De; E, E. G.; Piccart, M. J. (2017-11-01). <a rel="nofollow" class="external text" href="https://academic.oup.com/annonc/article/28/11/2901/3062455">"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)"</a>. <i>Annals of Oncology</i>. <b>28</b> (11): 2901–2905. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Fannonc%2Fmdw258">10.1093/annonc/mdw258</a></span>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0923-7534">0923-7534</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/27604385">27604385</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annals+of+Oncology&amp;rft.atitle=A+standardised%2C+generic%2C+validated+approach+to+stratify+the+magnitude+of+clinical+benefit+that+can+be+anticipated+from+anti-cancer+therapies%3A+the+European+Society+for+Medical+Oncology+Magnitude+of+Clinical+Benefit+Scale+%28ESMO-MCBS%29&amp;rft.volume=28&amp;rft.issue=11&amp;rft.pages=2901-2905&amp;rft.date=2017-11-01&amp;rft.issn=0923-7534&amp;rft_id=info%3Apmid%2F27604385&amp;rft_id=info%3Adoi%2F10.1093%2Fannonc%2Fmdw258&amp;rft.aulast=Cherny&amp;rft.aufirst=N.+I.&amp;rft.au=Sullivan%2C+R.&amp;rft.au=Dafni%2C+U.&amp;rft.au=Kerst%2C+J.+M.&amp;rft.au=Sobrero%2C+A.&amp;rft.au=Zielinski%2C+C.&amp;rft.au=Vries%2C+De&amp;rft.au=E%2C+E.+G.&amp;rft.au=Piccart%2C+M.+J.&amp;rft_id=https%3A%2F%2Facademic.oup.com%2Fannonc%2Farticle%2F28%2F11%2F2901%2F3062455&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-123"><span class="mw-cite-backlink"><b><a href="#cite_ref-123">^</a></b></span> <span class="reference-text"><cite id="CITEREFVivotJacotZeitounRavaud2017" class="citation journal cs1">Vivot, A.; Jacot, J.; Zeitoun, J.-D.; Ravaud, P.; Crequit, P.; Porcher, R. (2017-05-01). <a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Fannonc%2Fmdx053">"Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015"</a>. <i>Annals of Oncology</i>. <b>28</b> (5): 1111–1116. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Fannonc%2Fmdx053">10.1093/annonc/mdx053</a></span>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a>&#160;<a rel="nofollow" class="external text" href="https://www.worldcat.org/issn/0923-7534">0923-7534</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/28453694">28453694</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annals+of+Oncology&amp;rft.atitle=Clinical+benefit%2C+price+and+approval+characteristics+of+FDA-approved+new+drugs+for+treating+advanced+solid+cancer%2C+2000%E2%80%932015&amp;rft.volume=28&amp;rft.issue=5&amp;rft.pages=1111-1116&amp;rft.date=2017-05-01&amp;rft.issn=0923-7534&amp;rft_id=info%3Apmid%2F28453694&amp;rft_id=info%3Adoi%2F10.1093%2Fannonc%2Fmdx053&amp;rft.aulast=Vivot&amp;rft.aufirst=A.&amp;rft.au=Jacot%2C+J.&amp;rft.au=Zeitoun%2C+J.-D.&amp;rft.au=Ravaud%2C+P.&amp;rft.au=Crequit%2C+P.&amp;rft.au=Porcher%2C+R.&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1093%252Fannonc%252Fmdx053&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-124"><span class="mw-cite-backlink"><b><a href="#cite_ref-124">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.aging.senate.gov/hearings/sudden-price-spikes-in-off-patent-drugs_perspectives-from-the-front-lines">Sudden Price Spikes in Off-Patent Drugs: Perspectives from the Front Lines</a> United States Senate Special Committee on Aging, December 9, 2015, retrieved 2 February 2016</span>
</li>
<li id="cite_note-125"><span class="mw-cite-backlink"><b><a href="#cite_ref-125">^</a></b></span> <span class="reference-text"><cite id="CITEREFGingery2017" class="citation news cs1">Gingery, Derrick (24 July 2017). <a rel="nofollow" class="external text" href="https://pink.pharmamedtechbi.com/PS121171/Dems-Better-Deal-Would-Create-Drug-Price-Gouging-Enforcer">"Dems' 'Better Deal' Would Create Drug Price Gouging 'Enforcer'<span class="cs1-kern-right"></span>"</a>. <a href="/wiki/OTC_Markets_Group" title="OTC Markets Group">OTC Markets Group</a><span class="reference-accessdate">. Retrieved <span class="nowrap">27 July</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Dems%27+%27Better+Deal%27+Would+Create+Drug+Price+Gouging+%27Enforcer%27&amp;rft.date=2017-07-24&amp;rft.aulast=Gingery&amp;rft.aufirst=Derrick&amp;rft_id=https%3A%2F%2Fpink.pharmamedtechbi.com%2FPS121171%2FDems-Better-Deal-Would-Create-Drug-Price-Gouging-Enforcer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-Senate_Bill_17-126"><span class="mw-cite-backlink">^ <a href="#cite_ref-Senate_Bill_17_126-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Senate_Bill_17_126-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Senate_Bill_17_126-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://legiscan.com/CA/text/SB17/2017">"Senate Bill 17"</a>. <i>LegiScan</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=LegiScan&amp;rft.atitle=Senate+Bill+17&amp;rft_id=https%3A%2F%2Flegiscan.com%2FCA%2Ftext%2FSB17%2F2017&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-127"><span class="mw-cite-backlink"><b><a href="#cite_ref-127">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=201720180SB17">"SB-17 Health care: prescription drug costs"</a>. <i>California Legislative Information</i>. 10 September 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">7 August</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=California+Legislative+Information&amp;rft.atitle=SB-17+Health+care%3A+prescription+drug+costs&amp;rft.date=2017-09-10&amp;rft_id=https%3A%2F%2Fleginfo.legislature.ca.gov%2Ffaces%2FbillTextClient.xhtml%3Fbill_id%3D201720180SB17&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-128"><span class="mw-cite-backlink"><b><a href="#cite_ref-128">^</a></b></span> <span class="reference-text"><cite id="CITEREFMenon2001" class="citation journal cs1">Menon, Devidas (June 2001). <a rel="nofollow" class="external text" href="https://doi.org/10.1377%2Fhlthaff.20.3.92">"Pharmaceutical Cost Control in Canada: Does It Work?"</a>. <i>Health Affairs</i>. <b>20</b> (3): 92–103. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1377%2Fhlthaff.20.3.92">10.1377/hlthaff.20.3.92</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/11585186">11585186</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Affairs&amp;rft.atitle=Pharmaceutical+Cost+Control+in+Canada%3A+Does+It+Work%3F&amp;rft.volume=20&amp;rft.issue=3&amp;rft.pages=92-103&amp;rft.date=2001-06&amp;rft_id=info%3Adoi%2F10.1377%2Fhlthaff.20.3.92&amp;rft_id=info%3Apmid%2F11585186&amp;rft.aulast=Menon&amp;rft.aufirst=Devidas&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1377%252Fhlthaff.20.3.92&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-129"><span class="mw-cite-backlink"><b><a href="#cite_ref-129">^</a></b></span> <span class="reference-text"><cite id="CITEREFThe_Severyn_Group,_Inc.2003" class="citation web cs1">The Severyn Group, Inc. (2003). <a rel="nofollow" class="external text" href="https://assets.aarp.org/www.aarp.org_/articles/international/proceedingsbooklet.pdf">"AARP International Forum on Prescription Drug Policy"</a> <span class="cs1-format">(PDF)</span>. <i>AARP</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=AARP&amp;rft.atitle=AARP+International+Forum+on+Prescription+Drug+Policy&amp;rft.date=2003&amp;rft.au=The+Severyn+Group%2C+Inc.&amp;rft_id=https%3A%2F%2Fassets.aarp.org%2Fwww.aarp.org_%2Farticles%2Finternational%2Fproceedingsbooklet.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-onpoint-130"><span class="mw-cite-backlink">^ <a href="#cite_ref-onpoint_130-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-onpoint_130-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.wbur.org/onpoint/2018/10/18/drug-prices-tv-ads-us-pharma">"Transparency And Drug Prices: Will The New U.S. Mandate On TV Ads Drive Costs Down?"</a>. <i>www.wbur.org</i>. 18 October 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">Aug 13,</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.wbur.org&amp;rft.atitle=Transparency+And+Drug+Prices%3A+Will+The+New+U.S.+Mandate+On+TV+Ads+Drive+Costs+Down%3F&amp;rft.date=2018-10-18&amp;rft_id=https%3A%2F%2Fwww.wbur.org%2Fonpoint%2F2018%2F10%2F18%2Fdrug-prices-tv-ads-us-pharma&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-131"><span class="mw-cite-backlink"><b><a href="#cite_ref-131">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20190429062939/http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9298">"Formulary Management"</a>. <i>Academy of Managed Care Pharmacists</i>. 2015. Archived from <a rel="nofollow" class="external text" href="http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9298">the original</a> on 2019-04-29<span class="reference-accessdate">. Retrieved <span class="nowrap">2017-10-31</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Academy+of+Managed+Care+Pharmacists&amp;rft.atitle=Formulary+Management&amp;rft.date=2015&amp;rft_id=http%3A%2F%2Fwww.amcp.org%2FWorkArea%2FDownloadAsset.aspx%3Fid%3D9298&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-132"><span class="mw-cite-backlink"><b><a href="#cite_ref-132">^</a></b></span> <span class="reference-text"><cite id="CITEREFRabbaniAlexander_GC2009" class="citation journal cs1">Rabbani, A; Alexander GC (2009). "Cost savings associated with filling a 3-month supply of prescription medicines". <i>Applied Health Economics and Health Policy</i>. <b>7</b> (4): 255–264. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fbf03256159">10.1007/bf03256159</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/19905039">19905039</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a>&#160;<a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:73081736">73081736</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Applied+Health+Economics+and+Health+Policy&amp;rft.atitle=Cost+savings+associated+with+filling+a+3-month+supply+of+prescription+medicines.&amp;rft.volume=7&amp;rft.issue=4&amp;rft.pages=255-264&amp;rft.date=2009&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A73081736%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F19905039&amp;rft_id=info%3Adoi%2F10.1007%2Fbf03256159&amp;rft.aulast=Rabbani&amp;rft.aufirst=A&amp;rft.au=Alexander+GC&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-133"><span class="mw-cite-backlink"><b><a href="#cite_ref-133">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20170608154237/http://www.aha.org/content/16/aha-drug-policy-recommendations.pdf">"American Hospital Association: Drug Policy Recommendations"</a> <span class="cs1-format">(PDF)</span>. <i>AHA</i>. 2015. Archived from <a rel="nofollow" class="external text" href="http://www.aha.org/content/16/aha-drug-policy-recommendations.pdf">the original</a> <span class="cs1-format">(PDF)</span> on 2017-06-08.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=AHA&amp;rft.atitle=American+Hospital+Association%3A+Drug+Policy+Recommendations&amp;rft.date=2015&amp;rft_id=http%3A%2F%2Fwww.aha.org%2Fcontent%2F16%2Faha-drug-policy-recommendations.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-134"><span class="mw-cite-backlink"><b><a href="#cite_ref-134">^</a></b></span> <span class="reference-text"><cite id="CITEREFLove2017" class="citation news cs1">Love, Robert (2017). <a rel="nofollow" class="external text" href="https://www.aarp.org/health/drugs-supplements/info-2017/rx-prescription-drug-pricing.html">"Why Our Drugs Cost So Much"</a>. <i>AARP</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=AARP&amp;rft.atitle=Why+Our+Drugs+Cost+So+Much&amp;rft.date=2017&amp;rft.aulast=Love&amp;rft.aufirst=Robert&amp;rft_id=https%3A%2F%2Fwww.aarp.org%2Fhealth%2Fdrugs-supplements%2Finfo-2017%2Frx-prescription-drug-pricing.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-American_Hospital_Association:_Drug_Policy_Recommendations-135"><span class="mw-cite-backlink"><b><a href="#cite_ref-American_Hospital_Association:_Drug_Policy_Recommendations_135-0">^</a></b></span> <span class="reference-text">American Hospital Association</span>
</li>
<li id="cite_note-136"><span class="mw-cite-backlink"><b><a href="#cite_ref-136">^</a></b></span> <span class="reference-text"><cite id="CITEREFZulloDoreGalárraga2015" class="citation journal cs1">Zullo, Andrew R.; Dore, David D.; Galárraga, Omar (March 2015). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930104">"Development and validation of an index to predict personal prescription drug importation by adults in the United States"</a>. <i>Journal of Pharmaceutical Health Services Research</i>. <b>6</b> (1): 33–41. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1111%2Fjphs.12088">10.1111/jphs.12088</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a>&#160;<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930104">4930104</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a>&#160;<a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/27375777">27375777</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Pharmaceutical+Health+Services+Research&amp;rft.atitle=Development+and+validation+of+an+index+to+predict+personal+prescription+drug+importation+by+adults+in+the+United+States&amp;rft.volume=6&amp;rft.issue=1&amp;rft.pages=33-41&amp;rft.date=2015-03&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4930104%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F27375777&amp;rft_id=info%3Adoi%2F10.1111%2Fjphs.12088&amp;rft.aulast=Zullo&amp;rft.aufirst=Andrew+R.&amp;rft.au=Dore%2C+David+D.&amp;rft.au=Gal%C3%A1rraga%2C+Omar&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4930104&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-137"><span class="mw-cite-backlink"><b><a href="#cite_ref-137">^</a></b></span> <span class="reference-text"><cite id="CITEREFPallone2020" class="citation web cs1">Pallone, Frank (2020-09-08). <a rel="nofollow" class="external text" href="https://www.congress.gov/bill/116th-congress/house-bill/3">"H.R.3 – 116th Congress (2019–2020): Elijah E. Cummings Lower Drug Costs Now Act"</a>. <i>www.congress.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2021-08-31</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.congress.gov&amp;rft.atitle=H.R.3+%E2%80%93+116th+Congress+%282019%E2%80%932020%29%3A+Elijah+E.+Cummings+Lower+Drug+Costs+Now+Act&amp;rft.date=2020-09-08&amp;rft.aulast=Pallone&amp;rft.aufirst=Frank&amp;rft_id=https%3A%2F%2Fwww.congress.gov%2Fbill%2F116th-congress%2Fhouse-bill%2F3&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-138"><span class="mw-cite-backlink"><b><a href="#cite_ref-138">^</a></b></span> <span class="reference-text"><cite id="CITEREFMartin2021" class="citation journal cs1">Martin, Kristi (2021). <a rel="nofollow" class="external text" href="https://www.commonwealthfund.org/publications/explainer/2021/may/allowing-medicare-negotiate-drug-prices">"Allowing Medicare to Negotiate Drug Prices | Commonwealth Fund"</a>. <i>www.commonwealthfund.org</i>. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.26099%2Fkwg3-x115">10.26099/kwg3-x115</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2021-07-20</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=www.commonwealthfund.org&amp;rft.atitle=Allowing+Medicare+to+Negotiate+Drug+Prices+%7C+Commonwealth+Fund&amp;rft.date=2021&amp;rft_id=info%3Adoi%2F10.26099%2Fkwg3-x115&amp;rft.aulast=Martin&amp;rft.aufirst=Kristi&amp;rft_id=https%3A%2F%2Fwww.commonwealthfund.org%2Fpublications%2Fexplainer%2F2021%2Fmay%2Fallowing-medicare-negotiate-drug-prices&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-139"><span class="mw-cite-backlink"><b><a href="#cite_ref-139">^</a></b></span> <span class="reference-text">Biden, Joe. (2020-07-08). <a rel="nofollow" class="external text" href="https://joebiden.com/wp-content/uploads/2020/08/UNITY-TASK-FORCE-RECOMMENDATIONS.pdf#page=32">Biden-Sanders Unity Task Force Recommendations Press Release</a>.</span>
</li>
<li id="cite_note-140"><span class="mw-cite-backlink"><b><a href="#cite_ref-140">^</a></b></span> <span class="reference-text"><cite id="CITEREFSanders2019" class="citation web cs1">Sanders, Bernard (2019-04-10). <a rel="nofollow" class="external text" href="https://www.congress.gov/bill/116th-congress/senate-bill/1129/text">"Text – S.1129 – 116th Congress (2019–2020): Medicare for All Act of 2019"</a>. <i>www.congress.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2021-07-20</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.congress.gov&amp;rft.atitle=Text+%E2%80%93+S.1129+%E2%80%93+116th+Congress+%282019%E2%80%932020%29%3A+Medicare+for+All+Act+of+2019&amp;rft.date=2019-04-10&amp;rft.aulast=Sanders&amp;rft.aufirst=Bernard&amp;rft_id=https%3A%2F%2Fwww.congress.gov%2Fbill%2F116th-congress%2Fsenate-bill%2F1129%2Ftext&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-141"><span class="mw-cite-backlink"><b><a href="#cite_ref-141">^</a></b></span> <span class="reference-text"><cite id="CITEREFNordrum2014" class="citation news cs1">Nordrum, Amy (2014-09-24). <a rel="nofollow" class="external text" href="https://www.ibtimes.com/should-government-control-price-prescription-drugs-2112771">"Should Government Control The Price Of Prescription Drugs?"</a>. <i>IBTimes</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=IBTimes&amp;rft.atitle=Should+Government+Control+The+Price+Of+Prescription+Drugs%3F&amp;rft.date=2014-09-24&amp;rft.aulast=Nordrum&amp;rft.aufirst=Amy&amp;rft_id=https%3A%2F%2Fwww.ibtimes.com%2Fshould-government-control-price-prescription-drugs-2112771&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
<li id="cite_note-142"><span class="mw-cite-backlink"><b><a href="#cite_ref-142">^</a></b></span> <span class="reference-text"><cite id="CITEREFCockburnLanjouwSchankerman2014" class="citation journal cs1">Cockburn, Iain M.; Lanjouw, Jean O.; Schankerman, Mark (2014-09-11). <a rel="nofollow" class="external text" href="https://www.nber.org/papers/w20492">"Patents and the Global Diffusion of New Drugs"</a>. Working Paper Series. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.3386%2Fw20492">10.3386/w20492</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Patents+and+the+Global+Diffusion+of+New+Drugs&amp;rft.date=2014-09-11&amp;rft_id=info%3Adoi%2F10.3386%2Fw20492&amp;rft.aulast=Cockburn&amp;rft.aufirst=Iain+M.&amp;rft.au=Lanjouw%2C+Jean+O.&amp;rft.au=Schankerman%2C+Mark&amp;rft_id=https%3A%2F%2Fwww.nber.org%2Fpapers%2Fw20492&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span> <span class="cs1-visible-error citation-comment"><code class="cs1-code">{{<a href="/wiki/Template:Cite_journal" title="Template:Cite journal">cite journal</a>}}</code>: </span><span class="cs1-visible-error citation-comment">Cite journal requires <code class="cs1-code">&#124;journal=</code> (<a href="/wiki/Help:CS1_errors#missing_periodical" title="Help:CS1 errors">help</a>)</span></span>
</li>
<li id="cite_note-143"><span class="mw-cite-backlink"><b><a href="#cite_ref-143">^</a></b></span> <span class="reference-text"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://ascopost.com/issues/october-25-2015/delays-in-drug-approval-are-deadly-highlighting-the-need-for-improved-regulatory-efficiency/">"Delays in Drug Approval Are Deadly, Highlighting the Need for Improved Regulatory Efficiency – The ASCO Post"</a>. <i>ascopost.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2021-07-20</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=ascopost.com&amp;rft.atitle=Delays+in+Drug+Approval+Are+Deadly%2C+Highlighting+the+Need+for+Improved+Regulatory+Efficiency+%E2%80%93+The+ASCO+Post&amp;rft_id=https%3A%2F%2Fascopost.com%2Fissues%2Foctober-25-2015%2Fdelays-in-drug-approval-are-deadly-highlighting-the-need-for-improved-regulatory-efficiency%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States" class="Z3988"></span></span>
</li>
</ol></div>
<h2><span class="mw-headline" id="Further_reading">Further reading</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=32" title="Edit section: Further reading"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></h2>
<ul><li>Malcolm Gladwell <a rel="nofollow" class="external text" href="http://www.newyorker.com/magazine/2004/10/25/high-prices">High Prices. How to think about prescription drugs.</a> The New Yorker. October 25, 2004. accessed 28 November 2015.</li></ul>
<!-- 
NewPP limit report
Parsed by mw‐api‐int.eqiad.main‐777f6c8748‐t9jjm
Cached time: 20240405072121
Cache expiry: 2592000
Reduced expiry: false
Complications: [vary‐revision‐sha1, show‐toc]
CPU time usage: 1.684 seconds
Real time usage: 1.843 seconds
Preprocessor visited node count: 8587/1000000
Post‐expand include size: 282798/2097152 bytes
Template argument size: 4780/2097152 bytes
Highest expansion depth: 17/100
Expensive parser function count: 11/500
Unstrip recursion depth: 1/20
Unstrip post‐expand size: 503178/5000000 bytes
Lua time usage: 1.069/10.000 seconds
Lua memory usage: 7475112/52428800 bytes
Lua Profile:
    ?                                                                260 ms       22.8%
    dataWrapper <mw.lua:672>                                         100 ms        8.8%
    MediaWiki\Extension\Scribunto\Engines\LuaSandbox\LuaSandboxCallback::gsub      100 ms        8.8%
    MediaWiki\Extension\Scribunto\Engines\LuaSandbox\LuaSandboxCallback::callParserFunction       80 ms        7.0%
    MediaWiki\Extension\Scribunto\Engines\LuaSandbox\LuaSandboxCallback::getExpandedArgument       60 ms        5.3%
    <mw.lua:694>                                                      60 ms        5.3%
    MediaWiki\Extension\Scribunto\Engines\LuaSandbox\LuaSandboxCallback::anchorEncode       60 ms        5.3%
    MediaWiki\Extension\Scribunto\Engines\LuaSandbox\LuaSandboxCallback::match       60 ms        5.3%
    MediaWiki\Extension\Scribunto\Engines\LuaSandbox\LuaSandboxCallback::find       40 ms        3.5%
    <mw.title.lua:50>                                                 40 ms        3.5%
    [others]                                                         280 ms       24.6%
Number of Wikibase entities loaded: 0/400
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00% 1655.575      1 -total
 74.33% 1230.652      1 Template:Reflist
 25.18%  416.908     48 Template:Cite_journal
 24.89%  412.015     47 Template:Cite_web
  9.36%  155.004     25 Template:Cite_news
  5.20%   86.123      1 Template:Short_description
  3.96%   65.536      3 Template:Fix
  3.94%   65.152      4 Template:Rp
  3.70%   61.177      4 Template:R/superscript
  3.66%   60.553      1 Template:Tone
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:350292-0!canonical and timestamp 20240405072121 and revision id 1192719002. Rendering was triggered because: api-parse
 -->
</div><!--esi <esi:include src="/esitest-fa8a495983347898/content" /> --><noscript><img src="https://login.wikimedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" width="1" height="1" style="border: none; position: absolute;"></noscript>
<div class="printfooter" data-nosnippet="">Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;oldid=1192719002">https://en.wikipedia.org/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;oldid=1192719002</a>"</div></div>
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Pharmaceuticals_policy" title="Category:Pharmaceuticals policy">Pharmaceuticals policy</a></li><li><a href="/wiki/Category:Health_policy_in_the_United_States" title="Category:Health policy in the United States">Health policy in the United States</a></li><li><a href="/wiki/Category:Healthcare_reform_in_the_United_States" title="Category:Healthcare reform in the United States">Healthcare reform in the United States</a></li><li><a href="/wiki/Category:Pharmacy_in_the_United_States" title="Category:Pharmacy in the United States">Pharmacy in the United States</a></li><li><a href="/wiki/Category:Drug_pricing" title="Category:Drug pricing">Drug pricing</a></li><li><a href="/wiki/Category:Social_problems_in_medicine" title="Category:Social problems in medicine">Social problems in medicine</a></li><li><a href="/wiki/Category:Corruption_in_the_United_States" title="Category:Corruption in the United States">Corruption in the United States</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:CS1_errors:_missing_periodical" title="Category:CS1 errors: missing periodical">CS1 errors: missing periodical</a></li><li><a href="/wiki/Category:Webarchive_template_wayback_links" title="Category:Webarchive template wayback links">Webarchive template wayback links</a></li><li><a href="/wiki/Category:CS1_maint:_location_missing_publisher" title="Category:CS1 maint: location missing publisher">CS1 maint: location missing publisher</a></li><li><a href="/wiki/Category:CS1_maint:_multiple_names:_authors_list" title="Category:CS1 maint: multiple names: authors list">CS1 maint: multiple names: authors list</a></li><li><a href="/wiki/Category:Pages_containing_links_to_subscription-only_content" title="Category:Pages containing links to subscription-only content">Pages containing links to subscription-only content</a></li><li><a href="/wiki/Category:CS1_maint:_numeric_names:_authors_list" title="Category:CS1 maint: numeric names: authors list">CS1 maint: numeric names: authors list</a></li><li><a href="/wiki/Category:All_articles_with_dead_external_links" title="Category:All articles with dead external links">All articles with dead external links</a></li><li><a href="/wiki/Category:Articles_with_dead_external_links_from_October_2023" title="Category:Articles with dead external links from October 2023">Articles with dead external links from October 2023</a></li><li><a href="/wiki/Category:Articles_with_permanently_dead_external_links" title="Category:Articles with permanently dead external links">Articles with permanently dead external links</a></li><li><a href="/wiki/Category:Articles_with_short_description" title="Category:Articles with short description">Articles with short description</a></li><li><a href="/wiki/Category:Short_description_is_different_from_Wikidata" title="Category:Short description is different from Wikidata">Short description is different from Wikidata</a></li><li><a href="/wiki/Category:Wikipedia_articles_with_style_issues_from_January_2020" title="Category:Wikipedia articles with style issues from January 2020">Wikipedia articles with style issues from January 2020</a></li><li><a href="/wiki/Category:All_articles_with_style_issues" title="Category:All articles with style issues">All articles with style issues</a></li><li><a href="/wiki/Category:Articles_containing_potentially_dated_statements_from_2004" title="Category:Articles containing potentially dated statements from 2004">Articles containing potentially dated statements from 2004</a></li><li><a href="/wiki/Category:All_articles_containing_potentially_dated_statements" title="Category:All articles containing potentially dated statements">All articles containing potentially dated statements</a></li><li><a href="/wiki/Category:Wikipedia_articles_needing_clarification_from_July_2017" title="Category:Wikipedia articles needing clarification from July 2017">Wikipedia articles needing clarification from July 2017</a></li><li><a href="/wiki/Category:Wikipedia_neutral_point_of_view_disputes_from_September_2016" title="Category:Wikipedia neutral point of view disputes from September 2016">Wikipedia neutral point of view disputes from September 2016</a></li><li><a href="/wiki/Category:All_Wikipedia_neutral_point_of_view_disputes" title="Category:All Wikipedia neutral point of view disputes">All Wikipedia neutral point of view disputes</a></li><li><a href="/wiki/Category:Wikipedia_articles_needing_page_number_citations_from_February_2016" title="Category:Wikipedia articles needing page number citations from February 2016">Wikipedia articles needing page number citations from February 2016</a></li></ul></div></div>
				</div>
			</main>
			
		</div>
		<div class="mw-footer-container">
			
<footer id="footer" class="mw-footer" role="contentinfo" >
	<ul id="footer-info">
	<li id="footer-info-lastmod"> This page was last edited on 30 December 2023, at 23:26<span class="anonymous-show">&#160;(UTC)</span>.</li>
	<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_the_Creative_Commons_Attribution-ShareAlike_4.0_International_License">Creative Commons Attribution-ShareAlike License 4.0</a><a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_the_Creative_Commons_Attribution-ShareAlike_4.0_International_License" style="display:none;"></a>;
additional terms may apply. By using this site, you agree to the <a href="//foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Terms_of_Use">Terms of Use</a> and <a href="//foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
</ul>

	<ul id="footer-places">
	<li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Privacy_policy">Privacy policy</a></li>
	<li id="footer-places-about"><a href="/wiki/Wikipedia:About">About Wikipedia</a></li>
	<li id="footer-places-disclaimers"><a href="/wiki/Wikipedia:General_disclaimer">Disclaimers</a></li>
	<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
	<li id="footer-places-wm-codeofconduct"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Universal_Code_of_Conduct">Code of Conduct</a></li>
	<li id="footer-places-developers"><a href="https://developer.wikimedia.org">Developers</a></li>
	<li id="footer-places-statslink"><a href="https://stats.wikimedia.org/#/en.wikipedia.org">Statistics</a></li>
	<li id="footer-places-cookiestatement"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Cookie_statement">Cookie statement</a></li>
	<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
</ul>

	<ul id="footer-icons" class="noprint">
	<li id="footer-copyrightico"><a href="https://wikimediafoundation.org/"><img src="/static/images/footer/wikimedia-button.png" srcset="/static/images/footer/wikimedia-button-1.5x.png 1.5x, /static/images/footer/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation" loading="lazy" /></a></li>
	<li id="footer-poweredbyico"><a href="https://www.mediawiki.org/"><img src="/static/images/footer/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/static/images/footer/poweredby_mediawiki_132x47.png 1.5x, /static/images/footer/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"></a></li>
</ul>

</footer>

		</div>
	</div> 
</div> 
<div class="vector-settings" id="p-dock-bottom">
	<ul>
		<li>
		<button class="cdx-button cdx-button--icon-only vector-limited-width-toggle" id=""><span class="vector-icon mw-ui-icon-fullScreen mw-ui-icon-wikimedia-fullScreen"></span>

<span>Toggle limited content width</span>
</button>
</li>
	</ul>
</div>


</body>
</html> contentType 9 text/html url 79 https://en.wikipedia.org:443/wiki/Prescription_drug_prices_in_the_United_States responseCode 3 200 